# EDGAR Filing Document

**Accession Number:** 0001755672
**File Stem:** 0001755672-26-000010
**Filing Date:** 2026-5
**Character Count:** 408807
**Document Hash:** f8c329728f025b9a0e4974136c831547
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001755672-26-000010.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001755672-26-000010

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 124

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Corteva, Inc.
- **CENTRAL INDEX KEY:** 0001755672
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - CROPS [0100]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 824979096
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38710
- **FILM NUMBER:** 26949800

**BUSINESS ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
- **BUSINESS PHONE:** (833) 267-8382

**MAIL ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EIDP, Inc.
- **CENTRAL INDEX KEY:** 0000030554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTIC MATERIAL, SYNTH RESIN/RUBBER, CELLULOS (NO GLASS) [2820]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 510014090
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-00815
- **FILM NUMBER:** 26949801

**BUSINESS ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268
- **BUSINESS PHONE:** 8332678382

**MAIL ADDRESS:**
- **STREET 1:** 9330 ZIONSVILLE ROAD
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46268

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DUPONT E I DE NEMOURS & CO
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? ctva-20260331

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026** 

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from ____________ to ____________

**Commission File Number 001-38710** 

**Corteva, Inc.** 

(Exact Name of Registrant as Specified in its Charter)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **Delaware** | **82-4979096** | **82-4979096** |
| (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | (I.R.S. Employer Identification No.) |
| **9330 Zionsville Road,** | **Indianapolis,** | **Indiana** | **46268** | **(833)** | **267-8382** |
| **1000 N. West Street, Suite 900,** | **Wilmington,** | **Delaware** | **19801** | **(833)** | **267-8382** |
| (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Registrant's Telephone Number, including area code) | (Registrant's Telephone Number, including area code) |

---

**Commission File Number 1-815** 

**EIDP, Inc.** 

(Exact Name of Registrant as Specified in Its Charter)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **Delaware** | **51-0014090** | **51-0014090** |
| (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | (I.R.S. Employer Identification No.) |
| **9330 Zionsville Road,** | **Indianapolis,** | **Indiana** | **46268** | **(833)** | **267-8382** |
| **1000 N. West Street, Suite 900,** | **Wilmington,** | **Delaware** | **19801** | **(833)** | **267-8382** |
| (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Registrant's Telephone Number, including area code) | (Registrant's Telephone Number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | CTVA | New York Stock Exchange |

---

Securities registered pursuant to Section 12(b) of the Act for EIDP, Inc.:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| $3.50 Series Preferred Stock | CTAPrA | New York Stock Exchange |
| $4.50 Series Preferred Stock | CTAPrB | New York Stock Exchange |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Corteva, Inc. Yes ⌧ No □ <br> EIDP, Inc. Yes ⌧ No □

&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Corteva, Inc. Yes ⌧ No □ <br> EIDP, Inc. Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Corteva, Inc. | Large Accelerated Filer | ⌧ | Accelerated Filer □ | Non-Accelerated Filer | □ | Smaller reporting company □ | Emerging growth company □ |
| EIDP, Inc. | Large Accelerated Filer | □ | Accelerated Filer □ | Non-Accelerated Filer | ⌧ | Smaller reporting company □ | Emerging growth company □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Corteva, Inc. □ <br> EIDP, Inc. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Corteva, Inc. Yes □ No ⌧ <br> EIDP, Inc. Yes □ No ⌧

Corteva, Inc. had 668,820,000 shares of common stock, par value $0.01 per share, outstanding at April 29, 2026.

EIDP, Inc. had 200 shares of common stock, par value $0.30 per share, outstanding at April 29, 2026, all of which are held by Corteva, Inc.&nbsp;&nbsp;&nbsp;&nbsp;

**EIDP, Inc. meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.**

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Corteva, Inc.**

**EIDP, Inc.**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **[Explanatory Note](#iac468d4684194d39b58ae26bdb6a0a0b_10)** | | |
| **[Part I](#iac468d4684194d39b58ae26bdb6a0a0b_13)** | **[Financial Information](#iac468d4684194d39b58ae26bdb6a0a0b_13)** | |
| &nbsp;&nbsp;[Item 1.](#iac468d4684194d39b58ae26bdb6a0a0b_16) | &nbsp;&nbsp;[Consolidated Financial Statements (Unaudited)](#iac468d4684194d39b58ae26bdb6a0a0b_16) | |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Operations](#iac468d4684194d39b58ae26bdb6a0a0b_19) | [3](#iac468d4684194d39b58ae26bdb6a0a0b_19) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Comprehensive Income (Loss)](#iac468d4684194d39b58ae26bdb6a0a0b_22) | [4](#iac468d4684194d39b58ae26bdb6a0a0b_22) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Balance Sheets](#iac468d4684194d39b58ae26bdb6a0a0b_25) | [5](#iac468d4684194d39b58ae26bdb6a0a0b_25) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Cash Flows](#iac468d4684194d39b58ae26bdb6a0a0b_31) | [6](#iac468d4684194d39b58ae26bdb6a0a0b_31) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Equity](#iac468d4684194d39b58ae26bdb6a0a0b_34) | [7](#iac468d4684194d39b58ae26bdb6a0a0b_34) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Notes to the Interim Consolidated Financial Statements (Unaudited)](#iac468d4684194d39b58ae26bdb6a0a0b_40) | [8](#iac468d4684194d39b58ae26bdb6a0a0b_40) |
| &nbsp;&nbsp;[Item 2.](#iac468d4684194d39b58ae26bdb6a0a0b_133) | &nbsp;&nbsp;[Management's Discussion and Analysis of Financial Condition and Results of Operations](#iac468d4684194d39b58ae26bdb6a0a0b_133) | [41](#iac468d4684194d39b58ae26bdb6a0a0b_133) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Cautionary Statements About Forward-Looking Statements](#iac468d4684194d39b58ae26bdb6a0a0b_136) | [41](#iac468d4684194d39b58ae26bdb6a0a0b_136) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Recent Developments](#iac468d4684194d39b58ae26bdb6a0a0b_139) | [42](#iac468d4684194d39b58ae26bdb6a0a0b_139) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Overview](#iac468d4684194d39b58ae26bdb6a0a0b_142) | [42](#iac468d4684194d39b58ae26bdb6a0a0b_142) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Results of Operations](#iac468d4684194d39b58ae26bdb6a0a0b_145) | [43](#iac468d4684194d39b58ae26bdb6a0a0b_145) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Recent Accounting Pronouncements](#iac468d4684194d39b58ae26bdb6a0a0b_151) | [45](#iac468d4684194d39b58ae26bdb6a0a0b_151) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Segment Reviews](#iac468d4684194d39b58ae26bdb6a0a0b_154) | [45](#iac468d4684194d39b58ae26bdb6a0a0b_154) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Non-GAAP Financial Measures](#iac468d4684194d39b58ae26bdb6a0a0b_157) | [47](#iac468d4684194d39b58ae26bdb6a0a0b_157) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Liquidity & Capital Resources](#iac468d4684194d39b58ae26bdb6a0a0b_160) | [49](#iac468d4684194d39b58ae26bdb6a0a0b_160) |
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Contractual Obligations](#iac468d4684194d39b58ae26bdb6a0a0b_166) | [52](#iac468d4684194d39b58ae26bdb6a0a0b_166) |
| &nbsp;&nbsp;[Item 3.](#iac468d4684194d39b58ae26bdb6a0a0b_169) | &nbsp;&nbsp;[Quantitative and Qualitative Disclosures About Market Risk](#iac468d4684194d39b58ae26bdb6a0a0b_169) | [52](#iac468d4684194d39b58ae26bdb6a0a0b_169) |
| &nbsp;&nbsp;[Item 4.](#iac468d4684194d39b58ae26bdb6a0a0b_172) | &nbsp;&nbsp;[Controls and Procedures](#iac468d4684194d39b58ae26bdb6a0a0b_172) | [53](#iac468d4684194d39b58ae26bdb6a0a0b_172) |
| **[Part II](#iac468d4684194d39b58ae26bdb6a0a0b_175)** | **[Other Information](#iac468d4684194d39b58ae26bdb6a0a0b_175)** | |
| &nbsp;&nbsp;[Item 1.](#iac468d4684194d39b58ae26bdb6a0a0b_178) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Legal Proceedings](#iac468d4684194d39b58ae26bdb6a0a0b_178) | [54](#iac468d4684194d39b58ae26bdb6a0a0b_178) |
| &nbsp;&nbsp;[Item 1A.](#iac468d4684194d39b58ae26bdb6a0a0b_181) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Risk Factors](#iac468d4684194d39b58ae26bdb6a0a0b_181) | [56](#iac468d4684194d39b58ae26bdb6a0a0b_181) |
| &nbsp;&nbsp;[Item 2](#iac468d4684194d39b58ae26bdb6a0a0b_184). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Unregistered Sales of Equity Securities and Use of Proceeds](#iac468d4684194d39b58ae26bdb6a0a0b_184) | [56](#iac468d4684194d39b58ae26bdb6a0a0b_184) |
| &nbsp;&nbsp;[Item 3](#iac468d4684194d39b58ae26bdb6a0a0b_187). | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Defaults Upon Senior Securities](#iac468d4684194d39b58ae26bdb6a0a0b_187) | [57](#iac468d4684194d39b58ae26bdb6a0a0b_187) |
| &nbsp;&nbsp;[Item 5.](#iac468d4684194d39b58ae26bdb6a0a0b_190) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Other Information](#iac468d4684194d39b58ae26bdb6a0a0b_190) | [57](#iac468d4684194d39b58ae26bdb6a0a0b_190) |
| &nbsp;&nbsp;[Item 6.](#iac468d4684194d39b58ae26bdb6a0a0b_193) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Exhibits](#iac468d4684194d39b58ae26bdb6a0a0b_193) | [58](#iac468d4684194d39b58ae26bdb6a0a0b_193) |
| **[Exhibit Index](#iac468d4684194d39b58ae26bdb6a0a0b_196)** | | [58](#iac468d4684194d39b58ae26bdb6a0a0b_196) |
| **[Signature](#iac468d4684194d39b58ae26bdb6a0a0b_199)** | | [59](#iac468d4684194d39b58ae26bdb6a0a0b_199) |
| **[Consolidated Financial Statements of EIDP, Inc. (Unaudited)](#iac468d4684194d39b58ae26bdb6a0a0b_205)** | **[Consolidated Financial Statements of EIDP, Inc. (Unaudited)](#iac468d4684194d39b58ae26bdb6a0a0b_205)** | [60](#iac468d4684194d39b58ae26bdb6a0a0b_205) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Explanatory Note**

Corteva, Inc. owns all of the common equity interests in EIDP, Inc. EIDP, Inc. is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Securities Exchange Act of 1934, as amended.

Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Corteva" or "the company" refers to Corteva, Inc. and its consolidated subsidiaries (including EIDP);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "EIDP" refers to EIDP, Inc. (formerly known as E. I. du Pont de Nemours and Company) and its consolidated subsidiaries or EIDP, Inc. excluding its consolidated subsidiaries, as the context may indicate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "DowDuPont" refers to DowDuPont Inc. and its subsidiaries prior to the Corteva Separation (defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Historical Dow" refers to The Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization (defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Historical DuPont" refers to EIDP prior to the Internal Reorganization (defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Internal Reorganizations" refers to the series of internal reorganization and realignment steps undertaken by Historical DuPont and Historical Dow to realign its business into three subgroups: agriculture, materials science and specialty products. Refer to the company's Annual Report on Form 10-K for the year ended December 31, 2025 for further information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Dow Distribution" refers to the separation of DowDuPont's materials science business into a separate and independent public company on April 1, 2019 by way of a distribution of Dow Inc. through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow Inc.'s common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Merger" refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont on August 31, 2017;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Dow" refers to Dow Inc. after the Dow Distribution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "DuPont" refers to DuPont de Nemours, Inc. after the Corteva Separation (on June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc.);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Separation" or "Corteva Separation" refers to June 1, 2019, when Corteva, Inc. became an independent, publicly

traded company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Corteva Distribution" refers to the pro rata distribution of all of the then-issued and outstanding shares of Corteva, Inc.'s common stock on June 1, 2019, which was then a wholly-owned subsidiary of DowDuPont, to holders of DowDuPont's common stock as of the close of business on May 24, 2019;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Distributions" refers to the Dow Distribution and the Corteva Distribution; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• "Letter Agreement" refers to the Letter Agreement executed by DuPont and Corteva on June 1, 2019, which sets forth certain additional terms and conditions related to the Corteva Separation, including certain limitations on each party's ability to transfer certain businesses and assets to third parties without assigning certain of such party's indemnification obligations under the Corteva Separation Agreement to the other party to the transferee of such businesses and assets or meeting certain other alternative conditions.

This Quarterly Report on Form 10-Q is a combined report being filed separately by Corteva, Inc. and EIDP, Inc.. The information in this Quarterly Report on Form 10-Q is equally applicable to Corteva, Inc. and EIDP, Inc., except where otherwise indicated.

The separate EIDP, Inc. financial statements and footnotes for areas that differ from Corteva, Inc., are included within this Quarterly Report on Form 10-Q. Footnotes of EIDP, Inc. that are identical to that of Corteva, Inc. are cross-referenced accordingly.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**PART I. FINANCIAL INFORMATION** 

**Item 1. CONSOLIDATED FINANCIAL STATEMENTS**

**Corteva, Inc.**

**Consolidated Statements of Operations (Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions, except per share amounts)* | **2026** | **2025** |
| Net sales | $4905 | $4417 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 2372 | 2342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense | 341 | 335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 877 | 751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 160 | 162 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 92 | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 52 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) - net | (117) | 15 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 36 | 36 |
| Income (loss) from continuing operations before income taxes | 858 | 784 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) income taxes on continuing operations | 133 | 117 |
| Income (loss) from continuing operations after income taxes | 725 | 667 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations after income taxes | (2) | (11) |
| Net income (loss) | 723 | 656 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to noncontrolling interests | 3 | 4 |
| Net income (loss) attributable to Corteva | $720 | $652 |
| Basic earnings (loss) per share of common stock: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share of common stock from continuing operations | $1.07 | $0.97 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share of common stock from discontinued operations |  | (0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share of common stock | $1.07 | $0.95 |
| Diluted earnings (loss) per share of common stock: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share of common stock from continuing operations | $1.07 | $0.97 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share of common stock from discontinued operations |  | (0.02) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share of common stock | $1.07 | $0.95 |

---

See Notes to the Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Corteva, Inc.**

**Consolidated Statements of Comprehensive Income (Loss) (Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Net income (loss) | $723 | $656 |
| Other comprehensive income (loss) - net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustments | (129) | 186 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to pension benefit plans | (4) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to other benefit plans | (3) | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on investments | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative instruments | (8) | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | (143) | 198 |
| Comprehensive income (loss) | 580 | 854 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income (loss) attributable to noncontrolling interests - net of tax | 3 | 4 |
| Comprehensive income (loss) attributable to Corteva | $577 | $850 |

---

&nbsp;&nbsp;&nbsp;&nbsp;

See Notes to the Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Corteva, Inc.**

**Consolidated Balance Sheets (Unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions, except share amounts)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| **Assets** |  |  |  |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $1964 | $4521 | $2008 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 2 | 9 | 1 |
| &nbsp;&nbsp;&nbsp;Accounts and notes receivable - net | 9088 | 6371 | 8294 |
| &nbsp;&nbsp;&nbsp;Inventories | 5202 | 5667 | 5132 |
| &nbsp;&nbsp;&nbsp;Other current assets | 1129 | 767 | 1152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 17385 | 17335 | 16587 |
| Investment in nonconsolidated affiliates | 165 | 160 | 136 |
| Property, plant and equipment | 9617 | 9551 | 9244 |
| Less: Accumulated depreciation | 5434 | 5331 | 5139 |
| Net property, plant and equipment | 4183 | 4220 | 4105 |
| Goodwill | 10409 | 10465 | 10332 |
| Other intangible assets | 8147 | 8301 | 8718 |
| Deferred income taxes | 395 | 320 | 413 |
| Other assets | 2033 | 2044 | 1832 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $42717 | $42845 | $42123 |
| **Liabilities and Equity** |  |  |  |
| Current liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;Short-term borrowings | $1674 | $894 | $2291 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 4187 | 4398 | 3905 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 229 | 155 | 322 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 2773 | 3579 | 2631 |
| &nbsp;&nbsp;&nbsp;Accrued and other current liabilities | 2991 | 3099 | 2332 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 11854 | 12125 | 11481 |
| Long-term debt | 1682 | 1686 | 1792 |
| Other noncurrent liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;Deferred income tax liabilities | 290 | 251 | 369 |
| &nbsp;&nbsp;&nbsp;Pension and other post-employment benefits | 2388 | 2434 | 2239 |
| &nbsp;&nbsp;&nbsp;Other noncurrent obligations | 1898 | 1963 | 1715 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total noncurrent liabilities | 6258 | 6334 | 6115 |
| Commitments and contingent liabilities |  |  |  |
| Stockholders' equity |  |  |  |
| Common stock, $0.01 par value; 1,666,667,000 shares authorized; issued at March 31, 2026 - 670,044,000; December 31, 2025 - 672,163,000; and March 31, 2025 - 683,026,000 | 7 | 7 | 7 |
| Additional paid-in capital | 26859 | 27001 | 26962 |
| Retained earnings (accumulated deficit) | 436 | (67) | 587 |
| Accumulated other comprehensive income (loss) | (2940) | (2797) | (3271) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Corteva stockholders' equity | 24362 | 24144 | 24285 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 243 | 242 | 242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 24605 | 24386 | 24527 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Equity | $42717 | $42845 | $42123 |

---

See Notes to the Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Corteva, Inc.**

**Consolidated Statements of Cash Flows (Unaudited)**

---

| | | |
|:---|:---|:---|
| *(In millions)* | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|  | **2026** | **2025** |
| **Operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $723 | $656 |
| &nbsp;&nbsp;&nbsp;(Income) loss from discontinued operations after income taxes | 2 | 11 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 297 | 296 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) deferred income tax | (52) | (122) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension and OPEB (benefit) cost, net | (3) | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and OPEB contributions | (48) | (51) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (gain) loss on sales of property, businesses, consolidated companies and investments | 3 | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 92 | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other net loss | 157 | 75 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable | (2810) | (2505) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 439 | 379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (221) | (190) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (790) | (667) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (674) | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - continuing operations | (2885) | (2101) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - discontinued operations | (6) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities | (2891) | (2109) |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (81) | (94) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of property, businesses and consolidated companies - net of cash divested |  | 8 |
| &nbsp;&nbsp;&nbsp;Investments in and loans to nonconsolidated affiliates | (3) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from sales and maturities of investments | 8 | 62 |
| &nbsp;&nbsp;&nbsp;Other investing activities, net | (1) | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) investing activities | (77) | (34) |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net change in borrowings (less than 90 days) | 521 | 745 |
| &nbsp;&nbsp;&nbsp;Proceeds from debt | 268 | 637 |
| &nbsp;&nbsp;&nbsp;Payments on debt | (22) | (14) |
| &nbsp;&nbsp;&nbsp;Repurchase of common stock | (250) | (270) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 17 | 35 |
| &nbsp;&nbsp;&nbsp;Dividends paid to stockholders | (121) | (116) |
| &nbsp;&nbsp;&nbsp;Other financing activities, net | (24) | (22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) financing activities | 389 | 995 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (5) | 21 |
| &nbsp;&nbsp;&nbsp;Increase (decrease) in cash, cash equivalents and restricted cash equivalents | (2584) | (1127) |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 4725 | 3422 |
| **Cash, cash equivalents and restricted cash equivalents at end of period** <sup>1</sup> | $2141 | $2295 |

---

1. See Note 5 - Supplementary Information, to the interim Consolidated Financial Statements, for reconciliation of cash and cash equivalents and restricted cash equivalents presented in the interim Consolidated Balance Sheets to total cash, cash equivalents and restricted cash equivalents presented in the interim Consolidated Statements of Cash Flows.

See Notes to the Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Corteva, Inc.**

**Consolidated Statements of Equity (Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(In millions, except per share amounts)* | *Common Stock* | *Additional Paid-in Capital* | *Retained Earnings (Accum. Deficit)* | *Accumulated Other Comp. Income (Loss)* | *Non-Controlling Interests* | *Total Equity* |
| **2026** |  |  |  |  |  |  |
| Balance at January 1, 2026 | $7 | $27001 | $(67) | $(2797) | $242 | $24386 |
| Net income (loss) |  |  | 720 |  | 3 | 723 |
| Other comprehensive income (loss) |  |  |  | (143) |  | (143) |
| Share-based compensation |  | (2) |  |  |  | (2) |
| Common dividends ($0.18 per share) |  | (121) |  |  |  | (121) |
| Issuance of Corteva stock |  | 17 |  |  |  | 17 |
| Repurchase of common stock |  | (36) | (214) |  |  | (250) |
| Other - net |  |  | (3) |  | (2) | (5) |
| Balance at March 31, 2026 | $7 | $26859 | $436 | $(2940) | $243 | $24605 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(In millions, except per share amounts)* | *Common Stock* | *Additional Paid-in Capital* | *Retained Earnings (Accum. Deficit)* | *Accumulated Other Comp. Income (Loss)* | *Non-Controlling Interests* | *Total Equity* |
| **2025** |  |  |  |  |  |  |
| Balance at January 1, 2025 | $7 | $27196 | $55 | $(3469) | $241 | $24030 |
| Net income (loss) |  |  | 652 |  | 4 | 656 |
| Other comprehensive income (loss) |  |  |  | 198 |  | 198 |
| Share-based compensation |  | (2) |  |  |  | (2) |
| Common dividends ($0.17 per share) |  | (116) |  |  |  | (116) |
| Issuance of Corteva stock |  | 35 |  |  |  | 35 |
| Repurchase of common stock |  | (150) | (120) |  |  | (270) |
| Other - net |  | (1) |  |  | (3) | (4) |
| Balance at March 31, 2025 | $7 | $26962 | $587 | $(3271) | $242 | $24527 |

---

See Notes to the Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

---

| |
|:---|
| **Corteva, Inc.** |
| **Notes to the Interim Consolidated Financial Statements (Unaudited)** |

---

**Table of Contents**

---

| | | |
|:---|:---|:---|
| **Note** | | **Page** |
| <u>[1](#iac468d4684194d39b58ae26bdb6a0a0b_43)</u> | [Summary of Significant Accounting Policies](#iac468d4684194d39b58ae26bdb6a0a0b_43) | [9](#iac468d4684194d39b58ae26bdb6a0a0b_43) |
| <u>[2](#iac468d4684194d39b58ae26bdb6a0a0b_46)</u> | [Recent Accounting Guidance](#iac468d4684194d39b58ae26bdb6a0a0b_46) | [9](#iac468d4684194d39b58ae26bdb6a0a0b_46) |
| <u>[3](#iac468d4684194d39b58ae26bdb6a0a0b_55)</u> | [Revenue](#iac468d4684194d39b58ae26bdb6a0a0b_55) | [9](#iac468d4684194d39b58ae26bdb6a0a0b_55) |
| <u>[4](#iac468d4684194d39b58ae26bdb6a0a0b_61)</u> | [Restructuring and Asset Related Charges - Net](#iac468d4684194d39b58ae26bdb6a0a0b_61) | [11](#iac468d4684194d39b58ae26bdb6a0a0b_61) |
| <u>[5](#iac468d4684194d39b58ae26bdb6a0a0b_64)</u> | [Supplementary Information](#iac468d4684194d39b58ae26bdb6a0a0b_64) | [13](#iac468d4684194d39b58ae26bdb6a0a0b_64) |
| <u>[6](#iac468d4684194d39b58ae26bdb6a0a0b_67)</u> | [Income Taxes](#iac468d4684194d39b58ae26bdb6a0a0b_67) | [14](#iac468d4684194d39b58ae26bdb6a0a0b_67) |
| <u>[7](#iac468d4684194d39b58ae26bdb6a0a0b_73)</u> | [Earnings Per Share of Common Stock](#iac468d4684194d39b58ae26bdb6a0a0b_73) | [15](#iac468d4684194d39b58ae26bdb6a0a0b_73) |
| <u>[8](#iac468d4684194d39b58ae26bdb6a0a0b_76)</u> | [Accounts and Notes Receivable - Net](#iac468d4684194d39b58ae26bdb6a0a0b_76) | [16](#iac468d4684194d39b58ae26bdb6a0a0b_76) |
| <u>[9](#iac468d4684194d39b58ae26bdb6a0a0b_79)</u> | [Inventories](#iac468d4684194d39b58ae26bdb6a0a0b_79) | [17](#iac468d4684194d39b58ae26bdb6a0a0b_79) |
| <u>[10](#iac468d4684194d39b58ae26bdb6a0a0b_82)</u> | [Other Intangible Assets](#iac468d4684194d39b58ae26bdb6a0a0b_82) | [17](#iac468d4684194d39b58ae26bdb6a0a0b_82) |
| <u>[11](#iac468d4684194d39b58ae26bdb6a0a0b_91)</u> | [Short-Term Borrowings, Long-Term Debt and Available Credit Facilities](#iac468d4684194d39b58ae26bdb6a0a0b_91) | [18](#iac468d4684194d39b58ae26bdb6a0a0b_91) |
| <u>[12](#iac468d4684194d39b58ae26bdb6a0a0b_97)</u> | [Commitments and Contingent Liabilities](#iac468d4684194d39b58ae26bdb6a0a0b_97) | [19](#iac468d4684194d39b58ae26bdb6a0a0b_97) |
| <u>[13](#iac468d4684194d39b58ae26bdb6a0a0b_103)</u> | [Stockholders' Equity](#iac468d4684194d39b58ae26bdb6a0a0b_103) | [30](#iac468d4684194d39b58ae26bdb6a0a0b_103) |
| <u>[14](#iac468d4684194d39b58ae26bdb6a0a0b_115)</u> | [Pension Plans and Other Post Employment Benefits](#iac468d4684194d39b58ae26bdb6a0a0b_115) | [32](#iac468d4684194d39b58ae26bdb6a0a0b_115) |
| <u>[15](#iac468d4684194d39b58ae26bdb6a0a0b_118)</u> | [Financial Instruments](#iac468d4684194d39b58ae26bdb6a0a0b_118) | [33](#iac468d4684194d39b58ae26bdb6a0a0b_118) |
| <u>[16](#iac468d4684194d39b58ae26bdb6a0a0b_121)</u> | [Fair Value Measurements](#iac468d4684194d39b58ae26bdb6a0a0b_121) | [38](#iac468d4684194d39b58ae26bdb6a0a0b_121) |
| <u>[17](#iac468d4684194d39b58ae26bdb6a0a0b_124)</u> | [Segment Information](#iac468d4684194d39b58ae26bdb6a0a0b_124) | [38](#iac468d4684194d39b58ae26bdb6a0a0b_124) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in the company's Annual Report on Form 10-K for the year ended December 31, 2025, collectively referred to as the "2025 Annual Report." The interim Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained. The interim Consolidated Financial Statements and other financial information included in this Form 10-Q, unless otherwise specified, have been presented to separately show the effects of discontinued operations.

Since 2018, Argentina has been considered a highly-inflationary economy under U.S. GAAP and therefore the U.S. Dollar ("USD") is the functional currency for our related subsidiaries. Argentina contributes approximately 3 percent to the company's annual net sales and approximately 1 percent to each of the company's annual Seed and Crop Protection segment operating EBITDA. The company remeasures net monetary assets utilizing the official Argentine Peso ("Peso") to USD exchange rate. The ability to draw down Peso cash balances is limited at this time due to government restrictions and market availability of U.S. Dollars. The devaluation of the Peso relative to the USD over the last several years has resulted in the recognition of exchange losses (refer to Note 5 – Supplementary Information, to the interim Consolidated Financial Statements, and Note 6 – Supplementary Information, to the Consolidated Financial Statements, in the company's 2025 Annual Report). The Argentina government has offered USD-denominated bonds to importers, the proceeds from which can be used to pay off outstanding intercompany payables. As of March 31, 2026, the company holds these foreign government bonds with an amortized cost of $25 million as part of its strategy to manage its net monetary asset exposure in Argentina. Refer to the "Debt Securities" section in Note 15 – Financial Instruments, to the interim Consolidated Financial Statements, for additional information. As of March 31, 2026, a further 10 percent deterioration in the official Peso to USD exchange rate would not have a significant impact on the USD value of our net monetary assets or pre-tax earnings. The company will continue to assess the implications to our operations and financial reporting.

**NOTE 2 - RECENT ACCOUNTING GUIDANCE**

**Accounting Guidance Issued But Not Adopted as of March 31, 2026**

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU includes amendments that require entities to bifurcate specified expense line items on the income statement into underlying components, including purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion, as applicable. Qualitative descriptions of the remaining components are required. These enhanced disclosures are required for both interim and annual periods. Selling expenses must also be separately disclosed for both interim and annual periods, along with an annual qualitative description of the composition of selling expenses. In January 2025, the FASB subsequently issued ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, to provide clarification on the ASU's effective date. The new standard is effective for fiscal years beginning after December 15, 2026 on a prospective basis with the option to apply it retrospectively, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The adoption of this guidance will result in the company being required to include enhanced disclosures around income statement expenses.

**NOTE 3 - REVENUE**

**Remaining Performance Obligations**

Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. The company applies the practical expedient to disclose the transaction price allocated to the remaining performance obligations for only those contracts with an original duration of more than one year. The transaction price allocated to remaining performance obligations with an original duration of more than one year related to material rights granted to customers for contract renewal options were $147 million, $150 million and $135 million at March 31, 2026, December 31, 2025 and March 31, 2025, respectively. The company expects revenue to be recognized for the remaining performance obligations evenly over a period of six years.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**Contract Balances**

Contract liabilities primarily reflect deferred revenue from prepayments under contracts with customers where the company receives advance payments for products to be delivered in future periods. Corteva classifies deferred revenue as current or noncurrent based on the timing of when the company expects to recognize revenue. Contract assets primarily include amounts related to conditional rights to consideration for completed performance not yet invoiced. Accounts receivable are recorded when the right to consideration becomes unconditional.

---

| | | | |
|:---|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| **Contract Balances**<br>*(In millions)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Contract assets - current <sup>1</sup> | $34 | $34 | $30 |
| Contract assets - noncurrent <sup>2</sup> | $82 | $83 | $73 |
| Deferred revenue - current | $2773 | $3579 | $2631 |
| Deferred revenue - noncurrent <sup>3</sup> | $113 | $125 | $111 |

---

1. Included in other current assets in the interim Consolidated Balance Sheets.

2. Included in other assets in the interim Consolidated Balance Sheets.

3. Included in other noncurrent obligations in the interim Consolidated Balance Sheets.

Revenue recognized during the three months ended March 31, 2026 and 2025 from amounts included in deferred revenue at the beginning of the period was $1,268 million and $1,174 million, respectively.

**Disaggregation of Revenue**

Corteva's operations are classified into two operating segments: Seed and Crop Protection. The company disaggregates its revenue by major product line and geographic region, as the company believes it best depicts the nature, amount and timing of its revenue and cash flows. Net sales by major product line are included below:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;Corn | $2373 | $2069 |
| &nbsp;&nbsp;&nbsp;&nbsp;Soybean | 306 | 305 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other oilseeds | 245 | 223 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 99 | 110 |
| Seed | 3023 | 2707 |
| &nbsp;&nbsp;&nbsp;&nbsp;Herbicides | 1027 | 860 |
| &nbsp;&nbsp;&nbsp;&nbsp;Insecticides | 377 | 336 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fungicides | 334 | 304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Biologicals | 70 | 84 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 74 | 126 |
| Crop Protection | 1882 | 1710 |
| **Total** | $4905 | $4417 |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

Sales are attributed to geographic regions based on customer location. Net sales by geographic region and segment are included below:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
| **Seed**<br>*(In millions)* | **2026** | **2025** |
| North America <sup>1</sup> | $1770 | $1597 |
| EMEA <sup>2</sup> | 928 | 826 |
| Latin America | 224 | 185 |
| Asia Pacific | 101 | 99 |
| **Total** | $3023 | $2707 |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
| **Crop Protection**<br>*(In millions)* | **2026** | **2025** |
| North America <sup>1</sup> | $669 | $613 |
| EMEA <sup>2</sup> | 727 | 651 |
| Latin America | 282 | 257 |
| Asia Pacific | 204 | 189 |
| **Total** | $1882 | $1710 |

---

1. Represents U.S. and Canada.

2. Europe, Middle East and Africa ("EMEA").

**NOTE 4 - RESTRUCTURING AND ASSET RELATED CHARGES - NET** 

**2026 Restructuring Actions**

On March 15, 2026, management of the company approved a restructuring program designed to align the company's organizational structure and geographic footprint with the operational needs of each function as the company prepares for the intended separation of its businesses (the "2026 Restructuring Actions"). The restructuring actions primarily consist of workforce reductions across commercial and functional support areas and are intended to right-size the organization and support the future standalone operating models. The restructuring actions are expected to be substantially complete by December 2026.

The company expects to incur aggregate pre-tax restructuring and asset related charges of approximately $70 million to $80 million in connection with the 2026 Restructuring Actions, consisting solely of severance and related benefit costs. Reductions in workforce are subject to local regulatory requirements. For the three months ended March 31, 2026, the company recorded pre-tax restructuring and asset related charges of $78 million, which consist entirely of severance and related benefit costs and are classified as corporate-related charges. At March 31, 2026, the restructuring liability was $78 million.

Cash payments related to the 2026 Restructuring Actions are expected to total approximately $70 million to $80 million. Through March 31, 2026, the company has made no payments related to these restructuring actions; however, cash payments are expected to be paid over the course of the next year, with substantially all payments anticipated to occur during 2026. The company does not anticipate material revisions to the estimated costs or timing of payments related to the 2026 Restructuring Actions.

**Crop Protection Operations Strategy Restructuring Program**

On November 5, 2023, management of the company approved a plan to further optimize its Crop Protection network of manufacturing and external partners (the "Crop Protection Operations Strategy Restructuring Program"). The plan includes the exit of the company's production activities at its site in Pittsburg, California, as well as ceasing operations in select manufacturing lines at other locations. In October 2024, management of the company amended the Crop Protection Operations Strategy Restructuring Program to include updates to its previous estimates and decommissioning and demolition costs associated with the ceasing of operations, primarily at the Pittsburg, California site.

The company expects to record aggregate pre-tax restructuring and asset related charges of $650 million to $700 million, comprised of $85 million to $105 million of severance and related benefit costs, $320 million to $340 million of asset related and impairment charges and $245 million to $255 million of costs related to exiting the company's production activities and

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

ceasing operations (inclusive of contract terminations and decommissioning and demolition costs). Decommissioning and demolition costs are expensed on an as-incurred basis. Reductions in workforce are subject to local regulatory requirements. Through the first quarter of 2026, the company recorded net pre-tax restructuring and asset related charges of $625 million inception-to-date under the Crop Protection Operations Strategy Restructuring Program, consisting of $102 million of severance and related benefit costs, $340 million of asset related and impairment charges, $82 million of decommissioning and demolition costs, and $101 million of costs related to contract terminations.

Cash payments related to these charges are anticipated to be $330 million to $360 million, which primarily relate to the payment of severance and related benefits, decommissioning and demolition costs and contract terminations. Through the first quarter of 2026, the company paid $228 million associated with these charges. The restructuring actions associated with these charges are expected to be substantially complete by the end of 2026.

The following table is a summary of charges incurred related to the Crop Protection Operations Strategy Restructuring Program for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
| *(In millions)* | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
| *(In millions)* | **2026** | **2025** |
| Severance and related benefit costs <sup>1</sup> | $— | $9 |
| Asset related charges <sup>2</sup> |  | 12 |
| Decommissioning and demolition costs <sup>2</sup> | 12 | 5 |
| Contract termination charges <sup>2</sup> | 2 |  |
| Total restructuring and asset related charges - net | $14 | $26 |

---

1. Reflects corporate-related charges.

2. Reflects charges which are substantially all associated with the Crop Protection segment.

The following table summarizes changes to liability balances related to the Crop Protection Operations Strategy Restructuring Program for the quarter ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In millions)* | *Severance and Related Benefit Costs* | *Decommissioning and Demolition Costs* | *Contract Termination Charges* | *Total* |
| Balance at December 31, 2025 | $32 | $8 | $54 | $94 |
| Charges to income from continuing operations |  | 12 | 2 | 14 |
| Payments | (6) | (13) | (32) | (51) |
| Balance at March 31, 2026 | $26 | $7 | $24 | $57 |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 5 - SUPPLEMENTARY INFORMATION**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
| **Other Income (Expense) - Net**<br>*(In millions)* | **2026** | **2025** |
| Interest income | $34 | $32 |
| Equity in earnings (losses) of affiliates - net | 16 | 11 |
| Net gain (loss) on sales of businesses and other assets | (3) | 4 |
| Net exchange gains (losses) <sup>1</sup> | (67) | (27) |
| Non-operating pension and other post employment benefit credits (costs) <sup>2</sup> | 7 | (6) |
| Miscellaneous income (expenses) - net <sup>3</sup> | (104) | 1 |
| Other income (expense) - net | $(117) | $15 |

---

1. Includes net pre-tax exchange gains (losses) of $4 million and $— million associated with impacts from the devaluation of the Argentine Peso for the three months ended March 31, 2026 and 2025, respectively.

2. Includes non-service related components of net periodic benefit credits (costs), comprised of interest cost, expected return on plan assets, amortization of unrecognized gain (loss), amortization of prior service benefit and settlement gain (loss).

3. The three months ended March 31, 2026 includes a settlement charge associated with the Crop Protection loyalty program multi-district litigation plaintiffs and tax expense related to intellectual property realignment. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information related to the litigation matter. The three months ended March 31, 2025 includes miscellaneous immaterial items.

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results of operations. The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the U.S., whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income (expense) - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the interim Consolidated Statements of Operations.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| **Subsidiary Monetary Position Gain (Loss)** |  |  |
| Pre-tax exchange gain (loss) | $85 | $(47) |
| Local tax (expenses) benefits | (24) | (1) |
| Net after-tax impact from subsidiary exchange gain (loss) | $61 | $(48) |
| **Hedging Program Gain (Loss)** |  |  |
| Pre-tax exchange gain (loss) | $(152) | $20 |
| Tax (expenses) benefits | 34 | (2) |
| Net after-tax impact from hedging program exchange gain (loss) | $(118) | $18 |
| **Total Exchange Gain (Loss)** |  |  |
| Pre-tax exchange gain (loss) | $(67) | $(27) |
| Tax (expenses) benefits | 10 | (3) |
| Net after-tax exchange gain (loss) | $(57) | $(30) |

---

**Cash, cash equivalents and restricted cash equivalents** 

The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents presented in the interim Consolidated Balance Sheets to the total cash, cash equivalents and restricted cash equivalents presented in the interim Consolidated Statements of Cash Flows. Corteva classifies restricted cash equivalents as current or noncurrent based on the nature of the restrictions, and includes them within other current assets and other assets, respectively, in the interim Consolidated Balance Sheets.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Cash and cash equivalents | $1964 | $4521 | $2008 |
| Restricted cash equivalents | 177 | 204 | 287 |
| Total cash, cash equivalents and restricted cash equivalents | $2141 | $4725 | $2295 |

---

Restricted cash equivalents primarily relates to a trust funded by EIDP for cash obligations under certain non-qualified benefit and deferred compensation plans due to the Merger, which was a change in control event, and contributions to escrow accounts established for the settlement of certain legal matters and the settlement of legacy PFAS matters and the associated qualified spend. All of the company's restricted cash equivalents are classified as current as of March 31, 2026, December 31, 2025 and March 31, 2025, except for the $15 million MOU Escrow Account balance at March 31, 2025. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information.

**Accounts payable** 

At March 31, 2026, December 31, 2025 and March 31, 2025, accounts payable was $4,187 million, $4,398 million and $3,905 million, respectively, which includes accounts payable - trade of $2,066 million, $2,871 million, and $2,000 million, respectively. Included in accounts payable – trade was seed grower compensation of approximately $120 million, $420 million, and $145 million at March 31, 2026, December 31, 2025 and March 31, 2025, respectively, which is measured at fair value using Level 2 inputs for each period presented.

**NOTE 6 - INCOME TAXES** 

The effective tax rate for the three months ended March 31, 2026 and 2025 was 15.5 percent and 14.9 percent, respectively.

During the three months ended March 31, 2026 and 2025, the company recognized $51 million and $27 million, respectively, of net tax benefits for income taxes on continuing operations associated with changes in deferred taxes and accruals for certain prior year tax positions in various jurisdictions as well as from stock-based compensation. During the three months ended March 31, 2026, the company recognized a $35 million tax benefit related to intellectual property realignment. During the three months ended March 31, 2025, the company recognized a $55 million deferred tax benefit associated with a change in a legal entity's U.S. tax characterization.

The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of the program, which resides in the U.S., is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions, which can drive material impacts on the company's effective tax rate. For further discussion of pre-tax and after-tax impacts of the company's foreign currency hedging program and net monetary asset programs, refer to Note 5 - Supplementary Information, to the interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 7 - EARNINGS PER SHARE OF COMMON STOCK**

The following tables provide earnings per share calculations for the periods indicated below:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Net Income (Loss) for Earnings (Loss) Per Share Calculations - Basic and Diluted**<br>*(In millions)* | **2026** | **2025** |
| Income (loss) from continuing operations after income taxes | $725 | $667 |
| Net income (loss) attributable to continuing operations noncontrolling interests | 3 | 4 |
| Income (loss) from continuing operations available to Corteva common stockholders | 722 | 663 |
| Income (loss) from discontinued operations available to Corteva common stockholders | (2) | (11) |
| Net income (loss) available to common stockholders | $720 | $652 |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Earnings (Loss) Per Share Calculations - Basic**<br>*(Dollars per share)* | **2026** | **2025** |
| Earnings (loss) per share of common stock from continuing operations | $1.07 | $0.97 |
| Earnings (loss) per share of common stock from discontinued operations |  | (0.02) |
| Earnings (loss) per share of common stock | $1.07 | $0.95 |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Earnings (Loss) Per Share Calculations - Diluted**<br>*(Dollars per share)* | **2026** | **2025** |
| Earnings (loss) per share of common stock from continuing operations | $1.07 | $0.97 |
| Earnings (loss) per share of common stock from discontinued operations |  | (0.02) |
| Earnings (loss) per share of common stock | $1.07 | $0.95 |

---

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Share Count Information**<br>*(Shares in millions)* | **2026** | **2025** |
| Weighted-average common shares - basic | 672.5 | 684.9 |
| Plus: dilutive effect of equity compensation plans <sup>1</sup> | 1.1 | 1.7 |
| Weighted-average common shares - diluted | 673.6 | 686.6 |
| Potential shares of common stock excluded from EPS calculations <sup>2</sup> | 2.6 | 3.1 |

---

1. Diluted earnings (loss) per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

2. These outstanding potential shares of common stock relating to stock options, restricted stock units and performance-based restricted stock units were excluded from the calculation of diluted earnings (loss) per share because (i) the effect of including them would have been anti-dilutive; or (ii) the performance metrics have not yet been achieved for the outstanding potential shares relating to performance-based restricted stock units, which are deemed to be contingently issuable.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 8 - ACCOUNTS AND NOTES RECEIVABLE - NET**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Accounts receivable – trade <sup>1</sup> | $7262 | $4881 | $6765 |
| Notes receivable – trade <sup>1,2</sup> | 497 | 153 | 486 |
| Other <sup>3</sup> | 1329 | 1337 | 1043 |
| Total accounts and notes receivable - net | $9088 | $6371 | $8294 |

---

1. Accounts and notes receivable – trade are net of allowances of $286 million, $241 million and $190 million at March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

2. Notes receivable – trade primarily consists of receivables for deferred payment loan programs for the sale of seed and crop protection products to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid approval process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of March 31, 2026, December 31, 2025 and March 31, 2025, there were no significant impairments related to current loan agreements.

3. Other includes receivables in relation to indemnification assets, royalties, value added tax, general sales tax and other taxes. No individual group represents more than 5 percent of total current assets. In addition, Other includes amounts due from nonconsolidated affiliates of $111 million, $117 million and $130 million as of March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

Accounts and notes receivable are carried at the expected amount to be collected, which approximates fair value. The company establishes the allowance for doubtful receivables using a loss-rate method where the loss rate is developed using past events, historical experience, current conditions and forecasts that affect the collectability of the financial assets.

The following table summarizes changes in the allowance for doubtful receivables for the three months ended March 31, 2025 and 2026:

---

| | |
|:---|:---|
| *(In millions)* | *(In millions)* |
| **2025** |  |
| Balance at December 31, 2024 | $179 |
| Net provision for credit losses | 21 |
| Other - net of write-offs charged against allowance | (10) |
| Balance at March 31, 2025 | $190 |
| **2026** |  |
| Balance at December 31, 2025 | $241 |
| Net provision for credit losses | 49 |
| Other - net of write-offs charged against allowance | (4) |
| Balance at March 31, 2026 | $286 |

---

The company enters into various factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds. These financing arrangements result in a transfer of the company's receivables and risks to the third party. As these transfers qualify as true sales under the applicable accounting guidance, the receivables are derecognized from the interim Consolidated Balance Sheets upon transfer, and the company receives a payment for the receivables from the third party within a mutually agreed upon time period. For arrangements involving an element of recourse, which is typically provided through a guarantee of accounts in the event of customer default, the guarantee obligation is measured using market data from similar transactions and reported as a current liability in the interim Consolidated Balance Sheets.

Trade receivables sold under these agreements were $27 million and $26 million for the three months ended March 31, 2026 and 2025, respectively. The trade receivables sold that remained outstanding under these agreements which include an element of recourse as of March 31, 2026, December 31, 2025 and March 31, 2025 were $6 million, $17 million and $16 million, respectively. The net proceeds received are included in cash provided by (used for) operating activities in the interim Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in other income (expense) - net, in the interim Consolidated Statements of Operations. The loss on sale of receivables for the three months ended March 31, 2026 and 2025 was not material. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information on the company's guarantees.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 9 - INVENTORIES**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Finished products | $3044 | $2956 | $2827 |
| Semi-finished products | 1749 | 2276 | 1881 |
| Raw materials and supplies | 409 | 435 | 424 |
| Total inventories | $5202 | $5667 | $5132 |

---

**NOTE 10 - OTHER INTANGIBLE ASSETS** 

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
|<br>*(In millions)* | **Gross** | **Accumulated<br>Amortization** | **Net** | **Gross** | **Accumulated<br>Amortization** | **Net** | **Gross** | **Accumulated<br>Amortization** | **Net** |
| **Intangible assets subject to amortization (finite-lived):** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Germplasm | $6291 | $(1649) | $4642 | $6291 | $(1587) | $4704 | $6291 | $(1399) | $4892 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer-related | 2398 | (1059) | 1339 | 2394 | (1024) | 1370 | 2349 | (896) | 1453 |
| &nbsp;&nbsp;&nbsp;&nbsp;Developed technology | 1854 | (1313) | 541 | 1860 | (1283) | 577 | 1838 | (1197) | 641 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks/trade names | 2056 | (488) | 1568 | 2056 | (466) | 1590 | 2056 | (402) | 1654 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other <sup>1</sup> | 368 | (316) | 52 | 368 | (313) | 55 | 388 | (315) | 73 |
| &nbsp;&nbsp;&nbsp;Total other intangible assets with finite lives | 12967 | (4825) | 8142 | 12969 | (4673) | 8296 | 12922 | (4209) | 8713 |
| **Intangible assets not subject to amortization (indefinite-lived):** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;In-process research and development | 5 |  | 5 | 5 |  | 5 | 5 |  | 5 |
| &nbsp;&nbsp;&nbsp;Total other intangible assets with indefinite lives | 5 |  | 5 | 5 |  | 5 | 5 |  | 5 |
| **Total other intangible assets** | $12972 | $(4825) | $8147 | $12974 | $(4673) | $8301 | $12927 | $(4209) | $8718 |

---

1. Primarily consists of sales and farmer networks, marketing and manufacturing alliances and noncompetition agreements.

The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $160 million and $162 million for the three months ended March 31, 2026 and 2025, respectively. The current estimated aggregate pre-tax amortization expense from continuing operations for the remainder of 2026 and each of the next five years is approximately $478 million, $577 million, $555 million, $532 million, $522 million and $522 million, respectively.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 11 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES**

The following tables summarize Corteva's short-term borrowings and long-term debt:

---

| | | | |
|:---|:---|:---|:---|
| **Short-term borrowings** | **Short-term borrowings** | **Short-term borrowings** | **Short-term borrowings** |
| *(In millions)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Commercial paper | $667 | $— | $1357 |
| 364-Day Revolving Credit Facility |  |  |  |
| Other loans - various currencies | 216 | 112 | 261 |
| Long-term debt payable within one year | 791 | 782 | 673 |
| Total short-term borrowings | $1674 | $894 | $2291 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Long-term debt** | | | | | | |
| *(In millions)* | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| *(In millions)* | *Amount* | *Weighted Average Rate* | *Amount* | *Weighted Average Rate* | *Amount* | *Weighted Average Rate* |
| Promissory notes and debentures: |  |  |  |  |  |  |
| &nbsp;&nbsp;Maturing in July 2025 | $— |  | $— |  | $500 | 1.70% |
| &nbsp;&nbsp;Maturing in May 2026 | 600 | 4.50% | 600 | 4.50% | 600 | 4.50% |
| &nbsp;&nbsp;Maturing in July 2030 | 500 | 2.30% | 500 | 2.30% | 500 | 2.30% |
| &nbsp;&nbsp;Maturing in May 2032 | 500 | 5.125% | 500 | 5.125% |  |  |
| &nbsp;&nbsp;Maturing in May 2033 | 600 | 4.80% | 600 | 4.80% | 600 | 4.80% |
| Other loans: |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign currency loans | 191 | 15.65% | 182 | 12.70% | 173 | 12.70% |
| &nbsp;&nbsp;Medium-term notes, varying maturities through 2041 | 97 | 3.63% | 102 | 3.76% | 104 | 4.27% |
| Less: Unamortized debt discount and issuance costs | 15 |  | 16 |  | 12 |  |
| Less: Long-term debt due within one year | 791 |  | 782 |  | 673 |  |
| Total long-term debt | $1682 |  | $1686 |  | $1792 |  |

---

The estimated fair value of the company's short-term and long-term borrowings, including interest rate financial instruments, was determined using Level 2 inputs within the fair value hierarchy. Based on quoted market prices for the same or similar issuances, or on current rates offered to the company for debt of the same remaining maturities, the fair value of the company's short-term borrowings approximated carrying value.

The fair value of the company's long-term borrowings, including debt due within one year, was $2,448 million, $2,462 million and $2,404 million as of March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

*Debt Offering*

In May 2025, the company issued $500 million of 5.125 percent Senior Notes due in May 2032 (the "May 2025 Debt Offering"). The proceeds were used to repay the $500 million senior notes that matured in July 2025.

*Foreign Currency Loans*

The company enters into short-term and long-term foreign currency loans from time-to-time by accessing uncommitted revolving credit lines to fund working capital needs of foreign subsidiaries in the normal course of business. Interest rates are variable and determined at the time of borrowing. Total unused bank credit lines on the short-term and long-term foreign currency loans at March 31, 2026 was approximately $69 million. The company's short-term foreign currency loans have varying maturities through 2026. During the first quarter of 2026, the company's long-term foreign currency loans were amended to extend the maturity date to May 2026, which resulted in a corresponding change in the interest rate.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**Available Committed Credit Facilities**

The following table summarizes the company's credit facilities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Committed and available credit facilities at March 31, 2026** | **Committed and available credit facilities at March 31, 2026** | **Committed and available credit facilities at March 31, 2026** | **Committed and available credit facilities at March 31, 2026** | **Committed and available credit facilities at March 31, 2026** | **Committed and available credit facilities at March 31, 2026** |
| *(In millions)* | *Effective Date* | *Committed Credit* | *Credit Available* | *Maturity Date* | *Interest* |
| Revolving Credit Facility | June 2024 | $2850 | $2850 | June 2029 | Floating Rate |
| Revolving Credit Facility | June 2024 | 1900 | 1900 | June 2027 | Floating Rate |
| 364-Day Revolving Credit Facility | February 2026 | 1250 | 1250 | February 2027 | Floating Rate |
| Total committed and available credit facilities |  | $6000 | $6000 |  |  |

---

*Revolving Credit Facilities*

In May 2022, the company entered into a $3 billion, five-year revolving credit facility and a $2 billion, three-year revolving credit facility (the "Revolving Credit Facilities") expiring in May 2027 and May 2025, respectively. Borrowings under the Revolving Credit Facilities will have an interest rate equal to Adjusted Term SOFR, which is Term SOFR plus 0.10 percent, plus the applicable margin. In June 2024, the Revolving Credit Facilities were refinanced for purposes of extending the maturity dates for the five-year and three-year revolving credit facilities to June 2029 and June 2027, respectively, and lowering the facility amount of the five-year revolving credit facility to $2.85 billion and the three-year revolving credit facility to $1.90 billion. The Revolving Credit Facilities may serve as a substitute to the company's commercial paper program, and can be used, from time to time, for general corporate purposes including, but not limited to, the funding of seasonal working capital needs. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the Revolving Credit Facilities contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At March 31, 2026, the company was in compliance with these covenants.

*364-Day Revolving Credit Facility*

In February 2026, the company amended its January 2023 (as amended in July 2023, January 2024, February 2024 and February 2025) 364-day revolving credit agreement (the "364-Day Revolving Credit Facility"), increasing the facility amount from $750 million to $1.25 billion, extending the expiration date to February 2027 and amending the interest rate to Term SOFR plus the applicable margin. In February 2025, the company amended the 364-Day Revolving Credit Facility, decreasing the facility amount from $1 billion to $750 million and extending the expiration date to February 2026. The 364-Day Revolving Credit Facility includes a provision under which the company may convert any advances outstanding prior to the maturity date into term loans having a maturity date up to one year later. The 364-Day Revolving Credit Facility contains customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the 364-Day Revolving Credit Facility contains a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At March 31, 2026, the company was in compliance with these covenants.

**NOTE 12 - COMMITMENTS AND CONTINGENT LIABILITIES** 

**Guarantees**

*Indemnifications*

In connection with acquisitions and divestitures, the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited. See below for additional information relating to the indemnification obligations under the Chemours Separation Agreement and the Corteva Separation Agreement.

*Obligations for Supplier Finance Programs*

The company enters into supplier finance programs with various finance providers in which the company agrees to pay these finance providers the stated amount of confirmed invoices from participating suppliers by the original maturity date. The company or the finance provider may terminate the agreement upon providing, in most cases, at least thirty days' written notice. The payment terms that the company has with its finance providers under supplier finance programs are less than one year. At March 31, 2026, December 31, 2025 and March 31, 2025, the outstanding obligations under supplier finance programs was

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

$146 million, $121 million and $163 million, respectively, and included within accounts payable in the interim Consolidated Balance Sheets.

The rollforward of the company's outstanding obligations confirmed as valid under its supplier finance programs for the period ended March 31, 2026 is as follows:

---

| | |
|:---|:---|
| *(In millions)* |  |
| Confirmed obligations outstanding at December 31, 2025 | $121 |
| Invoices confirmed during the period | 176 |
| Confirmed invoices paid during the period | (151) |
| Confirmed obligations outstanding at March 31, 2026 | $146 |

---

*Obligations for Customers and Other Third Parties*

The company has directly guaranteed various debt obligations under agreements with third parties related to customers and other third parties. At March 31, 2026, December 31, 2025 and March 31, 2025, the company had directly guaranteed $78 million, $71 million and $73 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees in the event of default by the guaranteed party. The maximum future payments include $4 million, $5 million and $7 million at March 31, 2026, December 31, 2025 and March 31, 2025, respectively, of guarantees related to the various factoring agreements into which the company enters with third-party financial institutions to sell its trade receivables. See Note 8 - Accounts and Notes Receivable - Net, to the interim Consolidated Financial Statements, for additional information.

The maximum future payments also include agreements with lenders to establish programs that provide financing for select customers. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. The total amounts owed from customers to the lenders relating to these agreements was $138 million, $234 million and $130 million at March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

*Indemnifications under Separation Agreements*

The company has entered into various agreements where the company is indemnified for certain liabilities. The term of this indemnification is generally indefinite, with exceptions, and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable.

<u>Chemours Separation Agreement (Performance Chemicals)</u>

Pursuant to the Chemours Separation Agreement resulting from the 2015 spin-off of the Performance Chemicals segment from Historical DuPont, The Chemours Company ("Chemours") indemnifies the company against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the distribution. In 2017, the Chemours Separation Agreement was amended to provide for a limited sharing of potential future liabilities related to alleged historical releases of perfluorooctanoic acids and its ammonium salts ("PFOA") for a five-year period that began on July 6, 2017. Additionally, in January 2021, a binding memorandum of understanding as described below replaced the potential future liability sharing arrangements established in the 2017 amendment to the Chemours Separation Agreement. At March 31, 2026, December 31, 2025 and March 31, 2025, the indemnification assets from Chemours were $135 million, $138 million, and $40 million, respectively, within accounts and notes receivable - net and $470 million, $470 million and $301 million, respectively, within other assets in the interim Consolidated Balance Sheets. These indemnification assets are regularly assessed for collectability and the company has concluded that these assets are recoverable. The liabilities subject to Chemours indemnification are considered stray liabilities under the Corteva Separation Agreement. Therefore, if Chemours fails to indemnify the company, these stray liabilities are subject to proportionate cost sharing between Corteva and DuPont, on a 29 percent and 71 percent basis, respectively, as further described in this footnote below.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against DuPont, EIDP, and Corteva, seeking, among other things, to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement (the "Delaware Litigation"). On March 30, 2020, the Court of Chancery granted a

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

motion to dismiss. On December 15, 2020, the Delaware Supreme Court affirmed the judgment of the Court of Chancery. Meanwhile, a confidential arbitration process regarding the same and other claims proceeded (the "Arbitration").

On January 22, 2021, Chemours, DuPont, Corteva and EIDP entered into a binding memorandum of understanding resolving legal disputes originating from the Delaware Litigation and Arbitration, and establishing a cost sharing arrangement and escrow account supporting and managing potential future legacy per- and polyfluoroalkyl substances ("PFAS") liabilities arising out of pre-July 1, 2015 conduct (the "MOU"). The MOU replaced a prior 2017 amendment to the Chemours Separation Agreement. According to the terms of the MOU, Corteva and DuPont together, on one hand, and Chemours, on the other hand, agreed to a 50-50 split of certain qualified expenses related to PFAS liabilities incurred over a term not to exceed twenty years or $4 billion of qualified spend and escrow account contributions (see below for discussion of the escrow account) in the aggregate. DuPont's and Corteva's 50 percent share under the MOU will be limited to $2 billion, including qualified expenses and escrow account contributions. These expenses and escrow account contributions will be subject to the existing Letter Agreement, under which DuPont and Corteva will each bear 50 percent of the first $300 million (up to $150 million each), and thereafter DuPont bears 71 percent and Corteva bears the remaining 29 percent. Under the terms of the MOU, Corteva's estimated aggregate share of the potential $2 billion is approximately $600 million.

In order to support and manage any potential future PFAS liabilities, the parties also agreed to establish an escrow account ("MOU Escrow Account"). The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Over this period, Chemours will deposit a total of $500 million in the account and DuPont and Corteva will deposit an additional $500 million pursuant to the terms of the Letter Agreement. Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50 percent of the deposits and DuPont and Corteva together will make 50 percent of the deposits necessary to restore the balance of the escrow account to $700 million, pursuant to the terms of the Letter Agreement. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029, pursuant to the escrow account replenishment terms as set forth in the MOU. The MOU provides that no withdrawals from the MOU Escrow Account can be made before year six, except to fund mutually agreed upon third-party settlements in excess of $125 million. Starting with year six, withdrawals can only be made to fund qualified spend if the parties' aggregate qualified spend in that particular year is greater than $200 million. Beginning with year 11, the amounts in the MOU Escrow Account can be used to fund any qualified spend.

In April 2024, Corteva, EIDP, DuPont, and Chemours received a final judgment resolving all drinking water claims related to PFAS of a defined class of U.S. public water systems that serve the vast majority of the United States population (the "Nationwide Water District Settlement"). In connection with the Nationwide Water District Settlement, the MOU was supplemented to waive funding due to the MOU Escrow Account by Chemours, DuPont and Corteva for 2023 provided that each party fully funds its portion of the Nationwide Water District Settlement and said settlement is consummated. The funding obligation to the MOU Escrow Account with respect to 2024 and due September 30, 2024 was to be waived if (i) between October 1, 2023 and September 30, 2024, the parties had entered into settlement agreements resolving liabilities under the MOU that in the aggregate exceed $100 million; (ii) each company had fully funded its respective share, in accordance with the MOU, of such settlements; and (iii) such settlements were consummated. No such waiver was triggered for the 2024 escrow funding obligation due September 30, 2024 and, therefore, the company made its required contribution.

The company made its annual installment deposits due to the MOU Escrow Account through March 31, 2026. The MOU escrow account contains $105 million as of March 31, 2026, representing the aggregate contributions from Chemours, DuPont and Corteva, less withdrawals to fund related settlements.

After the term of this arrangement, Chemours' indemnification obligations under the original 2015 Chemours Separation Agreement, would continue unchanged, subject in each case to certain exceptions set out in the MOU. Under the MOU, Chemours waived specified claims regarding the construct of its 2015 spin-off transaction, and the parties dismissed the pending arbitration regarding those claims. Additionally, the parties have agreed to resolve the Ohio MDL PFOA personal injury litigation (as discussed below). The parties are expected to cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU.

The Chemours Separation Agreement obligates Chemours to defend and indemnify EIDP in legacy asbestos cases. As of March 31, 2026, there were approximately 900 pending lawsuits, with most being allegations of personal injury from Historical DuPont contractors. At March 31, 2026, an accrual and related indemnification asset have been established for this matter, substantially all of which are recorded in other noncurrent obligations and other assets, respectively.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

<u>Corteva Separation Agreement</u>

On April 1, 2019, in connection with the Dow Distribution, Corteva, DuPont and Dow entered into the Corteva Separation Agreement, the Tax Matters Agreement ("TMA"), the Employee Matters Agreement, and certain other agreements (collectively, the "Corteva Separation Agreements"). The Corteva Separation Agreements allocate among Corteva, DuPont and Dow assets, employees, certain liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) and provides for indemnification obligation among the parties. Under the Corteva Separation Agreement, DuPont indemnifies Corteva against certain litigation, environmental, tax, workers' compensation and other liabilities that arose prior to the Corteva Distribution, Dow indemnifies Corteva against certain litigation, environmental, tax, workers' compensation and other liabilities that relate to the Historical Dow business, and Corteva indemnifies DuPont and Dow for certain liabilities.

Indemnification matters under the Corteva Separation Agreements contain dispute resolution clauses. Corteva and DuPont were pursuing a resolution of a matter under the terms of the TMA that had the potential to significantly impact the current carrying value of our indemnification liability. On September 15, 2025, the dispute resolution firm issued a decision resulting in no material impact to the current carrying value of our indemnification liability.

Under the Corteva Separation Agreements, certain legacy EIDP liabilities from discontinued and/or divested operations and businesses of EIDP (including Performance Chemicals) (a "stray liability") were allocated to Corteva or DuPont. Costs and liabilities have been shared based on the terms of the Corteva Separation Agreement. All future stray liabilities are allocated to Corteva and DuPont proportionally on the basis of 29 percent and 71 percent, respectively, subject to a $1 million de minimis requirement.

On November 1, 2025, DuPont spun off its electronics business, Qnity Electronics, Inc. ("Qnity"). DuPont, Corteva and Qnity entered into a letter agreement, effective November 1, 2025, affirming that DuPont is not novated from its obligations with respect to Corteva for legacy liabilities allocated to Qnity in its spin-off ("Qnity Letter Agreement"). Additionally, under the Qnity Letter Agreement, Corteva has certain third-party beneficiary rights to enforce indemnity and payment obligations of DuPont's with respect to legacy liabilities allocated to Qnity subject to: (i) DuPont's consent; or (ii) Corteva's receipt of a judgment that includes payment obligations for legacy liabilities attributable to Qnity, and either DuPont does not use commercially reasonable efforts to enforce the payment obligation against Qnity, or DuPont files for bankruptcy.

At March 31, 2026, December 31, 2025 and March 31, 2025, the aggregate indemnification assets from DuPont and Dow were $103 million, $104 million and $40 million, respectively, within accounts and notes receivable - net and $283 million, $263 million and $138 million, respectively, within other assets in the interim Consolidated Balance Sheets. At March 31, 2026, December 31, 2025 and March 31, 2025, the aggregate indemnification liabilities to DuPont and Dow were $28 million, $26 million and $17 million, respectively, within accrued and other current liabilities and $103 million, $154 million and $149 million, respectively, within other noncurrent obligations in the interim Consolidated Balance Sheets.

<u>Discontinued Operations Activity</u>

The company recorded benefits (charges) of $(2) million and $(11) million for the three months ended March 31, 2026 and 2025, respectively, to income (loss) from discontinued operations after income taxes, in the interim Consolidated Statements of Operations. The after-tax charge for the three months ended March 31, 2026 and 2025 was driven by charges recognized relating to the MOU with Chemours and DuPont, relating to PFAS environmental remediation activities primarily at Chemours' Fayetteville Works facility, along with other environmental matters.

**Litigation**

The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva's current businesses but allocated to Corteva as part of the Corteva Separation from DuPont. It is not possible to predict the outcome of these various proceedings, as considerable uncertainty exists. The company records accruals for legal matters when the information available indicates that it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Accruals may reflect the impact and status of negotiations, settlements, rulings, advice from counsel and other information and events that may pertain to a particular matter. For the litigation matters discussed below, management believes that it is reasonably possible that the company could incur liabilities in excess of amounts accrued, for which the ultimate liability could be material to the results of operations and the cash flows in the period recognized. However, the company is unable to estimate the possible loss beyond amounts accrued due to various reasons, including, among others, that the underlying matters are either in early stages and/or have significant factual issues to be resolved. In addition, even when the company believes it has substantial defenses, the company may consider settlement of matters if it believes it is in the best interest of the company.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

At March 31, 2026, December 31, 2025 and March 31, 2025, current accrued litigation was $416 million, $874 million and $175 million respectively, within accrued and other current liabilities. A current indemnification asset of $182 million was recorded within accounts and notes receivable - net at March 31, 2026 in relation to the current accrued litigation. See the "Chemours Separation Agreement (Performance Chemicals)" and the "Corteva Separation Agreement" sections for further details on the indemnifications.

<u>Bayer Dispute</u>

In August 2022, Bayer filed a breach of contract/declaratory judgment lawsuit in Delaware state court against Corteva relating to an agrobacterium cross-license agreement and Enlist E3® soybeans. Bayer alleged that Corteva practiced two Bayer patents in developing Enlist E3® soybeans, and therefore, is entitled pursuant to the terms of the cross-license agreement to royalties for sales between 2019 through 2029, along with interest. In January 2025, the court issued several rulings precluding Corteva's invalidity and inequitable conduct defenses, while also aligning on key aspects of Corteva's patent claim construction. In May 2025, the Delaware state court granted Corteva's motion for partial summary judgment agreeing that U.S. Supreme Court precedent precludes the collection of royalties after patent expiration. Bayer's motion for reconsideration was denied in June 2025. In July 2025, a stipulated order allowed Bayer to appeal the summary judgment finding, while also allowing Corteva's cross-appeal of the dismissal of its invalidity and inequitable conduct defenses.

In August 2022, Corteva filed a lawsuit against Bayer CropScience LLP and Monsanto Company (collectively "Bayer") in federal court in Delaware for alleged infringement of Corteva's patented AAD-1 herbicide resistance technology used in Enlist® corn. The complaint for this lawsuit was amended to include additional patents that are closely related to this patented technology for soybeans. Corteva seeks to enjoin Bayer from continuing to infringe, as well as appropriate monetary damages. Bayer has filed an answer to the complaint and has asserted various affirmative defenses including invalidity. In August 2023, the court issued a decision adopting Corteva's claim construction for all five disputed patent terms subject to this litigation.

In December 2023, the Patent Trial and Appeal Board ("PTAB") authorized an Inter Partes Review ("IPR") proceeding initiated by Bayer to review the patentability of three patents subject to the AAD-1 litigation. Inari joined the IPR proceeding. In December 2024, the PTAB issued a decision invalidating these patents on the basis they were unpatentable. Corteva appealed this decision and Corteva's AAD-1 lawsuit remains stayed during pendency of the IPR appeal. Corteva holds numerous additional patents covering its Enlist® traits or Enlist® weed control system. Therefore, the IPR process is not expected to impact its ability to license and protect Enlist E3® traits.

In October 2022, Corteva filed a lawsuit against Bayer in Delaware state court seeking a declaration that, under the terms of Corteva's licensing agreement and the law, Bayer is not entitled to collect patent royalties on the Roundup Ready® Corn 2 trait after Bayer's U.S. patent protection expires, and therefore is no longer required to pay royalties under the licensing agreement and entitled to recover relevant royalties paid. In September 2024, the court granted Bayer's motion for summary judgment. Corteva's appeal was heard by the Delaware Supreme Court, en banc, in May 2025. Additionally, Corteva initiated arbitration of two additional agreements with Bayer seeking similar relief. The Delaware Supreme Court stayed the appeal proceedings pending resolution discussions between Corteva and Bayer.

As of January 2026, the parties agreed to settle the agrobacterium cross-license agreement dispute. In addition, Corteva and Bayer resolved several other disputes regarding post-patent royalties and other matters, including post-patent regulatory support, resulting in the termination or amendment of the related licenses, as applicable. As part of the resolution of these matters, the cross-license agreement has been terminated and Corteva agreed to drop its AAD-1 patent claims against Bayer, as well as a payment of $610 million of which approximately $546 million was paid through the first quarter of 2026 and the remainder due by September 15, 2026. Also as a result of the resolution of this litigation and the related license terminations and amendments, potential royalty obligations for Corteva's Enlist E3® soybeans, as well as future royalty payments due to Bayer under other licensing agreements in dispute were terminated. The settlement agreements support Corteva's product out-licensing growth in competitive corn, cotton and canola markets, including for the out-licensing of above and below ground triple-stack corn technology. In conjunction with resolution of these matters, the companies also agreed to new cotton licensing arrangements at terms reflective of market rates. There is no remaining litigation between the parties.

<u>Federal Trade Commission Investigation</u>

On May 26, 2020, Corteva received a subpoena from the Federal Trade Commission ("FTC") directing it to submit documents pertaining to its Crop Protection products generally, as well as business plans, rebate programs, offers, pricing and marketing materials specifically related to its acetochlor, oxamyl, rimsulfuron and other related products in order to determine whether Corteva engaged in unfair methods of competition through anticompetitive conduct. Corteva has fully cooperated with all requests related to this subpoena. On September 29, 2022, the FTC, along with ten state attorneys general in California, Colorado, Illinois, Indiana, Iowa, Minnesota, Nebraska, Oregon, Wisconsin, and Texas, filed a lawsuit against Corteva and

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

another competitor alleging the parties engaged in unfair methods of competition, unlawful conditioning of payments, unreasonably restrained trade, and have an unlawful monopoly (the "FTC lawsuit"). In December 2022, attorneys general in Tennessee and Washington joined the FTC lawsuit and the Arkansas state attorney general filed a separate lawsuit against Corteva and another competitor based on the allegations set forth in the FTC lawsuit. In July 2025, the Arkansas state attorney general amended the complaint to include methoxyfenozide, cyhalofop, picloram, triclopyr, and aminopyralid products. Several proposed private class action lawsuits were also filed in federal court alleging anticompetitive conduct based on the allegations set forth in the FTC lawsuit.

Virtually all of these private lawsuits were centralized into a multi-district litigation in the U.S. District Court for the Middle District of North Carolina. In January 2025, federal court for the multi-district litigation granted in part, and denied in part, Corteva's motion to dismiss. Specifically, the court order dismissed the plaintiff's federal damages claims and 13 of the 27 state consumer protection act claims. The plaintiffs amended their complaint to include methoxyfenozide products. Without admitting any wrongdoing, Corteva reached tentative settlements with the State of Arkansas in February 2026 and the multi-district litigation plaintiffs collectively in March 2026. The final terms of these settlements continue to be negotiated. The trial for the FTC claims is expected to begin in 2027. As of March 31, 2026, an accrual has been established for the estimated resolution of claims.

<u>Lorsban® Lawsuits</u>

As of March 31, 2026, there were asserted claims for personal injury against the former Dow Agrosciences LLC, alleging injuries related to chlorpyrifos exposure, the active ingredient in Lorsban®, an insecticide used by commercial farms for field fruit, nut and vegetable crops. Corteva ended its production of Lorsban® in 2020. Chlorpyrifos products are restricted-use pesticides, which are not available for purchase or use by the general public, and may only be sold to, and used by, certified applicators or someone under the certified applicator's direct supervision. These lawsuits do not relate to Dursban®, a residential type chlorpyrifos product that was authorized for indoor purposes, which was discontinued over two decades ago prior to the Merger and Corteva's formation and Separation. Claimants allege personal injury, including autism, developmental delays and/or decreased neurologic function, resulting from farm worker exposure and bystander drift and in utero exposure to chlorpyrifos. Certain claimants have also put forth remediation claims due to alleged property contamination from chlorpyrifos. As of March 31, 2026, an accrual has been established for the estimated resolution of certain claims.

*Litigation related to legacy EIDP businesses unrelated to Corteva's current businesses*

For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs").

EIDP is a party to various legal proceedings relating to the use of PFOA by its former Performance Chemicals segment for which potential liabilities would be subject to the cost sharing arrangement under the MOU as long as it remains effective.

<u>Leach Settlement and Ohio MDL Settlement</u>

EIDP has residual liabilities under its 2004 settlement of a West Virginia state court class action, Leach v. EIDP, which alleged that PFOA from EIDP's former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. The settlement class has about 80,000 members. In addition to relief that was provided to class members years ago, the settlement requires EIDP to continue providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members. As of March 31, 2026, approximately $2 million had been disbursed from the account since its establishment in 2012 and the remaining balance is approximately $1 million.

<u>PFOA Personal Injury Claims</u>

In December 2024, the defendants reached a settlement of all of the currently filed and unfiled personal injury cases in the Ohio MDL for $59 million, with $8 million contributed in aggregate by Corteva. The final installment was paid upon the court dissolving the MDL in March 2025.

<u>Other PFOA Matters</u>

EIDP is a party to other PFOA lawsuits involving claims for property damage, medical monitoring and personal injury. Defense costs and any future liabilities that may arise out of these lawsuits are subject to the MOU and the cost sharing arrangement disclosed above. Under the MOU, fraudulent conveyance claims associated with these matters are not qualified expenses, unless Corteva, Inc. and EIDP would prevail on the merits of these claims.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

EIDP did not make film-forming foams, PFOS, or PFOS products. While EIDP made surfactants and intermediaries that some manufacturers used in making foams, which may have contained PFOA as an unintended byproduct or an impurity, EIDP's products were not formulated with PFOA, nor was PFOA an ingredient of these products. EIDP has never made or sold PFOA as a commercial product.

*Aqueous Film-Forming Foams.* Approximately 12,000 cases filed against 3M and other defendants, including EIDP and Chemours, and some including Corteva and DuPont, alleging personal injury (primarily kidney, testicular, liver and thyroid cancer) from the use of aqueous film-forming foams ("AFFF") or contamination, in most cases due to migration from military installations or airports, consolidated in a multi-district litigation proceeding in federal district court in South Carolina ("SC MDL"). Most of these recent cases also assert claims that the EIDP and Chemours separation constituted a fraudulent conveyance.

In August 2025, the SC MDL entered multiple case management orders requiring cases filed outside the SC MDL to be transferred to the SC MDL, establishing a 21-day window for unfiled cases to be filed, and allowing the filing of multi-plaintiff complaints. A significant number of new cases asserting personal injury were filed or transferred to the SC MDL. Many of the personal injury cases both inside and outside the SC MDL include and continue to include, as new cases are threatened, multiple plaintiffs. Therefore, the number of plaintiffs asserting such claims is substantially higher than the number of cases set forth above. The first bellwether personal injury trial is expected to be scheduled for 2026. Discussions between the parties on a resolution to these cases remain ongoing.

*Nationwide Water District Settlement.* In April 2024, a compromise and settlement with Corteva, EIDP, Inc, DuPont, and Chemours (collectively, the "settling companies") was finalized to comprehensively resolve all drinking water claims related to PFAS of a defined class of U.S. public water systems that serve the vast majority of the United States population, including, but not limited to the AFFF claims in the SC MDL, under the Nationwide Water District Settlement, for $1.185 billion in the aggregate. PFAS, as defined in the settlement, includes PFOA and HFPO-DA, among a broad range of fluorinated organic substances.

The class represented by the Nationwide Water District Settlement is composed of all Public Water Systems, as defined in 42 U.S.C. § 300f, with a current detection of PFAS or that are currently required to monitor for PFAS under the Environmental Protection Agency's Fifth Unregulated Contaminant Monitoring Rule ("UCMR 5") or other applicable federal or state law (the "Class"). Approximately 88 percent of the U.S. is served by systems required to test under UCMR 5. The Class does not include water systems owned and operated by a State or the United States government; small systems that have not detected the presence of PFAS and are not currently required to monitor for it under federal or state requirements; and, unless they otherwise request to be included, water systems in the lower Cape Fear River Basin of North Carolina.

The total number of requests for exclusion ("opt-outs") was approximately 900 water districts while most public water districts (approximately 93 percent of the Class) remain in the class settlement. The company has been served complaints from opt-outs, as well as water district and municipal authority claims not covered by the Nationwide Water District Settlement.

*New Jersey*. In late March 2019, the New Jersey State Attorney General filed four lawsuits against EIDP, Chemours, and others alleging that operations at and discharges from former EIDP sites in New Jersey (Chambers Works, Parlin, Pompton Lakes and Repauno) damaged the State's natural resources. Two of these lawsuits (those involving the Chambers Works and Parlin sites) allege contamination from PFAS. DuPont and Corteva were subsequently added as defendants to these lawsuits. These lawsuits include claims for remediation, fraudulent conveyance, as well as claims under the New Jersey Water Pollution Control Act and the New Jersey Industrial Site Recovery Act ("ISRA").

On August 3, 2025, the company, together with Chemours and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey (the "NJ Statewide Settlement") to resolve all outstanding claims by the State of New Jersey pending against the companies related to the legacy use of a wide variety of substances of concern, including, but not limited to DNAPL (dense non-aqueous phase liquids), chemical solvents, and PFAS. Subject to a public notice and comment period and subject to court approval following that period, the NJ Statewide Settlement will also resolve legacy claims related to four Historical DuPont operating sites (Chambers Works, Parlin, Pompton Lakes and Repauno) in the State, including claims under ISRA, alleged statewide PFAS contamination, including from the use of AFFF, claims of fraudulent conveyance, and claims for known natural resource damages from these Historical DuPont sites that the State of New Jersey and its departments have, or may have, in the future against the companies.

The NJ Statewide Settlement, after the expiration of the public notice and comment period, is subject to court approval. The court hearing for this approval occurred in January 2026 with a conclusion on the approval expected during the first half of

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

2026. The NJ Statewide Settlement includes aggregate cash payments to the State of New Jersey of $875 million, payable over a period of 25 years (net present value of approximately $500 million, using an 8 percent discount rate), responsibility for which will be allocated among the settling companies in accordance with the terms of the MOU. Of the $875 million, approximately $16 million is allocated to statewide natural resource damages unrelated to the four Historical DuPont sites, 25 percent of which relates to alleged statewide AFFF contamination. Accordingly, in the second quarter of 2025, the company recorded a pre-tax loss of $72 million ($58 million after-tax) within discontinued operations, reflecting the net present value of the company's share of the aggregate cash payment in accordance with the MOU. The settling companies have agreed to count the NJ Statewide Settlement against the MOU limit at net present value as of the date of the NJ Statewide Settlement. Entry into the NJ Statewide Settlement suspended the companies' 2025 MOU escrow funding obligations and funding of the initial payment under the NJ Statewide Settlement, expected in 2026, will be deemed to satisfy these obligations for 2025.

In addition to the cash payment, the NJ Statewide Settlement obligates certain settling companies to continue to undertake remediation at the four Historical DuPont sites, which will be determined in accordance with applicable law and the respective cost sharing arrangements between the settling companies, to the extent applicable. DuPont and Chemours will be responsible for the remediation at the sites under their current respective ownership. As part of the NJ Statewide Settlement, the companies have agreed to a binding third party review process of the remedial funding source ("RFS") for each of the four Historical DuPont sites (in the form of a surety bond or similar financial instrument) to ensure available funds for future remediation of these sites. This review process could identify additional required remediation, and an increase to the RFS for each of these sites.

The company and DuPont will also establish a reserve fund (in the form of a surety bond or similar financial instrument) in the amount of $475 million (the "Reserve Fund") with DuPont funding 71 percent and the company bearing the remaining 29 percent. The Reserve Fund is further financial security, separate from, and secondary to, the RFS, and the Reserve Fund will be accessible only in the event the RFS for a site has been exhausted and the party responsible for a site is not otherwise performing the required remediation. If a responsible party under the NJ Statewide Settlement defaults on their remediation or payment obligations (subject first to the cost sharing arrangements under the Corteva Separation Agreements, which provides that these obligations are "stray liabilities"), EIDP will become responsible for such obligations.

Under the NJ Statewide Settlement, no settling party admits any liability or wrongdoing or agrees to waive any defenses as to any such liability or wrongdoing.

Pursuant to a separate agreement among the company, DuPont, and Chemours, DuPont and the company will purchase Chemours' future interest, if any, in certain insurance proceeds. DuPont and the company will make the purchase by contributing a total of $150 million, with $106 million from DuPont and $44 million from the company, into an escrow fund, with funds to be released to pay Chemours' share of the NJ Statewide Settlement. DuPont and the company will pay Chemours, as additional contingent consideration, amounts received from the acquired insurance proceeds in excess of $150 million plus an accrued fee. The accrued fee will equal the lesser of (a) $35 million, and (b) $3 million plus interest (at prime minus 2 percent) on an initial balance of $150 million, as reduced by any amounts received by DuPont and Corteva from the acquired insurance proceeds, until DuPont and the company have so received $150 million, plus the accrued fee. The purchase price to be paid to Chemours, and the insurance proceeds recovered, by DuPont and the company from the insurance proceeds acquired from Chemours, are subject to the sharing percentages under the Letter Agreement.

*Ohio*. EIDP is a defendant in two lawsuits, including an action by the State of Ohio based on alleged damage to natural resources. The natural resources damage claim was preliminarily resolved in December 2023. As of March 31, 2026, an accrual has been established for this matter. The second, a putative nationwide class action (the "Hardwick Class Action") brought on behalf of anyone who has detectable levels of PFAS in their blood serum seeks declaratory and injunctive relief, including the establishment of a "PFAS Science Panel." In December 2023, the Sixth Circuit Court of Appeals dismissed the Hardwick Class Action due to lack of standing by Mr. Hardwick. With further opportunities for appeals expired, the plaintiffs filed a new case, narrowing their original claims, in June 2024. EIDP's motion to dismiss the new case on the grounds it remains similar to the original claim was denied, but immediately certified an appeal to the Sixth Circuit and stayed all merits and class proceedings pending the Sixth Circuit's review of the district court's decision. The appellate review is expected to be as early as the fourth quarter of 2026.

*New York*. EIDP is a defendant in a putative class action (the "Baker Class Action"), brought by persons who live in and around Hoosick Falls, New York. These lawsuits assert claims for medical monitoring, property damage and personal injury based on alleged PFOA releases from manufacturing facilities owned and operated by co-defendants in Hoosick Falls. The lawsuits allege that EIDP and others supplied materials used at these facilities resulting in PFOA air and water contamination. A court approved settlement was reached between the plaintiffs and the other co-defendants regarding the Baker Class Action case. In September 2022, the class certification of the Baker Class Action was granted, with the court certifying three separate classes

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

consisting of a private well property damage class, a medical monitoring class and a nuisance class. A settlement in principle of the Baker Class Action was reached in June 2025. As of March 31, 2026, an accrual for Corteva's share of the expected settlement under the MOU has been established.

EIDP is a defendant in a lawsuit brought by the Town of East Hampton, New York alleging PFOA and PFOS contamination of the town's well water. This district submitted a timely opt-out request from the Nationwide Water District Settlement. EIDP and Chemours are also defendants in two lawsuits by a private water utility provider in New Jersey and New York alleging damages from PFAS releases into the environment, that impacted water sources that the utilities use to provide water, as well as product liability, negligence, nuisance, and trespass claims. The court dismissed the New York plaintiff's trespass claims and limited plaintiffs' nuisance claims to abatement damages.

*Other Natural Resource Damage Cases.* In addition to the natural resource damage cases in New Jersey and New York, natural resource damage lawsuits against EIDP, Chemours, and others, claiming, among other things, PFC (including PFOA) contamination of groundwater and drinking water, have been filed by attorneys general in 31 states, the District of Columbia and three U.S. territories. Certain cases also name DuPont and Corteva as defendants and include claims of fraudulent conveyance. The complaints seek reimbursement for past and future costs to monitor and remediate the alleged contamination and compensation for the loss of value and use of the state's natural resources, as well as punitive damages. Due to overlapping AFFF allegations, virtually all of these cases have been transferred, or are pending transfer to the SC MDL. These cases are largely in the discovery phase.

On July 13, 2021, Chemours, DuPont, EIDP and Corteva entered into a settlement agreement with the State of Delaware reflecting the companies' and the State's agreement to settle and fully resolve claims alleged against the companies regarding their historical Delaware operations, manufacturing, use and disposal of all chemical compounds, including PFAS. Under the settlement, if the companies, individually or jointly, within 8 years of the settlement, enter into a proportionally similar agreement to settle or resolve claims of another state for PFAS-related natural resource damages, for an amount greater than $50 million, the companies shall make a supplemental payment directly to the Natural Resources and Sustainability Trust (the "NRS Trust") in an amount equal to such other states' recovery in excess of $50 million ("Supplemental Payment"). Supplemental Payment(s), if any, will not exceed $25 million in the aggregate. All amounts paid by the companies under the settlement are subject to the MOU and the Corteva Separation Agreement. Due to the settlement of natural resource damages claims with the State of Ohio, the one-time Supplemental Payment will be triggered when the further opportunity for appeals expires under the Ohio judicial consent order process. As of March 31, 2026, an accrual has been established for Corteva's share under the MOU. Under the settlement, if the state sues other parties and those parties seek contribution from the companies, the companies will have protection from contribution up to the amounts previously paid under the settlement agreement. The companies will also receive a credit up to the amount of the payment if the state seeks natural resource damage claims against the companies outside the scope of the settlement's release of claims.

*Canada.* The Province of British Columbia, filed a class action against various defendants, including 3M, DuPont Canada, EIDP, and Chemours alleging harms caused by PFAS/AFFF. The class consists of all municipalities, regional districts, and other governance authorities and other persons in Canada that were responsible for a "Drinking Water System" from 1970 to the present. The plaintiff seeks to recover costs for the treatment and restoration of natural resources, as well as property, economic, and punitive damages. A putative class action was also filed in July 2024 on behalf of citizens of Quebec, Canada seeking class certification to recover for alleged PFAS and AFFF contamination of private wells and public water treatment facilities. In January 2024, a class action was also filed in Canada against 3M and other defendants, including EIDP and Chemours, alleging PFOS and PFOA environmental contamination and personal injury from use of AFFF. Additionally, several lawsuits on behalf of consumers of PFAS-infused products in the Province of British Columbia for personal injury and PFAS contamination in Manitoba, Canada have been filed.

*Netherlands*. In April 2021, four municipalities in the Netherlands filed complaints alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours. The municipalities seek to recover costs incurred due to the alleged emissions, including damages for investigation costs, construction project delays, depreciation of land, soil remediation, liabilities to contractors, and attorneys' fees. In September 2023, the court entered a second interlocutory judgment, ruling, inter alia, that defendants were liable to the municipalities for PFOA emissions during a certain time period, and the removal costs of deposited emissions on the municipalities' land infringes their property rights by an objective standard. In June 2024, Chemours and these Dutch municipalities signed a letter of intent that included the implementation of a specific remediation plan for the restoration of restricted vegetable gardens in certain areas of those municipalities to be funded by Chemours, sampling and developing a program to address a recreational lake, and further settlement discussions, including a potential fund to cover certain other expenditures aimed at environmental-related activities. While the letter of intent contemplates the possibility of settlement, discussions between the parties related to the resolution to these matters remain ongoing. Although the company believes a loss is probable, it is not estimable at this time due to various

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

reasons including, among others, the status of discussions between the parties. As of March 31, 2026, an accrual has been established for the estimated environmental remediation set forth in the letter of intent. Additionally, the Office of Public Prosecutor in the Netherlands opened a criminal investigation against certain Dutch subsidiaries of Chemours and Historical DuPont, as well as each subsidiary's directors, alleging unlawful PFOA and GenX emissions from Chemours' Dordrecht Works facility.

*Carpet Mill Cases.* The city of Centre, Alabama water district alleged defendants, including EIDP, Chemours, other chemical suppliers and large carpet mills, discharged PFAS in their industrial wastewater, and that this wastewater after treatment, resulted in PFAS contamination of drinking water supplies. The Centre, Alabama water district carpet mill case settled in February 2026 and an accrual has been established for this matter as of March 31, 2026. In July 2024, the town of Lyerly, Georgia filed a case making similar allegations as those brought in the Centre, Alabama case. Numerous carpet, textile, and paper manufacturers, their alleged suppliers and former suppliers, including EIDP and Chemours, and certain municipal or utility defendants are also subject to several lawsuits in Georgia, Alabama and South Carolina, alleging negligence, nuisance and trespass related to the release of PFOA, and requesting injunctive relief related to PFOA contamination.

<u>Fayetteville Works Facility, North Carolina</u>

Prior to the separation of Chemours, EIDP introduced GenX as a polymerization processing aid and a replacement for PFOA at the Fayetteville Works facility in Bladen County, North Carolina. The Historical DuPont facility is now owned and operated by Chemours, which continues to manufacture and use GenX. The current natural resources damage claims in North Carolina allege that direct discharges from this legacy facility are a source of PFOA contamination.

As of March 31, 2026, several actions, including personal injury, are pending in the North Carolina federal court against Chemours and EIDP relating to PFC discharges from the Fayetteville Works facility. One of these is a consolidated putative class action that asserts claims for medical monitoring and property damage on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority ("CFPUA") and Brunswick County, that seek actual and punitive damages as well as injunctive relief. EIDP and Chemours filed a motion for summary judgment on this consolidated action in March 2025. Cumberland County, North Carolina, which is not part of the forgoing consolidation action or the Nationwide Water District Settlement, filed an action for alleged PFOA contamination to its groundwater sources used in drinking water and seeking recovery for costs associated with water filtration, monitoring, and compliance costs. The pending mediation and trial for this matter are no longer scheduled.

In March 2023, CFPUA filed a Delaware Chancery Court action claiming the spin-off of Chemours and the Dow and Historical DuPont merger were unlawful and should be voided, so CFPUA is not precluded from recovering amounts it is entitled in its pending litigation. EIDP filed a motion to dismiss the Delaware Chancery Court action based upon failure to state a claim under Delaware law in June 2023, along with a counterclaim in October 2023. CFPUA's motion to stay the case was granted in January 2024.

In a state court action, approximately 2,400 private property owners near the Fayetteville Works facility seek compensatory and punitive damages for their claims of private nuisance, trespass, negligence, water monitoring and property damage allegedly caused by release of certain PFCs. In addition, several personal injury cases have been filed in the North Carolina federal court alleging thyroid disease, and prostate, breast and kidney cancers as a result of PFAS exposure.

Generally, site-related expenses related to GenX claims are subject to the cost sharing arrangements as defined in the MOU.

**Environmental**

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. These obligations are included in accrued and other current liabilities and other noncurrent obligations in the interim Consolidated Balance Sheets. It is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the company's results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration.

Refer to the allocation of environmental liabilities, which is discussed under the header "Chemours Separation Agreement (Performance Chemicals)" and "Corteva Separation Agreement" within Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

The accrued environmental obligations and indemnification assets include the following:

---

| | | | |
|:---|:---|:---|:---|
| | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** |
| *(In millions)* | Indemnification asset | Accrual balance <sup>3</sup> | Potential exposure above amount accrued <sup>3</sup> |
| *Environmental Remediation Stray Liabilities* |  |  |  |
| &nbsp;&nbsp;Chemours related obligations - subject to indemnity <sup>1,2</sup> | $251 | $263 | $205 |
| &nbsp;&nbsp;Other discontinued or divested businesses obligations <sup>1</sup> | 35 | 71 | 202 |
| Environmental remediation liabilities primarily related to DuPont - subject to indemnity from DuPont <sup>2</sup> | 49 | 54 | 53 |
| Environmental remediation liabilities not subject to indemnity |  | 113 | 106 |
| Indemnification liabilities related to the MOU <sup>4</sup> |  | 58 | 6 |
| Total | $335 | $559 | $572 |

---

1. Represents liabilities that are subject to the $200 million threshold and sharing arrangements as discussed in the section entitled "Corteva Separation Agreement" within Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

2. The company has recorded an indemnification asset related to these accruals, including $21 million related to the Superfund sites.

3. Accrual balance represents management's best estimate of the costs of remediation and restoration, although it is reasonably possible that the potential exposure, as indicated, could range above the amounts accrued, as there are inherent uncertainties in these estimates. Accrual balance includes $48 million for remediation of Superfund sites. Amounts do not include possible impacts from the remediation elements of the EPA's October 2021 PFAS Strategic Roadmap (as applicable), except as disclosed in the section entitled "Fayetteville Works Facility, North Carolina" within Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, relating to Chemours' remediation activities at the Fayetteville Works Facility pursuant to the Consent Order with the North Carolina Department of Environmental Quality ("NC DEQ").

4. Represents liabilities that are subject to the $150 million threshold and sharing agreements as discussed in the section entitled "Chemours Separation Agreement (Performance Chemicals)" within Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

*<u>Nebraska Department of Environment and Energy, AltEn Facility</u>*

The EPA and the Nebraska Department of Environment and Energy ("NDEE") are pursuing investigations, response and removal actions, litigation and enforcement action related to an ethanol plant located near Mead, Nebraska that is owned and operated by AltEn LLC ("AltEn"). The agencies have alleged violations under the Resource Conservation and Recovery Act ("RCRA") and other federal and state laws stemming from AltEn's lack of compliance with the terms and conditions of its operating permits and other regulatory requirements. Corteva is one of six seed companies, who were customers of AltEn (collectively, the "Facility Response Group"), participating in the NDEE's Voluntary Cleanup Program to address certain interim remediation needs at the site. In March 2025, the Facility Response Group reached an agreement to settle its lawsuit against AltEn and certain of its affiliates to preserve certain contractual and common law indemnification claims. The settlement agreement, among other things, limits AltEn's ability to dispose of the property or take any adverse action with respect to its property or assets. As of March 31, 2026, an accrual was established for Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans for the AltEn location.

*<u>California Department of Toxic Substances Control, Pittsburg Plant</u>*

The California Department of Toxic Substances Control ("DTSC") has filed a state court lawsuit over challenging whether the Pittsburg plant's high purity water system ("HPWS"), as operated by Dow and now Corteva, required a permit pursuant to the RCRA. Discussions between the parties remain ongoing and further litigation, including discovery, is stayed.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 13 - STOCKHOLDERS' EQUITY**

**Share Buyback Plan**

On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to

purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2024 Share Buyback Plan"). The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. In connection with the 2024 Share Buyback Plan, the company repurchased and retired 3,190,000 shares in the open market for a total cost (excluding excise taxes) of $250 million during the three months ended March 31, 2026.

On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2022 Share Buyback Plan"). The timing, price and volume of purchases were based on market conditions, relevant securities laws and other factors. The company completed the 2022 Share Buyback Plan during the second quarter of 2025 and repurchased and retired 7,815,000, 17,909,000, and 10,026,000 shares in the open market and through privately-negotiated transactions for a cost (excluding excise taxes) of $500 million, $1 billion and $500 million during the years ended December 31, 2025, 2024 and 2023, respectively. Included within the shares repurchased during the years ended December 31, 2025 and 2024 were $145 million and $125 million, respectively, of shares from the master trust fund of the principal U.S. pension plan, as part of the Pension Investment Committee's periodic portfolio rebalancing process. Shares were repurchased by the company at the prevailing market rate authorized and agreed to by a third-party independent fiduciary for the plan.

Shares repurchased pursuant to Corteva's share buyback plans are immediately retired upon repurchase. Repurchased common stock is reflected as a reduction of stockholders' equity. The company's accounting policy related to its share repurchases is to reduce its common stock based on the par value of the shares and to reduce its retained earnings for the excess of the repurchase price over the par value. When Corteva has an accumulated deficit balance, the excess over the par value is applied to additional paid-in capital ("APIC"). When Corteva has retained earnings, the excess is charged entirely to retained earnings.

**Noncontrolling Interest**

Corteva, Inc. owns 100 percent of the outstanding common shares of EIDP. However, EIDP has preferred stock outstanding to third parties which is accounted for as a non-controlling interest in Corteva's interim Consolidated Balance Sheets. Each share of EIDP Preferred Stock - $4.50 Series and EIDP Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EIDP and was unaffected by the Corteva Distribution.

Below is a summary of the EIDP Preferred Stock at March 31, 2026, December 31, 2025 and March 31, 2025, which is classified as noncontrolling interests in Corteva's interim Consolidated Balance Sheets.

---

| | |
|:---|:---|
| *(Shares in thousands)* | **Number of Shares** |
| Authorized | 23000 |
| $4.50 Series, callable at $120 | 1673 |
| $3.50 Series, callable at $102 | 700 |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**Other Comprehensive Income (Loss)** 

The changes and after-tax balances of components comprising accumulated other comprehensive income (loss) are summarized below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Cumulative Translation Adjustment* <sup>1</sup>  | *Derivative Instruments* | *Pension Benefit Plans* | *Other Benefit Plans* | *Unrealized Gain (Loss) on Investments* | *Total* |
| **2025** |  |  |  |  |  |  |
| Balance at January 1, 2025 | $(3472) | $16 | $(226) | $219 | $(6) | $(3469) |
| Other comprehensive income (loss) before reclassifications | 186 | 10 | 1 |  | 2 | 199 |
| Amounts reclassified from accumulated other comprehensive income (loss) |  | 2 |  | (3) |  | (1) |
| Net other comprehensive income (loss) | 186 | 12 | 1 | (3) | 2 | 198 |
| Balance at March 31, 2025 | $(3286) | $28 | $(225) | $216 | $(4) | $(3271) |
| **2026** |  |  |  |  |  |  |
| Balance at January 1, 2026 | $(2605) | $(7) | $(378) | $193 | $— | $(2797) |
| Other comprehensive income (loss) before reclassifications | (129) | (11) | (3) |  | 1 | (142) |
| Amounts reclassified from accumulated other comprehensive income (loss) |  | 3 | (1) | (3) |  | (1) |
| Net other comprehensive income (loss) | (129) | (8) | (4) | (3) | 1 | (143) |
| Balance at March 31, 2026 | $(2734) | $(15) | $(382) | $190 | $1 | $(2940) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

1. The cumulative translation adjustment loss for the three months ended March 31, 2026 was primarily driven by the strengthening of the USD against the Euro ("EUR") and Indian Rupee ("INR"), partially offset by the weakening of the USD against the Brazilian Real ("BRL"). The cumulative translation adjustment gain for the three months ended March 31, 2025 was primarily driven by the weakening of the USD against the Brazilian Real, Euro and South African Rand ("ZAR").

The tax (expense) benefit on the net activity related to each component of other comprehensive income (loss) was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Derivative instruments | $(6) | $(13) |
| Pension benefit plans - net | (1) | 1 |
| Other benefit plans - net | 1 | 2 |
| Unrealized gains (losses) on investments |  |  |
| (Provision for) benefit from income taxes related to other comprehensive income (loss) items | $(6) | $(10) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

A summary of the reclassifications out of accumulated other comprehensive income (loss) is provided as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| **Derivative instruments** <sup>1</sup>**:** | $3 | $13 |
| Tax (benefit) expense <sup>2</sup> |  | (11) |
| After-tax | $3 | $2 |
| **Amortization of pension benefit plans:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior service (benefit) cost <sup>3,4</sup> | $(1) | $(1) |
| Total before tax | (1) | (1) |
| Tax (benefit) expense <sup>2</sup> |  | 1 |
| After-tax | $(1) | $— |
| **Amortization of other benefit plans:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actuarial (gains) losses <sup>3,4</sup> | $(4) | $(5) |
| Total before tax | (4) | (5) |
| Tax (benefit) expense <sup>2</sup> | 1 | 2 |
| After-tax | $(3) | $(3) |
| **Total reclassifications for the period, after-tax** | $(1) | $(1) |

---

1. Reflected in cost of goods sold in the interim Consolidated Statements of Operations.

2. Reflected in provision for (benefit from) income taxes from continuing operations in the interim Consolidated Statements of Operations.

3. These accumulated other comprehensive income (loss) components are included in the computation of net periodic benefit (credit) cost of the company's pension and other benefit plans. See Note 14 - Pension Plans and Other Post Employment Benefits, to the interim Consolidated Financial Statements, for additional information.

4. Reflected in other income (expense) - net in the interim Consolidated Statements of Operations.

**NOTE 14 - PENSION PLANS AND OTHER POST EMPLOYMENT BENEFITS**

The following sets forth the components of the company's net periodic benefit (credit) cost for defined benefit pension plans and other post employment benefits ("OPEB"):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| *Defined Benefit Pension Plans:* |  |  |
| &nbsp;&nbsp;&nbsp;Service cost | $4 | $4 |
| &nbsp;&nbsp;&nbsp;Interest cost | 138 | 157 |
| &nbsp;&nbsp;&nbsp;Expected return on plan assets | (148) | (155) |
| &nbsp;&nbsp;&nbsp;Amortization of prior service (benefit) cost | (1) | (1) |
| &nbsp;&nbsp;&nbsp;Net periodic benefit (credit) cost | $(7) | $5 |
| *Other Post Employment Benefits:* |  |  |
| &nbsp;&nbsp;&nbsp;Interest cost | $8 | $10 |
| &nbsp;&nbsp;&nbsp;Amortization of unrecognized (gain) loss | (4) | (5) |
| &nbsp;&nbsp;&nbsp;Net periodic benefit (credit) cost | $4 | $5 |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 15 - FINANCIAL INSTRUMENTS** 

**Time Deposits and Money Market Funds**

At March 31, 2026, December 31, 2025 and March 31, 2025, the company held investments in held-to-maturity securities at amortized cost, which approximates fair value. At March 31, 2025, the company held additional held-to-maturity securities, and at March 31, 2026, December 31, 2025 and March 31, 2025, the company also held available-for-sale securities, consisting of investments in foreign government bonds which are discussed further in the section entitled "Debt Securities." Reclassifications of certain prior year held-to-maturity balances have been made in the current year to disaggregate between those that are time deposits and foreign government bonds.

The following table summarizes investments in time deposits and money market funds classified as held-to-maturity securities at March 31, 2026, December 31, 2025 and March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Held-to-Maturity Securities** | **Held-to-Maturity Securities** | **Amortized Cost** | **Amortized Cost** | **Amortized Cost** |
| *(in millions)* | **Balance Sheet Location** | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Time deposits and money market funds | Cash equivalents <sup>1</sup> | $1113 | $3431 | $1314 |
| Time deposits | Marketable securities <sup>2</sup> | $1 | $1 | $1 |

---

1. Maturity at time of purchase was three months or less.

2. Maturity at time of purchase was more than three months to less than one year.

**Derivative Instruments**

*Objectives and Strategies for Holding Derivative Instruments*

In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency and commodity price risks. The company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. The company has not designated any non-derivatives as hedging instruments.

The company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges, and multinational grain exporters. The company is exposed to credit loss in the event of nonperformance by these counterparties. The company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

The aggregate notional amounts for the company's derivative instruments (both designated and not designated) was a net buy position of $1,027 million, $1,280 million and $1,252 million at March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

**Foreign Currency Risk**

The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility associated with foreign currency rate changes and to mitigate the exposure of certain investments in foreign subsidiaries against changes in the EUR/USD exchange rate. Accordingly, the company enters into various contracts that change in value as foreign exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments, investments and cash flows.

The company uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, after related tax effects, are minimized. The company also uses foreign currency exchange contracts to offset a portion of the company's exposure to certain forecasted transactions as well as the translation of foreign currency-denominated earnings. The company also frequently uses commodity contracts to offset risks associated with foreign currency devaluation in certain countries.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**Commodity Price Risk**

Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as corn and soybeans. The company enters into over-the-counter and exchange-traded derivative commodity instruments to hedge the commodity price risk associated with agricultural commodity exposures.

**Derivatives Designated as Cash Flow Hedges**

*Commodity Contracts*

The company enters into over-the-counter and exchange-traded derivative commodity instruments, including options, forwards, futures and swaps, to hedge the commodity price risk associated with agricultural commodity exposures.

While each risk management program has a different maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring.

The following table summarizes the after-tax effect of commodity contract cash flow hedges on accumulated other comprehensive income (loss):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Beginning balance | $9 | $(49) |
| Additions and revaluations of derivatives designated as cash flow hedges | 21 | 2 |
| Clearance of hedge results to earnings | 3 | 15 |
| Ending balance | $33 | $(32) |

---

At March 31, 2026, an after-tax net gain of $8 million is expected to be reclassified from accumulated other comprehensive income (loss) into earnings over the next twelve months.

*Foreign Currency Contracts*

The company enters into forward contracts to hedge the foreign currency risk associated with forecasted transactions within certain foreign subsidiaries.

While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring.

The following table summarizes the after-tax effect of foreign currency cash flow hedges on accumulated other comprehensive income (loss):

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Beginning balance | $5 | $13 |
| Additions and revaluations of derivatives designated as cash flow hedges | (32) |  |
| Clearance of hedge results to earnings |  | (13) |
| Ending balance | $(27) | $— |

---

At March 31, 2026, an after-tax net loss of $(27) million is expected to be reclassified from accumulated other comprehensive income (loss) into earnings over the next twelve months.

**Derivatives Designated as Net Investment Hedges**

*Foreign Currency Contracts*

In March 2025, the company designated €1.7 billion of forward contracts to exchange Euro as net investment hedges. Of these hedges, €1.2 billion expired and were settled in May 2025, while the remaining €500 million expired and were settled in December 2025. The purpose of these forward contracts is to mitigate foreign exchange exposure related to a portion of the

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

company's Euro net investments in certain foreign subsidiaries against changes in EUR/USD exchange rates. The company elected to apply the spot method in testing for effectiveness of the hedging relationship.

**Derivatives not Designated in Hedging Relationships**

*Foreign Currency Contracts*

The company uses foreign exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The company also frequently uses foreign currency exchange contracts to offset a portion of the company's exposure to the translation of certain foreign currency-denominated earnings so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated earnings over the relevant aggregate period.

*Commodity Contracts*

The company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as corn and soybeans. The company uses commodity contracts to offset a portion of the company's exposure to commodity price fluctuations so that gains and losses on the contracts offset changes in the commodity price over the relevant aggregate period. The company uses forward agreements, with durations of less than one year, to buy and sell USD-priced commodities in order to reduce its exposure to currency devaluation for a portion of its local currency cash balances. Counterparties to the forward sales agreements are multinational grain exporters and subject to the company's financial risk management procedures.

**Fair Value of Derivative Instruments**

Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Consolidated Balance Sheets. The presentation of the company's derivative assets and liabilities is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| *(In millions)* | *Balance Sheet Location* | *Gross* | *Counterparty and Cash Collateral Netting* <sup>1</sup> | *Net Amounts Included in the Interim Consolidated Balance Sheets* |
| **Asset derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | $5 | $— | $5 |
| &nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | 28 | (28) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Commodity contracts | Other current assets | 2 |  | 2 |
| &nbsp;&nbsp;&nbsp;Total asset derivatives |  | $35 | $(28) | $7 |
| **Liability derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | $24 | $— | $24 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | 153 | (28) | 125 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 3 |  | 3 |
| &nbsp;&nbsp;&nbsp;Total liability derivatives |  | $181 | $(28) | $153 |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| *(In millions)* | *Balance Sheet Location* | *Gross* | *Counterparty and Cash Collateral Netting* <sup>1</sup> | *Net Amounts Included in the Consolidated Balance Sheets* |
| **Asset derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | $5 | $— | $5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 1 |  | 1 |
| &nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | 23 | (21) | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 3 |  | 3 |
| &nbsp;&nbsp;&nbsp;Total asset derivatives |  | $32 | $(21) | $11 |
| **Liability derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | $1 | $— | $1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 3 |  | 3 |
| &nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | 40 | (21) | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 6 |  | 6 |
| &nbsp;&nbsp;&nbsp;Total liability derivatives |  | $50 | $(21) | $29 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| *(In millions)* | *Balance Sheet Location* | *Gross* | *Counterparty and Cash Collateral Netting* <sup>1</sup> | *Net Amounts Included in the Interim Consolidated Balance Sheets* |
| **Asset derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | $12 | $— | $12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Other current assets | 2 |  | 2 |
| &nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Other current assets | 101 | (58) | 43 |
| &nbsp;&nbsp;&nbsp;&nbsp; Commodity contracts | Other current assets | 5 |  | 5 |
| &nbsp;&nbsp;&nbsp;Total asset derivatives |  | $120 | $(58) | $62 |
| **Liability derivatives:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | $2 | $— | $2 |
| &nbsp;&nbsp;&nbsp;Derivatives not designated as hedging instruments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | Accrued and other current liabilities | 63 | (58) | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | Accrued and other current liabilities | 5 |  | 5 |
| &nbsp;&nbsp;&nbsp;Total liability derivatives |  | $70 | $(58) | $12 |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

*Effect of Derivative Instruments*

---

| | | |
|:---|:---|:---|
| | **Amount of Gain (Loss) Recognized in** <br>**OCI - Pre-Tax** <sup>1</sup> | **Amount of Gain (Loss) Recognized in** <br>**OCI - Pre-Tax** <sup>1</sup> |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Derivatives designated as hedging instruments: |  |  |
| &nbsp;&nbsp;&nbsp;Net investment hedges: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | $— | $10 |
| &nbsp;&nbsp;&nbsp;Cash flow hedges: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts | (32) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 27 | 2 |
| Total derivatives designated as hedging instruments | $(5) | $12 |

---

1. OCI is defined as other comprehensive income (loss).

---

| | | |
|:---|:---|:---|
| | **Amount of Gain (Loss) Recognized in Income - Pre-Tax** <sup>1</sup> | **Amount of Gain (Loss) Recognized in Income - Pre-Tax** <sup>1</sup> |
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Derivatives designated as hedging instruments: |  |  |
| &nbsp;&nbsp;&nbsp;Cash flow hedges: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts <sup>2</sup> | $— | $6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts <sup>2</sup> | (3) | (19) |
| Total derivatives designated as hedging instruments | $(3) | $(13) |
| Derivatives not designated as hedging instruments: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts <sup>3</sup> | $(152) | $20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency contracts <sup>2</sup> | (11) | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts <sup>2,4</sup> | 8 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts <sup>3</sup> |  |  |
| Total derivatives not designated as hedging instruments | $(155) | $18 |
| Total derivatives | $(158) | $5 |

---

1. For cash flow hedges, this represents the portion of the gain (loss) reclassified from accumulated OCI into income during the period.

2. Recorded in cost of goods sold in the interim Consolidated Statements of Operations.

3. Recognized in other income (expense) - net in the interim Consolidated Statements of Operations. Note that net gain (loss) from foreign currency contracts was partially offset by the related gain (loss) on the foreign currency-denominated monetary assets and liabilities of the company's operations. See Note 5 - Supplementary Information, to the interim Consolidated Financial Statements, for additional information.

4. The net gain (loss) relating to commodity contracts that are not designated as hedging instruments that were recorded in cost of goods sold, in the interim Consolidated Statements of Operations, are mostly offset by the related net gain (loss) on third-party grower contracts denominated as liabilities.

**Debt Securities**

The company held debt securities, which consisted of foreign government bonds classified as available-for-sale securities, at March 31, 2026, December 31, 2025 and March 31, 2025. The company's investments in available-for-sale securities are recorded at fair value with unrealized gains and losses recorded in accumulated other comprehensive income (loss), within the interim Consolidated Statements of Equity, or current period earnings if an allowance for credit losses has been established, within the interim Consolidated Statements of Operations.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Available-for-Sale Securities** | **Available-for-Sale Securities** | **Fair Value** | **Fair Value** | **Fair Value** |
| *(in millions)* | **Balance Sheet Location** | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| Foreign government bonds | Marketable securities <sup>1</sup> | $1 | $8 | $— |
| Foreign government bonds | Other assets <sup>2</sup> | $23 | $22 | $99 |

---

1. Maturity at time of purchase was more than three months to less than one year.

2. Maturity at time of purchase was more than one year.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

At March 31, 2026, available-for-sale debt securities with contractual maturities of less than one year and of one year through five years included gross unrealized gains (losses) of $— million and $1 million, respectively.

The estimated fair value of the available-for-sale securities as of March 31, 2026, December 31, 2025 and March 31, 2025 was determined using Level 2 inputs within the fair value hierarchy. Level 2 measurements were based on the end of period quoted closing market prices in active markets for identical assets and liabilities.

**NOTE 16 - FAIR VALUE MEASUREMENTS**

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

---

| | | | |
|:---|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
|<br>*(In millions)* | **Level 2** <sup>1</sup> | **Level 2** <sup>1</sup> | **Level 2** <sup>1</sup> |
| Assets at fair value: |  |  |  |
| &nbsp;&nbsp;&nbsp;Marketable securities | $1 | $1 | $1 |
| &nbsp;&nbsp;&nbsp;Debt securities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign government bonds <sup>2</sup> | 24 | 30 | 99 |
| &nbsp;&nbsp;&nbsp;Derivatives relating to: <sup>3</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency | 28 | 28 | 113 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 7 | 4 | 7 |
| Total assets at fair value | $60 | $63 | $220 |
| Liabilities at fair value: |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivatives relating to: <sup>3</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency | $177 | $41 | $63 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commodity contracts | 4 | 9 | 7 |
| Total liabilities at fair value | $181 | $50 | $70 |

---

1. Reflects significant other observable inputs.

2. Represents the company's investments in debt securities that are classified as available-for-sale, which are included in marketable securities and other assets in the interim Consolidated Balance Sheets.

3. See Note 15 - Financial Instruments, to the interim Consolidated Financial Statements, for the classification of derivatives in the interim Consolidated Balance Sheets.

**NOTE 17 - SEGMENT INFORMATION**

Corteva's reportable segments reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance, which is at the operating segment level (Seed and Crop Protection). The company's CODM is the Chief Executive Officer. The primary measure used by Corteva's CODM for purposes of allocating resources to the segments and assessing segment performance is segment operating EBITDA.

Segment operating EBITDA is primarily utilized in the annual planning and monthly forecasting processes. On a monthly basis, the CODM considers variances between comparable prior year actual results and current year actual or forecasted results when evaluating the company's success in delivering its innovative proprietary technology to farmers and monitoring of expected savings from cost and productivity actions. The CODM also utilizes segment operating EBITDA when evaluating the impacts of market-driven trends on segment performance, such as input costs and inflationary and currency impacts. The CODM does not use segment assets to inform resource allocation decisions or assess segment performance.

The company defines segment operating EBITDA as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the respective segment results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

---

| | | | |
|:---|:---|:---|:---|
| **As of and for the Three Months Ended March 31,**<br>*(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **2026** |  |  |  |
| Net sales | $3023 | $1882 | $4905 |
| Segment operating EBITDA | 1034 | 434 | 1468 |
| Depreciation and amortization | 192 | 105 | 297 |
| Purchases of property, plant and equipment | 51 | 30 | 81 |
| **2025** |  |  |  |
| Net sales | $2707 | $1710 | $4417 |
| Segment operating EBITDA | 842 | 377 | 1219 |
| Depreciation and amortization | 191 | 105 | 296 |
| Purchases of property, plant and equipment | 47 | 47 | 94 |

---

**Reconciliation of Segment Profitability**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **For the Three Months Ended March 31, 2026** |  |  |  |
| Net sales | $3023 | $1882 | $4905 |
| Cost of goods sold | 1306 | 1057 | 2363 |
| Other expenses <sup>1</sup>  | 683 | 391 | 1074 |
| Segment operating EBITDA | $1034 | $434 | $1468 |
| *(In millions)* | **Seed** | **Crop Protection** | **Total** |
| **For the Three Months Ended March 31, 2025**  |  |  |  |
| Net sales | $2707 | $1710 | $4417 |
| Cost of goods sold | 1275 | 1018 | 2293 |
| Other expenses <sup>1</sup> | 590 | 315 | 905 |
| Segment operating EBITDA | $842 | $377 | $1219 |

---

1.&nbsp;&nbsp;&nbsp;&nbsp;Other expenses consisted primarily of selling, general and administrative expenses and research and development expense, net of depreciation add-back.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**Reconciliation to Interim Consolidated Financial Statements**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Income (loss) from continuing operations after income taxes to segment operating EBITDA**<br>*(In millions)* | **2026** | **2025** |
| Income (loss) from continuing operations after income taxes | $725 | $667 |
| Provision for (benefit from) income taxes on continuing operations | 133 | 117 |
| Income (loss) from continuing operations before income taxes | $858 | $784 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 297 | 296 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (34) | (32) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 36 | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exchange (gains) losses - net | 67 | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating (benefits) costs - net | (18) | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges | 3 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Significant items (benefit) charge | 177 | 59 |
| &nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 52 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate expenses | 30 | 30 |
| Segment operating EBITDA | $1468 | $1219 |

---

**Significant Pre-tax (Charges) Benefits Not Included in Segment Operating EBITDA**

The three months ended March 31, 2026 and 2025, respectively, included the following significant pre-tax (charges) benefits which are excluded from segment operating EBITDA:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Corporate** | **Total** |
| **For the Three Months Ended March 31, 2026** |  |  |  |  |
| Restructuring and asset related charges - net <sup>1</sup> | $— | $(14) | $(78) | $(92) |
| Litigation settlement <sup>2</sup> |  | (85) |  | (85) |
| Total | $— | $(99) | $(78) | $(177) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(In millions)* | **Seed** | **Crop Protection** | **Corporate** | **Total** |
| **For the Three Months Ended March 31, 2025** |  |  |  |  |
| Restructuring and asset related charges - net <sup>1</sup> | $(3) | $(14) | $(5) | $(22) |
| AltEn facility remediation charges <sup>3</sup> | (37) |  |  | (37) |
| Total | $(40) | $(14) | $(5) | $(59) |

---

1. Includes restructuring plans and asset related charges. See Note 4 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements, for additional information.

2. Relates to a settlement charge associated with the Crop Protection loyalty program multi-district litigation plaintiffs. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information.

3. Relates to a charge to increase the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** 

**Cautionary Statements About Forward-Looking Statements**

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; the anticipated benefits, impacts, and timing of the Proposed Separation; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the company's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the company's business, results of operations and financial condition. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) effect of changes in agricultural and related policies of governments and international organizations; (vi) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vii) effect of climate change and unpredictable seasonal and weather factors; (viii) effect of competition in the company's industry; (ix) competitor's establishment of an intermediary platform for distribution of the company's products; (x) risks related to recent funding and staff reductions at U.S. government agencies; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in the company's input costs; (xiii) risks related to the company's global operations; (xiv) effect of industrial espionage and other disruptions to the company's supply chain, information technology or network systems; (xv) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the Corteva Separation; (xvi) impact of the company's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvii) failure of the company's customers to pay their debts to the company, including customer financing programs; (xviii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xix) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the company; (xx) increases in pension and other post-employment benefit plan funding obligations; (xxi) risks related to pandemics or epidemics; (xxii) capital markets sentiment towards sustainability matters; (xxiii) the company's intellectual property rights or defense against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) the company's dependence on intellectual property cross-license agreements; and (xxvi) risks related to Corteva's Separation from DowDuPont; and (xxvii) risks related to Corteva's Proposed Separation, including, but not limited to, whether the objectives of the proposed separation will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the proposed separation; the timing of any such separation or related action and whether any such separation will be consummated at all; the risk that the proposed separation could divert the attention and time of the company's management; the risk of any unexpected costs or expenses resulting from the proposed separation process or separation itself; and the risk of any litigation as a result of, or relating to, the Proposed Separation.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

looking statements is included in the "Risk Factors" section of Corteva's 2025 Annual Report, as modified by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

**Recent Developments**

***Proposed Separation***

On October 1, 2025, the company announced its intent to pursue, subject to the approval of the Board of Directors and any required regulatory approvals, its separation into two independent publicly traded companies - one for each of its Seed and Crop Protection businesses. The transaction is intended to be a tax-free spin-off for U.S. federal income tax purposes.

***2026 Restructuring Actions***

On March 15, 2026, management of the company approved a restructuring program designed to align the company's organizational structure and geographic footprint with the operational needs of each function as the company prepares for the intended separation of its businesses (the "2026 Restructuring Actions"). The restructuring actions primarily consist of workforce reductions across commercial and functional support areas and are intended to right-size the organization and support the future standalone operating models. The restructuring actions are expected to be substantially complete by December 2026.

The company expects to incur aggregate pre-tax restructuring and asset-related charges of approximately $70 million to $80 million in connection with the 2026 Restructuring Actions, consisting solely of severance and related benefit costs. Reductions in workforce are subject to local regulatory requirements. For the three months ended March 31, 2026, the company recorded pre-tax restructuring and asset-related charges of $78 million, which consist entirely of severance and related benefit costs and are classified as corporate-related charges. At March 31, 2026, the restructuring liability was $78 million.

The 2026 Restructuring Actions are expected to contribute to the company's ongoing cost and productivity improvement efforts through achieving an estimated $115 million to $125 million of savings on a run rate basis by 2027. See Note 4 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements, for further details.

**Overview**

The following is a summary of results from continuing operations for the three months ended March 31, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The company reported net sales of $4,905 million, up 11 percent versus the same quarter last year, reflecting a 6 percent increase in volume, a 4 percent favorable impact from currency and a 1 percent increase in price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cost of goods sold totaled $2,372 million in the first quarter of 2026, up from $2,342 million in the first quarter of 2025, which was driven by volume growth, with a partial offset from net cost and productivity benefits and net royalty improvement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Restructuring and asset related charges - net were $92 million in the first quarter of 2026, an increase from $22 million in the first quarter of 2025. The charges for the three months ended March 31, 2026 were primarily comprised of severance and related benefit costs associated with the 2026 Restructuring Actions, and contract termination charges and decommissioning and demolition costs associated with the Crop Protection Operations Strategy Restructuring Program.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Income (loss) from continuing operations after income taxes was $725 million, as compared to $667 million in the same quarter last year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating EBITDA was $1,438 million for the three months ended March 31, 2026, up from $1,189 million for the three months ended March 31, 2025, primarily driven by volume growth, pricing gains, net cost and productivity benefits, net royalty improvement and favorable currency effects, partially offset by higher selling expense and higher compensation. Refer to the company's non-GAAP financial measures for further discussion.

In addition to the financial highlights above, the following event occurred during the three months ended March 31, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The company returned approximately $370 million to shareholders during the three months ended March 31, 2026 under its previously announced share repurchase programs and through common stock dividends.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Results of Operations**

**Net Sales** 

Net sales were $4,905 million and $4,417 million for the three months ended March 31, 2026 and 2025, respectively. The increase was primarily driven by a 6 percent increase in volume, a 4 percent favorable impact from currency and a 1 percent increase in price.

Improvements in volume, with gains in all regions, were driven by Crop Protection due to strong demand for new products, while Seed experienced volume growth in North America from seasonal timing shifts in seed deliveries. The improvement in pricing, led by Seed, was driven by favorable product mix and continued execution on the company's price for value strategy, while a decline in Crop Protection pricing due to competitive market dynamics in Latin America served as an offset. The favorable currency impacts were led by the Euro and Brazilian Real.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
|  | Net Sales<br>*($ Millions)* | % | Net Sales<br>*($ Millions)* | % |
| Worldwide | $4905 | 100% | $4417 | 100% |
| &nbsp;&nbsp;&nbsp;North America <sup>1</sup> | 2439 | 50% | 2210 | 50% |
| &nbsp;&nbsp;&nbsp;EMEA <sup>2</sup> | 1655 | 34% | 1477 | 33% |
| &nbsp;&nbsp;&nbsp;Latin America | 506 | 10% | 442 | 10% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 305 | 6% | 288 | 7% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Q1 2026 vs. Q1 2025** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
|<br>($ In millions) | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| North America <sup>1</sup> | 10% | 1% | 9% | —% | —% |
| EMEA <sup>2</sup> | 12% | 2% | 2% | 8% | —% |
| Latin America | 14% | (2)% | 6% | 10% | —% |
| Asia Pacific | 6% | 1% | 4% | 1% | —% |
| **Total** | 11% | 1% | 6% | 4% | —% |

---

1. Represents U.S. & Canada.

2. Europe, Middle East and Africa ("EMEA").

**Cost of Goods Sold ("COGS")**

COGS was $2,372 million (48 percent of net sales) and $2,342 million (53 percent of net sales) for the three months ended March 31, 2026 and 2025, respectively, which was driven by volume growth, with a partial offset from lower input costs and net cost and productivity benefits.

**Research and Development Expense ("R&D")**

R&D expense was $341 million (7 percent of net sales) and $335 million (8 percent of net sales) for the three months ended March 31, 2026 and 2025, respectively. The increase in R&D expense is in support of the company's long-term investment plans and was primarily driven by unfavorable currency impacts and increases in salaries, depreciation, and field, lab and facilities costs, partially offset by cost recoveries received from third parties.

**Selling, General and Administrative Expenses ("SG&A")**

SG&A expenses were $877 million (18 percent of net sales) and $751 million (17 percent of net sales) for the three months ended March 31, 2026 and 2025, respectively. The change was primarily driven by unfavorable currency impacts and an increase in bad debt expense, variable compensation, commissions, consulting fees, and personnel and information technology costs.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Amortization of Intangibles**

Intangible asset amortization was $160 million and $162 million for the three months ended March 31, 2026 and 2025, respectively. See Note 10 - Other Intangible Assets, to the interim Consolidated Financial Statements, for additional information.

**Restructuring and Asset Related Charges - Net** 

Restructuring and asset related charges - net were $92 million and $22 million for the three months ended March 31, 2026 and 2025, respectively. The charges in the first quarter of 2026 primarily relate to severance and related benefits costs associated with the 2026 Restructuring Actions, and contract termination charges and decommissioning and demolition costs associated with the Crop Protection Operations Strategy Restructuring Program. The charges in the first quarter of 2025 primarily relate to charges associated with the Crop Protection Operations Strategy Restructuring Program, consisting of severance and related benefit costs, asset related charges, and decommissioning and demolition costs.

See Note 4 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements, for additional information.

**Other Income (Expense) - Net**

Other income (expense) - net was $(117) million and $15 million for the three months ended March 31, 2026 and 2025, respectively. Higher other expense was driven by an increase in net exchange losses compared to prior year and higher miscellaneous expenses, which are largely driven by a settlement charge associated with the Crop Protection loyalty program multi-district litigation plaintiffs and tax expense related to intellectual property realignment.

See Note 5 - Supplementary Information, to the interim Consolidated Financial Statements, for additional information.

**Interest Expense**

Interest expense was $36 million and $36 million for the three months ended March 31, 2026 and 2025, respectively. The results reflect lower short-term borrowings offset by higher interest for long-term debt.

**Provision for (Benefit from) Income Taxes on Continuing Operations**

The company's provision for income taxes on continuing operations was $133 million for the three months ended March 31, 2026 on pre-tax income from continuing operations of $858 million, resulting in an effective tax rate of 15.5 percent. The effective tax rate was favorably impacted by $35 million of net tax benefits related to intellectual property realignment, as well as $47 million of net tax benefits associated with changes in deferred taxes and accruals for certain prior year tax positions. Those favorable impacts were partially offset by withholding taxes on repatriation of cash held outside of the U.S. primarily from current year earnings.

The company's provision for income taxes on continuing operations was $117 million for the three months ended March 31, 2025 on pre-tax income from continuing operations of $784 million, resulting in an effective tax rate of 14.9 percent. The effective tax rate was favorably impacted by a $55 million deferred tax benefit associated with a change in a legal entity's U.S. tax characterization, as well as net tax benefits associated with changes in accruals for certain prior year tax positions. Those favorable impacts were partially offset by withholding taxes on repatriation of cash held outside of the U.S. primarily from current year earnings.

**Income (Loss) from Discontinued Operations After Tax**

Income (loss) from discontinued operations after tax was $(2) million and $(11) million for the three months ended March 31, 2026 and 2025, respectively. The after-tax charge for the three months ended March 31, 2026 and 2025 was driven by charges recognized relating to the MOU with Chemours and DuPont, relating to PFAS environmental remediation activities primarily at Chemours' Fayetteville Works facility, along with other environmental matters.

Refer to Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information.

**EIDP Analysis of Operations**

As discussed in EIDP Note 1 - Basis of Presentation, to the EIDP interim Consolidated Financial Statements, EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. There were no differences in the components of net income on the respective Corteva and EIDP interim Consolidated Statements of Operations.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Recent Accounting Pronouncements**

See Note 2 - Recent Accounting Guidance, to the interim Consolidated Financial Statements, for a description of recent accounting pronouncements.

**Segment Reviews**

The company operates in two reportable segments: Seed and Crop Protection.

*Seed*

The company's Seed segment is a global leader in developing and supplying commercial seed combining superior germplasm with advanced traits to produce high yield potential for farmers around the world. The segment offers seed and trait technologies that improve resistance to weather, diseases, pests and herbicides used to manage weeds. Its digital solutions provide data driven insights that assist farmer decision-making with a view to optimize product selection and, ultimately, help maximize yield and profitability. The segment competes in a wide variety of agricultural markets.

*Crop Protection*

The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment offers crop protection solutions and digital solutions that provide farmers the tools they need to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The segment is a leader in global herbicides, insecticides, nitrogen stabilizers, pasture and range management herbicides and biologicals.

Summarized below are comments on individual segment net sales and segment operating EBITDA for the three months ended March 31, 2026, compared with the same period in 2025. The company defines segment operating EBITDA as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. See Note 17 - Segment Information, to the interim Consolidated Financial Statements, for details related to significant pre-tax benefits (charges) excluded from segment operating EBITDA. All references to prices are based on local price unless otherwise specified.

A reconciliation of segment operating EBITDA to income (loss) from continuing operations after income taxes for the three months ended March 31, 2026 and 2025 is included in Note 17 - Segment Information, to the interim Consolidated Financial Statements.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Seed**<br>*(In millions)* | **2026** | **2025** |
| Net sales | $3023 | $2707 |
| Segment operating EBITDA  | $1034 | $842 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Q1 2026 vs. Q1 2025** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Seed**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;North America | 11% | 2% | 9% | —% | —% |
| &nbsp;&nbsp;&nbsp;EMEA | 12% | 4% | 1% | 7% | —% |
| &nbsp;&nbsp;&nbsp;Latin America | 21% | 8% | —% | 13% | —% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 2% | 7% | (3)% | (2)% | —% |
| **Total** | 12% | 3% | 6% | 3% | —% |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Q1 2026 vs. Q1 2025** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Seed**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;Corn | 15% | 4% | 7% | 4% | —% |
| &nbsp;&nbsp;&nbsp;Soybeans | —% | 1% | (2)% | 1% | —% |
| &nbsp;&nbsp;&nbsp;Other oilseeds | 10% | 5% | 1% | 4% | —% |
| &nbsp;&nbsp;&nbsp;Other | (10)% | (10)% | (3)% | 3% | —% |
| **Total** | 12% | 3% | 6% | 3% | —% |

---

**Seed** 

Seed net sales were $3,023 million in the first quarter of 2026, up 12 percent from $2,707 million in the first quarter of 2025. The sales increase over the prior period was driven by a 6 percent increase in volume, a 3 percent increase in price, and a 3 percent favorable impact from currency.

Price gains in all regions demonstrate demand for top technology and the strength of the portfolio. Volume increases in North America and EMEA are due to timing shifts and favorable weather in the northern hemisphere. Favorable currency impacts were led by the Euro.

Segment operating EBITDA was $1,034 million in the first quarter of 2026, up 23 percent from $842 million in first quarter of 2025. Volume, price execution, net cost and productivity benefits, and net royalty improvement more than offset higher selling expense and compensation. Segment operating EBITDA margin improved by approximately 310 basis points versus the prior-year period.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| **Crop Protection**<br>*(In millions)* | **2026** | **2025** |
| Net sales | $1882 | $1710 |
| Segment Operating EBITDA  | $434 | $377 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Q1 2026 vs. Q1 2025** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
| **Crop Protection**<br>*($ In millions)* | **Net Sales Change**<br>$**%** | **Price &**<br>**Product Mix** |<br>**Volume** |<br>**Currency** | **Portfolio /**<br>**Other** |
| &nbsp;&nbsp;&nbsp;North America | 9% | —% | 8% | 1% | —% |
| &nbsp;&nbsp;&nbsp;EMEA | 12% | (1)% | 3% | 10% | —% |
| &nbsp;&nbsp;&nbsp;Latin America | 10% | (9)% | 10% | 9% | —% |
| &nbsp;&nbsp;&nbsp;Asia Pacific | 8% | (3)% | 9% | 2% | —% |
| **Total** | 10% | (2)% | 6% | 6% | —% |
| **Crop Protection** | **Q1 2026 vs. Q1 2025** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** | **Percent Change Due To:** |
|  | **Net Sales Change** | **Price &** |  |  | **Portfolio /** |
| *($ In millions)* | $**%** | **Product Mix** | **Volume** | **Currency** | **Other** |
| &nbsp;&nbsp;&nbsp;Herbicides | 19% | (1)% | 14% | 6% | —% |
| &nbsp;&nbsp;&nbsp;Insecticides | 12% | (3)% | 11% | 4% | —% |
| &nbsp;&nbsp;&nbsp;Fungicides | 10% | (1)% | 3% | 8% | —% |
| &nbsp;&nbsp;&nbsp;Biologicals | (17)% | (4)% | (17)% | 4% | —% |
| &nbsp;&nbsp;&nbsp;Other | (41)% | (2)% | (36)% | (3)% | —% |
| **Total** | 10% | (2)% | 6% | 6% | —% |

---

**Crop Protection** 

Crop Protection net sales were $1,882 million in the first quarter of 2026, up 10 percent from $1,710 million in the first quarter of 2025. The sales increase over the prior period was driven by a 6 percent increase in volume and a 6 percent favorable impact from currency, partially offset by a 2 percent decrease in price.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

Volume improvement was driven by demand for new products and spinosyns, coupled with timing shifts in North America and EMEA. Price declines, primarily in Latin America and Asia Pacific, are due to continued competitive market dynamics in those regions. Favorable currency impacts were led by the Euro and Brazilian Real..

Segment operating EBITDA was $434 million in the first quarter of 2026, up 15 percent from $377 million in the first quarter of 2025. Volume growth, productivity savings, and favorable currency more than offset price pressure, higher selling expense and a charge related to intellectual property realignment. Segment operating EBITDA margin improved by approximately 100 basis points versus the prior-year period.

**Non-GAAP Financial Measures**

The company presents certain financial measures that do not conform to U.S. GAAP and are considered non-GAAP measures. These measures include Operating EBITDA and operating earnings (loss) per share. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the company and a more useful comparison of year over year results. These non-GAAP measures supplement the company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided below.

Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

The company also uses Free Cash Flow as a non-GAAP measure to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. Management believes that Free Cash Flow provides investors with meaningful information regarding the company's ongoing ability to generate cash through core operations, and the company's ability to service its indebtedness, pay dividends (when declared), make share repurchases, and meet its ongoing cash needs for its operations.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Reconciliation of Income (Loss) from Continuing Operations after Income Taxes to Operating EBITDA**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Income (loss) from continuing operations after income taxes **(GAAP)** | $725 | $667 |
| Provision for (benefit from) income taxes on continuing operations | 133 | 117 |
| **Income (loss) from continuing operations before income taxes (GAAP)** | $858 | $784 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 297 | 296 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (34) | (32) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 36 | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exchange (gains) losses - net | 67 | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating (benefits) costs - net | (18) | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges | 3 | 9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Significant items (benefit) charge | 177 | 59 |
| &nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 52 |  |
| **Operating EBITDA (Non-GAAP)** | $1438 | $1189 |

---

**Significant Items** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Restructuring and asset related charges - net | $(92) | $(22) |
| Litigation settlement <sup>1</sup> | (85) |  |
| AltEn facility remediation charges <sup>2</sup> |  | (37) |
| **Total pre-tax significant items benefit (charge)** | $(177) | $(59) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total tax (provision) benefit impact of significant items <sup>3</sup> | 42 | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax only significant item benefit (charge) <sup>4</sup> |  | 55 |
| **Total significant items benefit (charge), after tax** | $(135) | $10 |

---

1. Relates to a settlement charge associated with the Crop Protection loyalty program multi-district litigation plaintiffs. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information.

2. Relates to a charge to increase the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans. See Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for additional information.

3. Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

4. The tax only significant item benefit for the three months ended March 31, 2025 reflects a deferred tax benefit associated with a change in a legal entity's U.S. tax characterization.

**Reconciliation of Income (Loss) from Continuing Operations Attributable to Corteva and Earnings (Loss) Per Share of Common Stock from Continuing Operations - Diluted to Operating Earnings (Loss) and Operating Earnings (Loss) Per Share**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Income (loss) from continuing operations attributable to Corteva common stockholders **(GAAP)** | $722 | $663 |
| Less: Non-operating benefits (costs), after tax | (1) | (8) |
| Less: Amortization of intangibles (existing as of Corteva Separation), after tax | (106) | (109) |
| Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax | (3) | (7) |
| Less: Significant items benefit (charge), after tax | (135) | 10 |
| Less: Separation costs, after tax | (42) |  |
| **Operating Earnings (Loss) (Non-GAAP)** | $1009 | $777 |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Earnings (loss) per share of common stock from continuing operations attributable to Corteva common stockholders - diluted **(GAAP)** | $1.07 | $0.97 |
| Less: Non-operating benefits (costs), after tax |  | (0.01) |
| Less: Amortization of intangibles (existing as of Corteva Separation), after tax | (0.16) | (0.16) |
| Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax | (0.01) | (0.01) |
| Less: Significant items benefit (charge), after tax | (0.20) | 0.02 |
| Less: Separation costs, after tax | (0.06) |  |
| **Operating Earnings (Loss) Per Share (Non-GAAP)** | $1.50 | $1.13 |
| **Diluted Shares Outstanding** *(In millions)* | 673.6 | 686.6 |

---

**Liquidity and Capital Resources** 

Information related to the company's liquidity and capital resources can be found in the company's 2025 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity & Capital Resources. The discussion below provides the updates to this information for the three months ended March 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| *(In millions)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| **Cash, cash equivalents and marketable securities** | $1966 | $4530 | $2009 |
| **Total debt** | $3356 | $2580 | $4083 |

---

The increase in debt balances from December 31, 2025 was primarily due to higher short-term debt, which was used to fund the company's working capital needs, capital spending, dividend payments and share repurchases. See further information in Note 11 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, to the interim Consolidated Financial Statements.

The company believes its ability to generate cash from operations and access to capital markets and commercial paper markets will be adequate to meet anticipated cash requirements to fund its operations, including seasonal working capital, capital spending, dividend payments, share repurchases, pension obligations and litigation costs, net of recoveries. Corteva's strong financial position, liquidity and credit ratings will provide access as needed to capital markets and commercial paper markets to fund seasonal working capital needs. The company's liquidity needs can be met through a variety of sources, including cash provided by operating activities, commercial paper, syndicated credit lines, bilateral credit lines, long-term debt markets, bank financing and committed receivable repurchase facilities. Corteva considers the borrowing costs and lending terms when selecting the source to fund its operations and working capital needs.

The company had access to approximately $6.7 billion, $6.2 billion and $6.1 billion at March 31, 2026, December 31, 2025 and March 31, 2025, respectively, in committed and uncommitted unused credit lines, which includes the uncommitted revolving credit lines relating to the foreign currency loans. These facilities provide support to meet the company's short-term liquidity needs and for general corporate purposes, which may include funding of discretionary and non-discretionary contributions to certain benefit plans, severance payments, repayment and refinancing of debt, working capital, capital expenditures, repurchases and redemptions of securities, acquisitions and Corteva's costs and expenses, including the settlement of litigation and environmental remediation. These facilities are provided to the company by highly rated and well capitalized global financial institutions.

In June 2024, the Revolving Credit Facilities were refinanced for purposes of extending the maturity dates for the five-year and three-year revolving credit facilities to June 2029 and June 2027, respectively, and lowering the facility amount of the five-year revolving credit facility to $2.85 billion and the three-year revolving credit facility to $1.90 billion. Borrowings under the Revolving Credit Facilities will have an interest rate equal to Adjusted Term SOFR, which is Term SOFR plus 0.10 percent, plus the applicable margin. The Revolving Credit Facilities may serve as a substitute to the company's commercial paper program, and can be used, from time to time, for general corporate purposes including, but not limited to, the funding of seasonal working capital needs. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the Revolving Credit Facilities contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

Corteva and its consolidated subsidiaries not exceed 0.60. At March 31, 2026, the company was in compliance with these covenants.

In February 2026, the company amended its January 2023 (as amended in July 2023, January 2024, February 2024 and February 2025) 364-day revolving credit agreement (the "364-Day Revolving Credit Facility"), increasing the facility amount from $750 million to $1.25 billion, extending the expiration date to February 2027 and amending the interest rate to Term SOFR plus the applicable margin. In February 2025, the company amended the 364-Day Revolving Credit Facility, decreasing the facility amount from $1 billion to $750 million and extending the expiration date to February 2026. The 364-Day Revolving Credit Facility includes a provision under which the company may convert any advances outstanding prior to the maturity date into term loans having a maturity date up to one year later. The 364-Day Revolving Credit Facility contains customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the 364-Day Revolving Credit Facility contains a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At March 31, 2026, the company was in compliance with these covenants.

In May 2025, the company issued $500 million of 5.125 percent Senior Notes due in May 2032 (the "May 2025 Debt Offering"). The proceeds were used to repay the $500 million senior notes that matured in July 2025.

The company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations affecting manufacturing plants, mineral producing properties or research facilities located in the U.S. and the consolidated subsidiaries owning such plants, properties and facilities subject to certain limitations. The outstanding long-term debt also contains customary default provisions.

The company has meaningful seasonal working capital needs based in part on providing financing to its customers. Working capital is funded through multiple methods including cash, commercial paper, the Revolving Credit Facilities, the 364-Day Revolving Credit Facility, and factoring.

The company has factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds in an effort to reduce its receivables risk. For arrangements that include an element of recourse, the company provides a guarantee of the trade receivables in the event of customer default. Refer to Note 8 - Accounts and Notes Receivable - Net, to the interim Consolidated Financial Statements, for more information.

The company also organizes agreements with third-party financial institutions who directly provide financing for select customers of the company's Seed and Crop Protection products in each region. Terms of the third-party loans are less than a year and programs are renewed on an annual basis. In some cases, the company guarantees a portion of the extension of such credit to such customers. Refer to Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for more information on the company's guarantees.

In establishing the future capital structures of the two independent companies expected to be created through the Proposed Separation, the company evaluated making discretionary contributions to its principal U.S. pension plan. In April 2026, the Board of Directors approved a contribution to the principal U.S. pension plan of approximately $1.5 billion to be made on or before July 31, 2026. The company continues to expect both companies at separation to have strong balance sheets and investment grade credit ratings.

The company's cash, cash equivalents and marketable securities at March 31, 2026, December 31, 2025 and March 31, 2025 are $2.0 billion, $4.5 billion and $2.0 billion, respectively, of which $1.6 billion, $2.1 billion and $1.7 billion at March 31, 2026, December 31, 2025 and March 31, 2025, respectively, was held by subsidiaries in foreign countries, including United States territories. Cash, cash equivalents and marketable securities are concentrated subject to local restrictions with highly rated and well capitalized global financial institutions. The underlying credit worthiness and exposures to these counterparties are monitored on a regular basis in line with the company's overall risk management procedures. Upon actual repatriation, such earnings could be subject to withholding taxes, foreign and/or U.S. state income taxes, and taxes resulting from the impact of foreign currency movements. The cash held by foreign subsidiaries is generally used to finance the subsidiaries' operational activities and future foreign investments. At March 31, 2026, management believed that sufficient liquidity is available in the U.S. with global operating cash flows, borrowing capacity from existing committed credit facilities, and access to capital markets and commercial paper markets.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

*Summary of Cash Flows* 

Cash provided by (used for) operating activities - continuing operations was $(2,885) million for the three months ended March 31, 2026 compared to $(2,101) million for the three months ended March 31, 2025. The change was driven by the Bayer resolution payment, higher compensation payments, and lower customer prepayments partially offset by improved collections.

Cash provided by (used for) operating activities - discontinued operations was $(6) million for the three months ended March 31, 2026 compared to $(8) million for the three months ended March 31, 2025. The cash outflows were primarily related to PFAS activities that are subject to the MOU with Chemours and DuPont associated with environmental remediation activities primarily at Chemours' Fayetteville Works facility, along with litigation matters.

Cash provided by (used for) investing activities was $(77) million for the three months ended March 31, 2026 compared to $(34) million for the three months ended March 31, 2025. The change was primarily driven by lower proceeds from sales and maturities of investments.

Cash provided by (used for) financing activities was $389 million for the three months ended March 31, 2026 compared to $995 million for the three months ended March 31, 2025. The change was primarily due to lower short-term debt borrowings due to higher cash on-hand at the beginning of the period.

In January 2026, the company's Board of Directors authorized a common stock dividend of $0.18 per share, payable on March 16, 2026, to the shareholders of record on March 2, 2026. In April 2026, the company's Board of Directors authorized a common stock dividend of $0.18 per share, payable on June 15, 2026, to the shareholders of record on June 1, 2026.

On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2024 Share Buyback Plan"). The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. In connection with the 2024 Share Buyback Plan, the company repurchased and retired 3,190,000 shares in the open market for a total cost (excluding excise taxes) of $250 million during the three months ended March 31, 2026.

On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2022 Share Buyback Plan"). The timing, price and volume of purchases were based on market conditions, relevant securities laws and other factors. The company completed the 2022 Share Buyback Plan during the second quarter of 2025 and repurchased and retired 7,815,000, 17,909,000, and 10,026,000 shares in the open market and through privately-negotiated transactions for a cost (excluding excise taxes) of $500 million, $1 billion and $500 million during the years ended December 31, 2025, 2024 and 2023, respectively.

For the first half of 2026, the company expects repurchases of approximately $500 million under the 2024 Share Buyback Plan discussed above. The total amount, timing, manner, price and volume of purchases will be based on market conditions, relevant securities laws and other market and company specific factors.

See Note 13 - Stockholders' Equity, to the interim Consolidated Financial Statements, for additional information related to the share buyback plans.

**EIDP Liquidity Discussion**

As discussed in EIDP Note 1 - Basis of Presentation, to the EIDP interim Consolidated Financial Statements, EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The discussion below relates to EIDP only and is presented to provide a Liquidity discussion for the differences between EIDP and Corteva, Inc.

Beginning in the third quarter of 2025, the Board of Directors of EIDP authorizes and declares a quarterly dividend to Corteva, Inc., from which the proceeds are intended to be used to fund Corteva, Inc. share repurchases and common stock dividends during the subsequent quarter.

**Cash provided by (used for) operating activities - continuing operations**

EIDP's cash provided by (used for) operating activities - continuing operations was $(2,885) million and $(2,101) million for the three months ended March 31, 2026 and 2025, respectively. The change was primarily driven by the items noted above, in the section entitled "Summary of Cash Flows."

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Cash provided by (used for) operating activities - discontinued operations**

EIDP's cash provided by (used for) operating activities - discontinued operations was $(6) million and $(8) million for the three months ended March 31, 2026 and 2025, respectively. The change was primarily driven by the items noted above, in the section entitled "Summary of Cash Flows."

**Cash provided by (used for) investing activities**

EIDP's cash provided by (used for) investing activities was $(77) million and $(34) million for the three months ended March 31, 2026 and 2025, respectively. The change was primarily driven by the items noted above, in the section entitled "Summary of Cash Flows."

**Cash provided by (used for) financing activities**

EIDP's cash provided by (used for) financing activities was $389 million and $995 million for the three months ended March 31, 2026 and 2025, respectively. The change was primarily driven by the items noted above, in the section entitled "Summary of Cash Flows," as well as the issuance of cash dividends by EIDP to Corteva, Inc. during the first quarter of 2026.

*Guarantees and Off-Balance Sheet Arrangements*

For detailed information related to Guarantees, Indemnifications, and Obligations for Equity Affiliates and Others, see the company's 2025 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Off-Balance Sheet Arrangements and Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

**Contractual Obligations** 

Information related to the company's contractual obligations at December 31, 2025 can be found in the section entitled "Contractual Obligations" on the company's 2025 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. There have been no material changes to the company's contractual obligations outside the ordinary course of business from those reported in the company's 2025 Annual Report.

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** 

See Note 15 - Financial Instruments, to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the company's 2025 Annual Report, for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Item 4. CONTROLS AND PROCEDURES** 

**Corteva, Inc.**

a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of March 31, 2026, the company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in Internal Control over Financial Reporting

There have been no changes in the company's internal control over financial reporting that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

**EIDP, Inc.** 

a)&nbsp;&nbsp;&nbsp;&nbsp; Evaluation of Disclosure Controls and Procedures

EIDP maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in EIDP's reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of March 31, 2026, EIDP's CEO and CFO, together with management, conducted an evaluation of the effectiveness of EIDP's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b)&nbsp;&nbsp;&nbsp;&nbsp; Changes in Internal Control over Financial Reporting

There have been no changes in EIDP's internal control over financial reporting that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, EIDP's internal control over financial reporting.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**PART II. OTHER INFORMATION**

**Item 1. LEGAL PROCEEDINGS**

The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva's current businesses but allocated to Corteva as part of the Corteva Separation from DuPont.

Often these proceedings raise complex factual and legal issues, which are subject to risks and uncertainties and which could require significant amounts of the senior leadership team's time. Litigation and other claims, along with regulatory proceedings, against the company could also materially adversely affect its operations, reputation, and/or result in the incurrence of unexpected expenses and liability. Even when the company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the company, including avoidance of future distraction and litigation defense cost, and its shareholders. Information regarding certain of these matters is set forth below and in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

**Litigation related to Corteva's current businesses**

*Inari Disputes*

On September 27, 2023, Corteva filed a lawsuit in Delaware federal court against Inari Agriculture, Inc. and Inari Agriculture N.V. (collectively "Inari") asserting claims of Plant Variety Protection infringement, indirect patent infringement, breach of contract, and civil conversion. Corteva's lawsuit alleges Inari illegally obtained various varieties of seed technologies from a seed depository and illegally transported them abroad for the purpose of performing gene editing on the technologies and then filing a patent for such technologies. In August 2024, the court denied Inari's motion to dismiss the complaint. In September 2024, Corteva amended its complaint to include additional infringement claims with respect to soybean and corn technologies. In May 2025, the federal court dismissed Inari's claims of sham litigation, patent misuse, and state-based deceptive trade practices claims. This May 2025 order was amended to reinstate Inari's estoppel defense. The trial is expected to begin in the second half of 2026.

*Bayer Disputes*

Corteva resolved its outstanding litigation with Bayer. Further information with respect to these proceedings and their respective resolution is set forth under "Bayer Disputes" in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

*Other Matters*

Further information with respect to litigation matters related to Corteva's current business is set forth under "Federal Trade Commission Investigation" and "Lorsban® Lawsuits" in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

**Litigation related to legacy EIDP businesses unrelated to Corteva's current businesses**

As discussed below and in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, certain of the environmental proceedings and litigation allocated to Corteva as part of the Separation from DuPont relate to the legacy EIDP businesses, including their use of PFOA, which, for purposes of this report, means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs"). This litigation includes multiple natural resource damage lawsuits across the United States filed by municipalities and alleging PFOA contamination, as well as, lawsuits by four municipalities in the Netherlands alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours.

In addition to the matters set forth in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, on March 25, 2019, the New Jersey Department of Environmental Protection ("NJDEP") issued a Statewide PFAS Directive to several companies, including Chemours, DuPont, and EIDP. The Directive seeks information relating to the use and environmental release of PFAS and PFAS-replacement chemicals at and from two former EIDP sites in New Jersey, Chambers Works and Parlin, and a funding source for costs related to the NJDEP's investigation of PFAS issues and PFAS testing and remediation. This matter will be resolved upon the court's approval of the NJ Statewide Settlement described in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Other Environmental Proceedings**

The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The matters below involve the potential for $1 million or more in monetary fines and are included per Item 103(3)(c)(iii) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

*Related to Corteva's current businesses* 

*Nebraska Department of Environment and Energy, AltEn Facility*

The EPA and the Nebraska Department of Environment and Energy ("NDEE") are pursuing investigations, response and removal actions, litigation and enforcement action related to an ethanol plant located near Mead, Nebraska and owned and operated by AltEn LLC ("AltEn"). Corteva is one of six seed companies, who were customers of AltEn (collectively, the "Facility Response Group"), participating in the NDEE's Voluntary Cleanup Program to address certain interim remediation needs at the site. Further information with respect to these proceedings is set forth under "Nebraska Department of Environment and Energy, AltEn Facility" in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

*AZ Concordia Chile Site*

On February 9, 2026, a water reservoir at the AZ Concordia site overflowed during a refilling, resulting in the collapse of part of the embankment and the release of all stored water beyond Corteva's facilities resulting in flooding and other damage impacting government-managed infrastructure and wastewater systems. Corteva is working with local authorities on the resolution of matters related to this incident.

*Related to legacy EIDP businesses unrelated to Corteva's current businesses*

*Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection*

In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC ("Denka") neoprene manufacturing facility in La Place, Louisiana. EIDP sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. In the spring of 2017, the EPA, the DOJ, the Louisiana Department of Environmental Quality, EIDP and Denka began discussions relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. In March 2025, the EPA and DOJ dismissed the action against Denka and EIDP. Following the dismissal, a private action mirroring the government's original claims was filed, as well as adding allegations of violations of the U.S. Resource Conservation and Recovery Act and U.S. Clean Water Act. Under the Separation Agreement, DuPont is defending and indemnifying the company in this matter.

*New Jersey Directive Pompton Lakes* 

On March 27, 2019, the NJDEP issued to Chemours and EIDP a Natural Resource Damages Directive relating to chemical contamination (non-PFAS) at and around EIDP's former Pompton Lakes facility in New Jersey. The Directive alleges that this contamination has harmed the natural resources of New Jersey. It seeks $125,000 as reimbursement for the cost of preparing a natural resource damages assessment, which the State will use to determine the extent of such damage and the amount it expects to seek to restore the affected natural resources to their pre-damage state. This matter will be resolved upon the court's approval of the NJ Statewide Settlement described in Note 12 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

*EPA CERCLA Claim*

In April 2024, the U.S. Environmental Protection Agency ("EPA") also designated PFOA and PFAS as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"). In November 2024, the EPA issued a letter to DuPont, EIDP and Corteva asserting CERCLA claims related to alleged PFAS contamination from six historical and present DuPont and Chemours sites and providing a demand for cleanup and restoration costs. In September 2025, the EPA announced its intent to retain the designation of PFOA and PFOS as CERCLA hazardous substances. Discussions among the parties are ongoing.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Item 1A. RISK FACTORS** 

There have been no material changes in the company's risk factors discussed in Part I, Item 1A, Risk Factors, in the company's most recently filed 2025 Annual Report.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

**Issuer Purchases of Equity Securities**

The following table summarizes information with respect to the company's purchase of its common stock during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Month** | **Total Number of Shares Purchased** | **Average Price <br>Paid per Share** | **Total Number of** <br>**Shares Purchased as Part of the Company's Publicly Announced Share Buyback Program** <sup>1</sup> | **Approximate Value** <br>**of Shares that May** <br>**Yet Be Purchased** <br>**Under the Program** <sup>1</sup> ***(Dollars in millions)*** |
| January 2026 |  | $— |  | $2430 |
| February 2026 | 1494622 | 76.58 | 1494622 | 2316 |
| March 2026 | 1695413 | 79.93 | 1695413 | 2180 |
| Total | 3190035 | $78.36 | 3190035 | $2180 |

---

1. On November 19, 2024, Corteva, Inc. announced that its Board of Directors authorized a $3 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Item 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**Item 5. OTHER INFORMATION**

None.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**Item 6. EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| [2.1](https://www.sec.gov/Archives/edgar/data/1755672/000119312519106808/d615112dex21.htm) | Separation and Distribution Agreement by and among DowDuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit No. 2.1 to Amendment 3 to Corteva's Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019). |
| [3.1](https://www.sec.gov/Archives/edgar/data/0001755672/000175567224000010/certificateofincorporation.htm) | Amended and Restated Certificate of Incorporation of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva's Current Report on Form 8-K (Commission file number 001-38710), filed on May 2, 2024). |
| [3.2](https://www.sec.gov/Archives/edgar/data/1755672/000119312522310161/d768701dex31.htm) | Amended and Restated Bylaws of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva's Current Report on Form 8-K (Commission file number 001-38710), filed on December 21, 2022). |
| [3.3](https://www.sec.gov/Archives/edgar/data/30554/000175567223000011/exhibit33.htm) | Amended and Restated Certificate of Incorporation of EIDP, Inc. (incorporated by reference to Exhibit No. 3.3 to Corteva's and EIDP's Quarterly Report on Form 10-Q (Commission file numbers 001-38710 and 001-00815), filed on May 4, 2023). |
| [3.4](https://www.sec.gov/Archives/edgar/data/30554/000119312517274840/d438565dex32.htm) | Amended and Restated Bylaws of EIDP, Inc. (incorporated by reference to Exhibit 3.2 to EIDP's Current Report on Form 8-K (Commission file number 001-00815) dated September 1, 2017). |
| 4 | Corteva agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of Corteva and its subsidiaries. |
| [10.1](exhibit101-employmentagree.htm) | Employment Agreement between Corteva, Inc. and Luke Kissam, dated April 10, 2026. |
| [10.2](exhibit102-formofrestricte.htm) | Form of Restricted Stock Unit Agreement |
| [10.3](exhibit103-formofperforman.htm) | Form of Performance Stock Unit Agreement |
| [10.4](exhibit104-formofrestricte.htm) | Form of Restricted Stock Unit Agreement for Directors |
| [10.5](https://www.sec.gov/Archives/edgar/data/30554/000175567224000013/exhibit102.htm) | Form of Option Agreement |
| [10.6](https://www.sec.gov/Archives/edgar/data/1755672/000119312519138437/d615112dex105.htm) | Corteva, Inc. 2019 Omnibus Incentive Plan. (incorporated by reference to Exhibit No. 10.5 to Corteva's Registration Statement on Form 10 (Commission file number 001-38710), filed on May 6, 2019). |
| [10.7](https://www.sec.gov/Archives/edgar/data/1755672/000119312520287000/d826078dex43.htm) | Corteva, Inc. Global Omnibus Employee Stock Purchase Plan (incorporated by reference from Exhibit 4.3 to Corteva's Registration Statement on Form S-8 (Commission file number 333-249887), filed November 5, 2020). |
| [31.1](corteva-3312026xex311.htm) | Rule 13a-14(a)/15d-14(a) Certification of the company's and EIDP's Principal Executive Officer. |
| [31.2](corteva-3312026xex312.htm) | Rule 13a-14(a)/15d-14(a) Certification of the company's and EIDP's Principal Financial Officer. |
| [32.1](corteva-3312026xex321.htm) | Section 1350 Certification of the company's and EIDP's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. |
| [32.2](corteva-3312026xex322.htm) | Section 1350 Certification of the company's and EIDP's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended. |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File – The Cover Page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101.INS) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**SIGNATURE**

**Corteva, Inc.** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Corteva, Inc. | Corteva, Inc. |
| (Registrant) | (Registrant) |
| Date: | May 6, 2026 |
| By: | /s/ Brian Titus |
|  | Brian Titus |
|  | Vice President, Controller |
|  | (Principal Accounting Officer) |

---

**EIDP, Inc.**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| EIDP, Inc. | EIDP, Inc. |
| (Registrant) | (Registrant) |
| Date: | May 6, 2026 |
| By: | /s/ Brian Titus |
|  | Brian Titus |
|  | Vice President, Controller |
|  | (Principal Accounting Officer) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**EIDP, Inc.**

**Index to the Consolidated Financial Statements**

---

| | |
|:---|:---|
| | Page(s) |
| Consolidated Financial Statements (Unaudited): |  |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Operations](#iac468d4684194d39b58ae26bdb6a0a0b_211) | [61](#iac468d4684194d39b58ae26bdb6a0a0b_211) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Comprehensive Income (Loss)](#iac468d4684194d39b58ae26bdb6a0a0b_214) | [62](#iac468d4684194d39b58ae26bdb6a0a0b_214) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Balance Sheets](#iac468d4684194d39b58ae26bdb6a0a0b_217) | [63](#iac468d4684194d39b58ae26bdb6a0a0b_217) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Cash Flows](#iac468d4684194d39b58ae26bdb6a0a0b_223) | [64](#iac468d4684194d39b58ae26bdb6a0a0b_223) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Consolidated Statements of Equity](#iac468d4684194d39b58ae26bdb6a0a0b_226) | [65](#iac468d4684194d39b58ae26bdb6a0a0b_226) |
| &nbsp;&nbsp;&nbsp;&nbsp;[Notes to the Interim Consolidated Financial Statements (Unaudited)](#iac468d4684194d39b58ae26bdb6a0a0b_232) | [66](#iac468d4684194d39b58ae26bdb6a0a0b_232) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**CONSOLIDATED FINANCIAL STATEMENTS OF EIDP, Inc.**

**EIDP, Inc.**

**Consolidated Statements of Operations (Unaudited)** 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended <br>March 31,** | **Three Months Ended <br>March 31,** |
|<br>*(In millions, except per share amounts)* | **2026** | **2025** |
| Net sales | $4905 | $4417 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 2372 | 2342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense | 341 | 335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 877 | 751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangibles | 160 | 162 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 92 | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separation costs | 52 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) - net | (117) | 15 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 36 | 36 |
| Income (loss) from continuing operations before income taxes | 858 | 784 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) income taxes on continuing operations | 133 | 117 |
| Income (loss) from continuing operations after income taxes | 725 | 667 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from discontinued operations after income taxes | (2) | (11) |
| Net income (loss) | 723 | 656 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to noncontrolling interests | 1 | 1 |
| Net income (loss) attributable to EIDP, Inc. | $722 | $655 |

---

See Notes to the EIDP Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**EIDP, Inc.**

**Consolidated Statements of Comprehensive Income (Loss) (Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| Net income (loss) | $723 | $656 |
| Other comprehensive income (loss) - net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustments | (129) | 186 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to pension benefit plans | (4) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to other benefit plans | (3) | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on investments | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative instruments | (8) | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) | (143) | 198 |
| Comprehensive income (loss) | 580 | 854 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income (loss) attributable to noncontrolling interests - net of tax | 1 | 1 |
| Comprehensive income (loss) attributable to EIDP, Inc. | $579 | $853 |

---

See Notes to the EIDP Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**EIDP, Inc.**

**Consolidated Balance Sheets (Unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| *(In millions, except share amounts)* | **March 31, 2026** | **December 31, 2025** | **March 31, 2025** |
| **Assets** |  |  |  |
| Current assets |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $1964 | $4521 | $2008 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 2 | 9 | 1 |
| &nbsp;&nbsp;&nbsp;Accounts and notes receivable - net | 9088 | 6371 | 8294 |
| &nbsp;&nbsp;&nbsp;Inventories | 5202 | 5667 | 5132 |
| &nbsp;&nbsp;&nbsp;Other current assets | 1129 | 767 | 1152 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 17385 | 17335 | 16587 |
| Investment in nonconsolidated affiliates | 165 | 160 | 136 |
| Property, plant and equipment | 9617 | 9551 | 9244 |
| Less: Accumulated depreciation | 5434 | 5331 | 5139 |
| Net property, plant and equipment | 4183 | 4220 | 4105 |
| Goodwill | 10409 | 10465 | 10332 |
| Other intangible assets | 8147 | 8301 | 8718 |
| Deferred income taxes | 395 | 320 | 413 |
| Other assets | 2033 | 2044 | 1832 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $42717 | $42845 | $42123 |
| **Liabilities and Equity** |  |  |  |
| Current liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;Short-term borrowings | $1674 | $894 | $2291 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 4187 | 4398 | 3905 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 229 | 155 | 322 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 2773 | 3579 | 2631 |
| &nbsp;&nbsp;&nbsp;Accrued and other current liabilities | 3369 | 3223 | 2321 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 12232 | 12249 | 11470 |
| Long-term debt | 1682 | 1686 | 1792 |
| Other noncurrent liabilities |  |  |  |
| &nbsp;&nbsp;&nbsp;Deferred income tax liabilities | 290 | 251 | 369 |
| &nbsp;&nbsp;&nbsp;Pension and other post-employment benefits | 2388 | 2434 | 2239 |
| &nbsp;&nbsp;&nbsp;Other noncurrent obligations | 1898 | 1963 | 1715 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total noncurrent liabilities | 6258 | 6334 | 6115 |
| Commitments and contingent liabilities |  |  |  |
| Stockholders' equity |  |  |  |
| Preferred stock, without par value – cumulative; 23,000,000 shares authorized; issued at March 31, 2026, December 31, 2025, and March 31, 2025: |  |  |  |
| &nbsp;&nbsp;&nbsp;$4.50 Series – 1,673,000 shares (callable at $120) | 169 | 169 | 169 |
| &nbsp;&nbsp;&nbsp;&nbsp;$3.50 Series – 700,000 shares (callable at $102) | 70 | 70 | 70 |
| Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200 issued at March 31, 2026, December 31, 2025, and March 31, 2025 |  |  |  |
| Additional paid-in capital | 24624 | 24610 | 24497 |
| Retained earnings (accumulated deficit) | 2300 | 2207 | 3070 |
| Accumulated other comprehensive income (loss) | (2940) | (2797) | (3271) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total EIDP, Inc. stockholders' equity | 24223 | 24259 | 24535 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 4 | 3 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 24227 | 24262 | 24538 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Equity | $42717 | $42845 | $42123 |

---

See Notes to the EIDP Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**EIDP, Inc.**

**Consolidated Statements of Cash Flows (Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|<br>*(In millions)* | **2026** | **2025** |
| **Operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $723 | $656 |
| &nbsp;&nbsp;&nbsp;(Income) loss from discontinued operations after income taxes | 2 | 11 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 297 | 296 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) deferred income tax | (52) | (122) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension and OPEB (benefit) cost, net | (3) | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and OPEB contributions | (48) | (51) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net (gain) loss on sales of property, businesses, consolidated companies, and investments | 3 | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset related charges - net | 92 | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other net loss | 157 | 75 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable | (2810) | (2505) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 439 | 379 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (221) | (190) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (790) | (667) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (674) | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - continuing operations | (2885) | (2101) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities - discontinued operations | (6) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) operating activities | (2891) | (2109) |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (81) | (94) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of property, businesses, and consolidated companies - net of cash divested |  | 8 |
| &nbsp;&nbsp;&nbsp;Investments in and loans to nonconsolidated affiliates | (3) |  |
| &nbsp;&nbsp;&nbsp;Proceeds from sales and maturities of investments | 8 | 62 |
| &nbsp;&nbsp;&nbsp;Other investing activities, net | (1) | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) investing activities | (77) | (34) |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net change in borrowings (less than 90 days) | 521 | 745 |
| &nbsp;&nbsp;&nbsp;Net payments from (advances to) Parent on in-house banking arrangement |  | 129 |
| &nbsp;&nbsp;&nbsp;Proceeds from debt | 268 | 637 |
| &nbsp;&nbsp;&nbsp;Payments on debt | (22) | (14) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of stock options | 17 | 35 |
| &nbsp;&nbsp;&nbsp;Dividends paid to Parent | (371) | (513) |
| &nbsp;&nbsp;&nbsp;Other financing activities, net | (24) | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by (used for) financing activities | 389 | 995 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (5) | 21 |
| &nbsp;&nbsp; Increase (decrease) in cash, cash equivalents and restricted cash equivalents | (2584) | (1127) |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 4725 | 3422 |
| **Cash, cash equivalents and restricted cash equivalents at end of period** | $2141 | $2295 |

---

See Notes to the EIDP Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**EIDP, Inc.**

**Consolidated Statements of Equity (Unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Preferred Stock* | *Common Stock* | *Additional Paid-in Capital* | *Due from Parent* | *Retained Earnings (Accum. Deficit)* | *Accum. <br>Other Comp. Income (Loss)* | *Non-Controlling Interests* | *Total Equity* |
| **2026** |  |  |  |  |  |  |  |  |
| Balance at January 1, 2026 | $239 | $— | $24610 | $— | $2207 | $(2797) | $3 | $24262 |
| Net income (loss) |  |  |  |  | 722 |  | 1 | 723 |
| Other comprehensive income (loss) |  |  |  |  |  | (143) |  | (143) |
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) |  |  |  |  | (2) |  |  | (2) |
| Issuance of Corteva stock |  |  | 17 |  |  |  |  | 17 |
| Share-based compensation |  |  | (2) |  |  |  |  | (2) |
| Dividend to Parent |  |  |  |  | (627) |  |  | (627) |
| Other - net |  |  | (1) |  |  |  |  | (1) |
| Balance at March 31, 2026 | $239 | $— | $24624 | $— | $2300 | $(2940) | $4 | $24227 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *(In millions)* | *Preferred Stock* | *Common Stock* | *Additional Paid-in Capital* | *Due from Parent* | *Retained Earnings (Accum. Deficit)* | *Accum. Other Comp. Income (Loss)* | *Non-Controlling Interests* | *Total Equity* |
| **2025** |  |  |  |  |  |  |  |  |
| Balance at January 1, 2025 | $239 | $— | $24464 | $(129) | $2930 | $(3469) | $2 | $24037 |
| Net income (loss) |  |  |  |  | 655 |  | 1 | 656 |
| Other comprehensive income (loss) |  |  |  |  |  | 198 |  | 198 |
| Due from Parent |  |  |  | 129 |  |  |  | 129 |
| Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) |  |  |  |  | (3) |  |  | (3) |
| Issuance of Corteva stock |  |  | 35 |  |  |  |  | 35 |
| Share-based compensation |  |  | (2) |  |  |  |  | (2) |
| Dividend to Parent |  |  |  |  | (513) |  |  | (513) |
| Other - net |  |  |  |  | 1 |  |  | 1 |
| Balance at March 31, 2025 | $239 | $— | $24497 | $— | $3070 | $(3271) | $3 | $24538 |

---

See Notes to the EIDP Interim Consolidated Financial Statements.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

---

| |
|:---|
| **EIDP, Inc.** |
| **Notes to the Interim Consolidated Financial Statements (Unaudited)** |

---

**Table of Contents**

---

| | | |
|:---|:---|:---|
| **Note** | | **Page** |
| 1 | [Basis of Presentation](#iac468d4684194d39b58ae26bdb6a0a0b_235) | [67](#iac468d4684194d39b58ae26bdb6a0a0b_235) |
| 2 | [Related Party Transactions](#iac468d4684194d39b58ae26bdb6a0a0b_238) | [67](#iac468d4684194d39b58ae26bdb6a0a0b_238) |

---

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

**NOTE 1 - BASIS OF PRESENTATION**

Corteva, Inc. owns 100 percent of the outstanding common stock of EIDP. EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The primary differences between Corteva, Inc. and EIDP are outlined below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Preferred Stock** - EIDP has preferred stock outstanding to third parties which is accounted for as a non-controlling interest at the Corteva, Inc. level. Each share of EIDP Preferred Stock - $4.50 Series and EIDP Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EIDP and was unaffected by the Corteva Distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Master In-House Banking Agreement** - A Master In-House Banking Agreement exists to which EIDP is a party, along with Corteva and certain consolidated subsidiaries, as more fully described in EIDP Note 2 - Related Party Transactions, to the EIDP interim Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Dividends -** The Board of Directors of EIDP authorizes and declares a quarterly dividend to Corteva, Inc., from which the proceeds are intended to be used to fund Corteva, Inc. share repurchases and common stock dividends during the subsequent quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Capital Structure** - At March 31, 2026, Corteva, Inc.'s capital structure consists of 670,044,000 issued shares of common stock, par value $0.01 per share.

The accompanying footnotes relate to EIDP only, and not to Corteva, Inc., and are presented to show differences between EIDP and Corteva, Inc.

For the footnotes listed below, refer to the following footnotes of the Corteva interim Consolidated Financial Statements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 1 - Summary of Significant Accounting Policies

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 2 - Recent Accounting Guidance

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 3 - Revenue

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 4 - Restructuring and Asset Related Charges - Net

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 5 - Supplementary Information

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 6 - Income Taxes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 7 - Earnings Per Share of Common Stock - Not applicable for EIDP

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 8 - Accounts and Notes Receivable - Net

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 9 - Inventories

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 10 - Other Intangible Assets

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 11 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 12 - Commitments and Contingent Liabilities

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 13 - Stockholders' Equity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 14 - Pension Plans and Other Post Employment Benefits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 15 - Financial Instruments

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 16 - Fair Value Measurements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Note 17 - Segment Information

**NOTE 2 - RELATED PARTY TRANSACTIONS**

**Transactions with Corteva**

EIDP and Corteva, including certain consolidated subsidiaries (collectively the "Participating Companies"), are party to a Master In-House Banking Agreement, which established banking arrangements to facilitate the management of the cash and liquidity needs of the Participating Companies.

In February and March 2026, the Board of Directors of EIDP authorized and declared cumulative dividends of $627 million to Corteva, Inc., from which the proceeds are intended to be used to fund Corteva, Inc. share repurchases and common stock dividends during the first and second quarters of 2026. As of March 31, 2026, EIDP had a dividend payable to Corteva, Inc. of $390 million.

For the three months ended March 31, 2026, EIDP declared cash dividends to Corteva, Inc. amounting to $627 million, of which $371 million were paid to Corteva, Inc. during the period. For the three months ended March 31, 2025, EIDP declared cash dividends to Corteva, Inc. amounting to $513 million, all of which were paid to Corteva, Inc. during the period.

------

<u>[**Table of Contents**](#iac468d4684194d39b58ae26bdb6a0a0b_7)</u>

**NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

As of March 31, 2026, December 31, 2025 and March 31, 2025, EIDP had payables to Corteva, Inc. of $28 million, $27 million and $17 million included in accrued and other current liabilities, respectively, and $103 million, $154 million and $149 million included in other noncurrent obligations, respectively, in the interim Consolidated Balance Sheets related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements (refer to the section entitled "Guarantees" of Note 15 - Commitments and Contingent Liabilities, to the interim Corteva Consolidated Financial Statements, for further details of the Separation Agreements).

## Exhibit 10.1

**Exhibit 10.1**

![imagea.jpg](imagea.jpg)

April 10, 2026

Luther "Luke" Kissam

Dear Luke:

Corteva, Inc. (the <u>"Company")</u> is pleased to offer you employment on the terms described in this letter agreement (this <u>"Agreement").</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.**<u>Term.</u>** The term of this Agreement and your employment with the Company is expected to begin on June 1, 2026 (your first day of employment, the <u>"Hire Date")</u> and will continue until your employment terminates for any reason, except that the provisions of this Agreement will survive the termination of your employment as is necessary to give effect to their express terms. You will become an employee of Corteva, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.**<u>Title and Role.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.From your Hire Date until the spinoff of the Company's Seed business (currently anticipated, but not guaranteed, to occur on October 1, 2026) you will serve as Chief Executive Officer of the Crop Protection Business Unit, reporting directly to Chuck Magro.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Immediately after the spinoff of the Company's Seed business, you will serve as Chief Executive Officer of Corteva, Inc., reporting directly to the Board of Directors of the Company (the "Board"). In such role, you will be the most senior executive of the Company to whom all other executives and employees of the Company report, directly or indirectly, and will have all the duties and authorities customarily associated therewith. Promptly after the spinoff of the Company's Seed business, the Board will appoint you to become a member of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.You will devote substantially all your business time and attention to your duties hereunder, except for approved vacation and time-off periods and reasonable periods of illness or other incapacities permitted by the Company's general employment policies. Nothing in this Agreement will prohibit or restrict you from engaging in civic, charitable or religious activities or sitting on non-profit boards, in each case, provided such endeavors or service do not materially interfere with your obligations under this Agreement. You agree that prior to your Hire Date, you will no longer serve as a director on the board of directors of DuPont. In addition, you will not join the board of directors of any for-profit company without the prior approval of the Board; provided that you will not serve on more than one public company board in addition to the Board.

------

**Exhibit 10.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.**<u>Location.</u>** Your primary work location will be at the Company's corporate headquarters in the United States. The Company is still in the process of determining the post-separation headquarters of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.**<u>Base Salary.</u>** You will receive a base salary at the annual rate of USD1,200,000, payable in accordance with the Company's regular payroll practices.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.**<u>Annual Cash Bonus.</u>** With respect to each calendar year, you will be eligible to receive an annual cash bonus under the Company's Performance Reward Program (an "Annual Bonus"). Your target Annual Bonus opportunity each calendar year will be equal to 150% of your annual base salary, except that your target Annual Bonus opportunity for 2026 will be prorated based on the Hire Date. Your right to payment of each Annual Bonus will be conditioned on the Board's certifying the achievement of the goals established for the applicable calendar year and on your continued employment at the time of the bonus payment. Payment of any earned Annual Bonus for a calendar year will be made no later than March 15th of the following calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.**<u>Annual Equity Awards.</u>** With respect to each calendar year beginning with 2027, you will be eligible to participate in the long-term incentive and equity plans of the Company with a target grant date value (determined using the Company's customary methodology) of USD7,500,000. The type of awards granted to you each year, and the other terms and conditions thereof, will be determined by the Board (or an appropriate committee thereof) and will be subject to the applicable terms and conditions of the Company's 2019 Omnibus Incentive Plan, but will be consistent with the grants awarded to other senior executives of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.**<u>One-Time Off-Cycle LTI Award.</u>** You will receive a USD3,750,000 off-cycle 2026 annual award on your Hire Date (50% PSU / 50% RSU). Additional details will be provided in the Award Terms, which you will receive after the awards have been granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.**<u>Benefit Plans.</u>** You will be eligible to participate in (a) the Company's Retirement Savings Plan, Retirement Savings Restoration Plan, Management Deferred Compensation Plan and (b) the Company's standard employee benefit programs (including health and welfare) made available to other U.S. senior management employees, including the executive health program and executive financial management program, in each case, subject to the terms and conditions of such programs. You will be eligible to receive up to twenty (20) days of Choice Time in each calendar year (except that your Choice Time for 2026 will be prorated based on the Hire Date) and certain paid holidays. The Company reserves the right to amend any benefit plans or programs in accordance with their terms. For the avoidance of doubt, your participation in such programs will be on a basis that is no less favorable than any other senior executive of the Company. In addition, the Company will reimburse you for documented business expenses properly incurred by you on behalf of the Company in accordance with the Company's applicable business expense reimbursement policies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.**<u>Relocation Assistance.</u>** You will receive domestic relocation assistance in accordance with the Company's standard relocation policies (not eligible for guaranteed buyout or loss of sale benefits); provided that (a) as a condition to such assistance, you must provide the applicable documentation of any reimbursable expense no later than January 30 of the year following the year in which such expense was incurred, (b) all reimbursements will be made no later than March 15 of the year following the year in which the applicable expense was incurred, (c) upon

------

**Exhibit 10.1**

your termination of employment for any reason, you will cease to be eligible for or receive any such assistance (other than reimbursement for expenses incurred prior to such termination) and (d) the aggregate value of all allowances and reimbursements made to you will not exceed USD750,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.**<u>Termination of Employment; Severance.</u>** You agree that your employment with the Company is not for any specific duration or period of time and that you are an employee at-will. Your employment may be terminated at any time by you or the Company, with or without cause and with or without notice. Notwithstanding the foregoing, effective as of the Hire Date, you will participate in the Company's Change in Control and Executive Severance Plan, as in effect from time to time, as the "CEO" (as defined therein), which will govern the termination of your employment and any payments or benefits to which you may be entitled as a result thereof. You are eligible under the plan to be eligible for certain severance protections upon a Qualifying Termination, which includes either termination of employment by the Company without cause or Good Reason, which has the meaning assigned to such term or an analogous term in any individual service, employment or severance agreement or Award Agreement with the Participant or, if no such agreement exists or if such agreement does not define "Good Reason" or an analogous term, then "Good Reason" shall mean (i) a material diminution in the Participant's base compensation, (ii) a material diminution in the Participant's authority, duties, or responsibilities, or (iii) a material change in the geographic location at which the Participant must perform his/her services for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.**<u>Other Matters.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.You acknowledge and agree that, as a condition of your employment hereunder, you will execute and deliver the Company's standard employee agreement, in the form attached hereto as <u>Schedule A,</u> to be effective as of the Hire Date. In addition, you acknowledge and agree that you will comply with any ongoing confidentiality or other restrictive covenant obligations that you may have with any former employer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.You will be entitled to the same director and officer indemnification provided to other executive officers pursuant to the Company's Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws. In addition, you will be provided coverage under the Company's director and officer insurance policy on the same basis as the other executive officers of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.You acknowledge and agree that you are subject to the Company's policies for executives and for employees generally, as amended from time to time, including, without limitation, the Company's insider trading policy, stock ownership policy, compensation recovery policy and code of ethics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Following the termination of your employment with the Company, you acknowledge and agree that you will cooperate with requests of the Company regarding any legal matters or proceedings of any kind, which will include making yourself available for interviews or testimony if reasonably requested by the Company. The Company will reimburse you for any reasonable expenses incurred in connection with such requests or assistance if approved by the Company and supported by required documentation. No payment made to you hereunder is intended to be or will be interpreted as payment for any particular testimony or assistance with respect to the legal matters specified above or any other matter. You understand that you are to provide your good faith assistance and agree to provide truthful responses to any requests for information or testimony.

------

**Exhibit 10.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.As is customary, this offer is contingent upon: (i) successful completion of pre-employment screening, including a drug screen and background check. In some instances, a medical evaluation or other required screening must be successfully completed within Corteva's guidelines, (ii) presentation of sufficient document(s) to complete the I-9 Employment Eligibility Verification establishing your identity and employment eligibility as required by the Immigration Reform and Control Act of 1986 which makes it unlawful for an employer to hire an individual not authorized for employment in the U.S. Please see link for acceptable documentation: https://www.uscis.gov/i-9-central/acceptable-documents), (iii) completion of the Company Director's Officer and Officers Questionnaire and confirmation that you are free of conflicts of interest, and (iv) certification that you have read and will comply with the Company's Code of Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.**<u>Miscellaneous.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.**<u>Governing Law.</u>** The validity, interpretation, construction and performance of this Agreement, and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto will be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. Unless otherwise prohibited by law, you and the Company agree to have any disputes arising out of this Agreement resolved in a forum having a substantial body of law and experience, so both you and the Company agree that any action or proceeding arising out of this Agreement will be brought exclusively in the state or federal courts of Delaware and both you and the Company further agree to the personal jurisdiction of those courts. Both you and the Company waive any objection that either party may now or later have to the venue of any such action in such court(s), and further both you and the Company waive any claim that either party may now or later have that any action brought in such court(s) has been brought in an inconvenient forum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.**<u>Entire Agreement.</u>** This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes all prior or contemporaneous discussions, understandings, term sheets and agreements, whether oral or written, between you and the Company relating to the subject matter hereof. No amendment, modification or change to this Agreement will be enforceable unless reduced to writing and executed by both you and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.**<u>Taxes.</u>** All amounts payable to you hereunder will be subject to any applicable tax withholdings or deductions. This Agreement is intended to comply with Section 409A of the Internal Revenue Code <u>("Section 409A")</u> or an exemption thereunder and will be construed and administered in accordance with Section 409A. Payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. For purposes of Section 409A, each installment payment provided under this Agreement will be treated as a separate payment. Any payments to be made under this Agreement that constitute "deferred compensation" within the mention of Section 409A upon a termination of employment will only be made upon a "separation from service" within the meaning of Section 409A. To the extent required under Section 409A, amounts that would otherwise be payable under this Agreement during the six (6) month period immediately following Employee's separation from service shall instead be paid on the first business day after the date that is six (6) months following Employee's separation from service (or, if earlier, Employee's date of death). Any reimbursements of expenses or in-kind benefits provided under this Agreement that are not otherwise exempt from Section 409A will comply with the requirements of Treasury Regulation Section l.409A-3(i)(l)(iv) (or successor provisions). The amount of any such expenses reimbursed, or benefits provided during one taxable year will not

------

**Exhibit 10.1**

affect the amount of expenses eligible for payment or reimbursement in any other taxable year. Any such expenses reimbursed, or benefits provided will be made on or before the last day of your taxable year following the taxable year in which the expense was incurred. Any such right to reimbursement or benefits is not subject to liquidation or exchange for any other benefit. In the event of non-compliance with Section 409A, Employee shall be responsible for the payment of taxes, penalties, interest or other expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.**<u>Successors and Assigns.</u>** This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.

To indicate your acceptance of this Agreement, please sign and date this Agreement in the space provided below.

Very truly yours,

CORTEVA, lNC.

By:<u>/s/ Gregory R. Page</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gregory R. Page

Chair, Corteva Board of Directors

ACCEPTED AND AGREED:

By:<u>/s/ Luke Kissam</u>

Luke Kissam

------

**Exhibit 10.1**

<u>Schedule A</u>

**<u>EMPLOYEE AGREEMENT</u>**

This is my Employee Agreement ("Agreement") with Corteva, Inc. and its affiliated, subsidiary, and successor companies (the "Company").

In consideration for my employment with the Company, and the financial and other benefits I receive from that employment, the Company and I agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.**<u>Employment at Will:</u>** My employment with the Company is not for any specific duration or period of time, and I am an employee at-will of the Company. This means that the employment relationship between the Company and me may be terminated by either of us at any time, with or without cause and with or without notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.**<u>Application of Agreement to Affiliates, Subsidiaries, and/or Successors</u> <u>and Changes in Position:</u>** This Agreement and my commitments under it will apply with and are assigned by the Company to its affiliates, subsidiaries, or successors in connection with my work for or employment with those affiliates, subsidiaries, or successors. I understand that this Agreement will continue to apply even as my job duties and compensation change during my employment. All references in this Agreement to "the Company" apply equally to any affiliated or successor entity by which I am employed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.**<u>Duty of Loyalty:</u>** During my employment with the Company, I will devote my full work time, energy, and best efforts to the business of the Company. I will avoid conflicts of interest, comply with the Company's policies, and its Code of Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.**<u>Inventions and Discoveries:</u>** I will promptly identify and fully disclose to the Company's HR and/or Legal Intellectual Property Function all inventions, copyright eligible works, ideas, improvements, software, discoveries, and other intellectual property that I develop, discover, or create that: (i) relate to the Company's business, or to any actual or demonstrably anticipated research, future work, or projects of the Company, whether or not conceived or developed alone or with others, and whether or not conceived or developed during regular working hours; or (ii) result from any work that I have performed for the Company, performed on Company time, or performed using the Company's property or resources. These works and materials described in subsections (i) and (ii) of this Section 4(a) are referred to as "Company Inventions and Intellectual Property." All Company Inventions and Intellectual Property, and the rights to them, moral and otherwise, are and will remain as the Company's exclusive property unless otherwise agreed by both me and the Company in writing. While employed, and as necessary after my employment ends, I agree that I will assist the Company in obtaining patents or copyrights on all Company Inventions and Intellectual Property that that Company seeks to protect and execute all documents and do everything requested of me to assist the Company in pursuing and securing the complete benefits of Company's Inventions and Intellectual Property. I hereby assign to the Company or its designee all rights, title, and interest to all Company Inventions or Intellectual Property that I have conceived, developed, discovered, or created or will develop, discover or create in the future during my employment or association with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)I represent and warrant that I have disclosed to the Company all intellectual property in which I had an ownership interest *prior to* the commencement of my employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)To the extent that the state law where I reside requires it, this is my notice that no provision in this Agreement requires me to assign any of my rights to an invention for which no

------

**Exhibit 10.1**

equipment, supplies, facility, or Confidential Information of the Company was used and which was developed entirely on my own time, unless: (i) the invention relates at the time of conception, or reduction to practice of the invention, to the business of the Company or to the Company's actual or demonstrably anticipated research or development; or (ii) the invention results from any work performed by me for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **<u>Confidential Information:</u>**

I acknowledge that during my employment with the Company, I will come into contact with and learn various forms of Confidential Information and Trade Secrets, as defined below, which are the property of the Company. Confidential Information and Trade Secrets are items of information relating to the Company that are of great competitive value to the Company, which may be disclosed to me or of which I may become aware because of my relationship with the Company, which are not generally known or available to the general public or the Company's competitors, and which have been developed, compiled, or acquired by the Company at its great effort and expense. **"Confidential Information"** includes, but is not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)financial and business information,<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)product and technical information,<sup>2</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)marketing information,<sup>3</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)customer and prospective customer information,<sup>4</sup> and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)employees, contractors, and consultants' skills and abilities, and other personnel information.<sup>5</sup>

 <u><br></u>

<sup>1</sup> Some examples of financial and business information include information with respect to costs, commissions, fees, profits, sales, sales margins, capital structure, operating results, borrowing arrangements, strategies and plans for future business, pending projects and proposals, and potential acquisitions or divestitures.

<sup>2</sup> Some examples of product and technical information include new and innovative ideas, research and development projects, investigations, new business development, trademarks and brand names under development, sketches, plans, drawings, prototypes, methods, procedures, manufacturing processes, sourcing, experimental and testing results, devices, machines, equipment, data processing programs, software, software codes, and computer models.

<sup>3</sup> Some examples of marketing information include new marketing ideas, strategies, initiatives, business plans, markets, and mailing lists.

<sup>4</sup> Some examples of customer information include the identity of the Company's customers and prospective customers, their names, the names of representatives of the Company's customers and prospective customers responsible for entering into contracts with the Company, the financial arrangements between the Company and its customers, the existence and terms of contracts with customers or any future contracts with customers or prospective customers, specific needs, requirements, and preferences of customers, and leads and referrals to certain prospective customers.

<sup>5</sup> Examples of personnel information may include the identity and number of the Company's employees, consultants, and contractors; contractor or consultant billing rates; qualifications; and performance metrics.

------

**Exhibit 10.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;**<u>"Trade Secrets"</u>** are a subset of Confidential Information that meet the requirements of applicable federal and/or state trade secret law. Confidential Information and Trade Secrets can be in any form, including, without limitation, oral, written, machine readable, or digital.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Throughout my employment with the Company and at all times following the end of my employment, whether voluntary or involuntary: (i) I will hold all Confidential Information and Trade Secrets in the strictest confidence, take all reasonable precautions to prevent inadvertent disclosure to any unauthorized person, and follow all Company policies protecting Confidential Information and Trade Secrets; (ii) I will not, directly or indirectly, use, disclose, or make available to any other person or entity any Confidential Information or Trade Secrets other than in the proper performance of my duties during my employment with the Company; and (iii) I will not use the Company's Confidential Information or Trade Secrets to attempt to solicit, induce, recruit, or take away clients or customers of the Company. **I understand and acknowledge that my confidentiality obligations will terminate only if and when the Confidential Information or Trade Secrets in question become generally known to the public through no wrongful act by me or others who are under confidentiality obligations.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Agreement prohibits me from disclosing information in connection with the exercise of any legally protected right. I am not prevented from filing a charge with or participating, testifying, or assisting in any investigation, hearing, whistleblowing proceeding, or other proceeding before any federal, state, or local government agency. Also, under the federal Defend Trade Secrets Act of 2016, I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to the attorney defending me in a lawsuit for retaliation against me for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **<u>Return of Company Property:</u>** Immediately, or as soon as practicable, upon the end of my employment or at any time the Company requests, I agree to return to the Company any and all property belonging to it that is in my possession or under my control.<sup>6</sup>

 <u><br></u>

6 Examples of Company property include, without limitation, all computers and computer equipment; office equipment; phones provided by the Company; vehicles and keys assigned to me by the Company; office keys, passes, and passcards; documents (whether in hard copy of electronic form), books, and notebooks; and computer files, databases, programs, thumb drives, external drives, disks, and computer access codes.

------

**Exhibit 10.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **<u>Post-Employment Covenants:</u>** In addition to my ongoing confidentiality obligations in Section 5, I agree to the following covenants that will survive the end of my employment with the Company **("Post-Employment Covenants").**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;**<u>Non-Competition Covenant:</u>** The Company is engaged in a highly competitive global business, and I understand and acknowledge that through my position and responsibilities in the Company, I may gain business knowledge such that if I engage in a business that directly competes with the Company, it may cause the Company great and irreparable harm. Therefore, subject to any state or local law, or rule, that may apply to me, I agree that for a period of one (1) year after my employment with the Company ends, whether it ends voluntarily or involuntarily, the Company has the right, in its sole discretion, to require that I not directly or indirectly perform for any Competing Business the same or similar duties that I performed for the Company7 during the two (2) years preceding the end of my employment **("Exercise the Non-Compete"** or **"Exercise of Non-Compete").** A "Competing Business" means any individual or entity that develops, manufactures, sells, and/or distributes a product or service that competes with those products or services offered or under development by the Company. Although the Company conducts business globally, this Non-Competition Covenant will apply only to those regions, states and territories of the United States of America, and, if applicable, those countries of the world outside of the United States of America, in which I was employed or had responsibility within the last two (2) years of my employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;**<u>Notice to Company:</u>** During and for the one (I) year period following the end of my employment, whether voluntary or involuntary, I must provide written notice to the Company of any offers of employment that I intend to accept, including the name of the potential new employer and a description of the role that I have been offered. This information shall be submitted the *HR Direct Service Center* with a copy to my former Company leader. The Company will have ten (10) days to consider whether my new employment opportunity: (i) involves the same or similar duties that I performed for the Company during the last two years of my employment and (ii) is for a Competing Business, such that the Company needs to Exercise the Non-Compete. I agree to immediately provide the Company with any additional information that it may request in order to analyze whether my new employment opportunity poses a competitive risk to the Company's business interests. The Company has the sole discretion to determine whether or not to Exercise the Non-Compete with respect to my new job opportunity.

 <u><br></u>

7 Generally, the same or similar duties that I would be restricted from performing for a Competing Business might involve current or developing products, services, manufacturing, research and development, and any other strategic role: (a) for which I had responsibility or worked with in the last two (2) years of my employment, or (b) about which I acquired knowledge of or access to Confidential Information and Trade Secrets in the last two (2) years of my employment.

------

**Exhibit 10.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;**<u>Non-Solicitation/Non-Service of Customers:</u>** For a period of one

(1) year after my employment with the Company ends, whether voluntarily or involuntarily, I will not directly or indirectly solicit, contact, or communicate with (regardless of who initiates the communication) customers of the Company for the purpose of inducing or encouraging customers to stop or reduce doing business with the Company or in an attempt to sell or provide any product or service that competes with those products or services offered by the Company. "Customers" in this Section means only those customers, prospective customers, and end users *(i.e.,* customers of retailers or dealers) of the Company: (i) with whom I had personal contact within the last two (2) years of my employment, or (ii) about whom I learned Confidential Information or Trade Secrets during the last two (2) years of my employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;**<u>Non-Solicitation of Employees:</u>** For a period of one (1) year after my employment with the Company ends, whether voluntarily or involuntarily, I will not directly or indirectly interfere with the Company's relationship with its employees by (a) soliciting or communicating with an employee to induce or encourage him or her to leave the Company's employ (regardless of who first initiates the communication); (b) helping another person or entity evaluate a Company employee as an employment candidate; or (c) otherwise helping any person or entity hire an employee away from the Company. This restriction applies only to employees: (i) I worked with or supervised, or (ii) about whom I learned Confidential Information during the last two (2) years of my employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;**<u>Non-Interference with Business Partners:</u>** For a period of one (I) year after my employment with the Company ends, whether voluntarily or involuntarily, I will not directly or indirectly interfere with, disrupt, or attempt to disrupt the Company's relationship, contractual or otherwise, with its vendors, suppliers, contractors, and consultants (collectively "Business Partners") or diminish or attempt to diminish the services being provided to the Company by any Business Partners where permitted by law. This restriction shall apply only to those Business Partners of the Company with whom I came into contact during the last two (2) years of my employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Enforcement:</u>** If litigation or other formal action is required to enforce this Agreement, I agree that the prevailing party shall be entitled to recover its reasonable costs and attorney's fees. Further, I understand that if I breach my Post-Employment Covenants, the restrictive periods will not continue to run and will, instead, be tolled for the period of time that I am in breach. Accordingly, the restrictive periods will be extended for a period equal to the duration of my breach, where permitted by law. If any part of this Agreement is held void, illegal, or unenforceable, or in conflict with any applicable law, every other term of this Agreement will remain valid and fully enforceable. If any court refuses to enforce any part of this Agreement as written, the court may modify that part to the minimum extent necessary to make it enforceable under applicable law, and shall enforce it as modified.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Confidential Information Belonging to Others:</u>** I affirm that I am not presently subject to a restrictive covenant or other contract or agreement of any kind that prohibits, restricts, or limits my employment with the Company, or, alternatively, that I have disclosed such agreement to the Company prior to starting employment with the Company. If I later learn that I may be subject to a restrictive covenant or other prior agreement of which I am currently unaware that may prohibit or restrict my employment with the Company, I will immediately notify the Company. If I have a restrictive covenant that interferes with my employment with the

------

**Exhibit 10.1**

Company, the Company may elect to end my employment and enforce the restrictive covenants in this Agreement, but under such circumstances, I will not be entitled to any compensation for the non-compete restrictions as set forth in Section 7(c) above. I also agree that I will not disclose to the Company, use for the Company's benefit, or induce the Company to use any trade secret or confidential information that I may possess or any intellectual property belonging to any former employer or other third party to whom I owe a duty of confidentiality.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Data Usage and Protection:</u>** I acknowledge and agree that in the ordinary course of business, the Company has or may be collecting, processing, and storing (electronically or otherwise) certain family, personal, and personnel data in accordance with the Company's Privacy Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;**<u>No Expectation of Privacy:</u>** I acknowledge and agree that during my employment with the Company, I have no expectation of privacy with respect to the Company's telecommunications, networking, or information processing systems (including, without limitation, stored files, e-mail messages, text messages, and voice messages). I agree that at any time, without notice, the Company may monitor my use of such Company systems and any files or messages created, sent, or received by me on any of those systems. I agree that any property owned by the Company and any of my property located on Company's premises, including disks, other storage media, filing cabinets, lockers, vehicles, and work areas, are subject to inspection by the Company at any time, without notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Entire Agreement:</u>** This Agreement supersedes any prior employee agreements that I may have with Corteva, Inc. or any affiliated predecessor company, including but not limited to Dow AgroSciences LLC, E.I. du Pont de Nemours and Company, and Pioneer Hi-Bred International, except to the extent I have an ongoing obligation of confidentiality to such predecessor. In addition, to the extent the Post-Employment Covenants in this agreement conflict with or are different from any agreements regarding equity awards that I may have with Corteva, Inc. or any affiliated predecessor company, the terms in my equity award agreement will control in such circumstance. I acknowledge that I have not relied on any representations, promises, or agreements of any kind made to me in connection with my acceptance of this Agreement, except for those set forth in this Agreement. I **also understand that** I **am free to consult an attorney before** I **sign the Agreement, if** I **choose to do so.** No amendment, modification, or waiver to this Agreement will be binding upon either me or the Company unless it is in writing and signed by both of us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Governing Law and Choice of Forum:</u>** This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to its conflict of laws provisions. Unless otherwise prohibited by law, the Company and I desire to have any disputes arising out of this Agreement resolved in a forum having a substantial body of law and experience, so we agree that any action or proceeding arising out of this Agreement shall be brought exclusively in the state or federal courts of Delaware, Iowa or Indiana, and we further agree to the personal jurisdiction of those courts. Both the Company and I waive any objection we may now or later have to the venue of any such action in such court(s), and further we waive any claim we may now or later have that any action brought in such court(s) has been brought in an inconvenient forum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;**<u>Disclosure of Agreement:</u>** I agree that I will promptly disclose the existence of this Agreement and the Post-Employment Covenants in it to all of my subsequent employers or prospective employers until all Post-Employment Covenants have expired.

------

**Exhibit 10.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15.&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Signature:</u>** I received this Agreement electronically with sufficient time to review it, ask questions, and consult my attorney, if I chose to do so. I have also had the opportunity to download a copy of the Agreement and understand that additional copies are available to me. I understand that checking my acknowledgement and agreement to the terms of this Agreement constitutes my electronic signature.

**Signature:**

**Email:**

**Signature:**

**Email:**

## Exhibit 10.2

**Exhibit 10.2**

**AWARD TERMS OF**

**TIME-VESTED RESTRICTED STOCK UNITS GRANTED UNDER THE**

**CORTEVA, INC. 2019 OMNIBUS INCENTIVE PLAN**

**FOR GRANTEES LOCATED IN THE U.S. (OUTSIDE OF CALIFORNIA)**

---

| | |
|:---|:---|
| **Introduction/ Grant of Award** | You have been granted time-vested Restricted Stock Units under the Corteva, Inc. 2019 Omnibus Incentive Plan ("Plan"), subject to the following Award Terms. This grant is also subject to the terms of the Plan, which is hereby incorporated by reference. However, to the extent that an Award Term conflicts with the Plan, the Plan shall govern. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in these Award Terms, including any appendices to these Award Terms (hereinafter, collectively referred to as the "Agreement"). A copy of the Plan, and other Plan-related materials, such as the Plan prospectus, are available at: www.benefits.ml |

---

---

| | |
|:---|:---|
| **Grant Award Acceptance** | You must expressly accept the terms and conditions of your Award as set forth in this Agreement. To accept, log on to Merrill Lynch Benefits OnLine at www.benefits.ml.com, select **Equity Plan > Grant Information > Pending Acceptanc**e<br>**IF YOU DO NOT ACCEPT YOUR RESTRICTED STOCK UNITS IN THE MANNER INSTRUCTED BY THE COMPANY, YOUR RESTRICTED STOCK UNITS WILL BE SUBJECT TO CANCELLATION.** |

---

---

| | |
|:---|:---|
| **Date of Grant** | **February 24, 2026** ("Date of Grant") |
| **Type of Awards** | Time-vested Restricted Stock Units |

---

---

| | |
|:---|:---|
| **Dividend Equivalents** | Dividends payable on the Shares represented by your Restricted Stock Units (including whole and fractional Restricted Stock Units) will be allocated to your account in the form of additional Restricted Stock Units based upon the closing Share price on the date of the dividend payment. Dividend Equivalents will not vest until such time as the underlying Award vests. |

---

------

**Exhibit 10.2**

---

| | |
|:---|:---|
| **Restricted Period** | You may not sell, gift, or otherwise transfer or dispose of any of the Restricted Stock Units during the "Restricted Period." The Restricted Period commences on the Date of Grant and lapses as set forth herein.<br>On **February 24, 2027**, the Restricted Period will lapse with respect to one-third (1/3) of the Restricted Stock Units, including dividend equivalents. <br>On **February 24, 2028**, the Restricted Period will lapse with respect to one-third (1/3) of the Restricted Stock Units, including dividend equivalents.<br>&nbsp;&nbsp;&nbsp;&nbsp;<br>On **February 24, 2029**, the Restricted Period will lapse with respect to the remaining Restricted Stock Units, including dividend equivalents. |

---

**Termination**

**of Employment**

---

| | |
|:---|:---|
| **Under Sum of 65 Rule** | If you terminate employment after attainment of age 55 and a minimum of 65 combined years of age and service and you are an active employee for six months following the Date of Grant, the Restricted Stock Units will remain subject to the Restricted Period set forth above for one year from the termination date of employment. When one year from the termination date of employment is reached, all other remaining unvested units will be forfeited. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Due to Disability, or Death** | The Restricted Period on all units will lapse. |
| **Due to Involuntary Termination Giving Rise to Severance Benefits or Divestiture to Entity Less Than 50% Owned by Corteva, Inc.** | The Restricted Period on all units will lapse. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Due to Any Other Reason (such as voluntary termination, involuntary termination without severance benefits, or for Cause)** | Restricted Stock Units that are subject to a Restricted Period will be forfeited. |

---

For purposes of this Agreement, transfer of employment among Corteva, Inc. and any of its Affiliates is not a termination of employment.

**Payment** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the case of termination due to Disability or death, Restricted Stock Units shall be paid to you or your estate, as applicable, within seventy days of the date on which the Restricted Period lapses as a result of the termination. Restricted Stock Units are payable in one Share for each whole Restricted Stock Unit and a cash payment for any fraction of a Restricted Stock Unit. The value of each fractional Restricted Stock Unit will be based on the closing price of the Shares as reported on the effective date of payment.

**Section 409A of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**To the extent that an amount that is considered "nonqualified

**Code &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**deferred compensation" subject to Section 409A of the Code ("deferred compensation") is payable on, or by reference to, the date of your termination of employment, no amounts shall be paid hereunder on account thereof unless such termination of employment constitutes a "separation from service," within the meaning of Section 409A of

------

**Exhibit 10.2**

the Code. If you are a "specified employee," within the meaning of Section 409A of the Code, no amount that is deferred compensation shall be paid or delivered, on, or by reference to, the date of your separation from service, earlier than the date that is six months after such separation from service. Amounts otherwise payable during that six-month period shall be paid on the date that is six months and one day after your separation from service. If an amount that constitutes deferred compensation is payable upon a Disability that does not constitute a "disability" within the meaning of Section 409A of the Code, it shall be paid to you when the Restricted Period lapses in accordance with the schedule set forth under "Restricted Period."

The Restricted Stock Units are intended to be exempt from or compliant with Section 409A of the Code and the U.S. Treasury Regulations relating thereto so as not to subject you to the payment of additional taxes and interest under Section 409A of the Code or other adverse tax consequences. In furtherance of this intent, the provisions of this Agreement will be interpreted, operated, and administered in a manner consistent with these intentions. The Committee may modify the terms of this Agreement, the Plan or both, without your consent, in the manner that the Committee may determine to be necessary or advisable in order to comply with Section 409A of the Code or to mitigate any additional tax, interest and/or penalties or other adverse tax consequences that may apply under Section 409A of the Code if compliance is not practical. This section does not create an obligation on the part of the Company to modify the terms of this Agreement or the Plan and does not guarantee that the Restricted Stock Units or the delivery of Shares upon vesting/settlement of the Restricted Stock Units will not be subject to taxes, interest and penalties or any other adverse tax consequences under Section 409A of the Code. In no event whatsoever shall the Company be liable to any party for any additional tax, interest or penalties that may be imposed on you by Section 409A of the Code or any damages for failing to comply with Section 409A of the Code.

**Restricted Conduct &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**If you engage in any of the conduct described in subparagraphs (i) through (v) below for any reason, in addition to all remedies in law and/or equity available to the Company: (1) you shall forfeit all Restricted Stock Units (whether or not vested) and shall immediately pay to the Company, with respect to previously vested Restricted Stock Units, a cash amount equal to the Fair Market Value of the Shares plus the cash payment for any fraction of a Restricted Stock Unit received, without regard to any Tax-Related Items (as defined below) that may have been deducted from such amount; (2) the Company shall be entitled to monetary damages incurred as a result of such conduct; (3) the Company shall be entitled to injunctions, both preliminary and permanent, enjoining or restraining such conduct; and (4) the Company shall be entitled to all reasonable sums and costs, including attorneys' fees, incurred to defend or enforce the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of subparagraphs (i) through (v) below, "Company" shall mean Corteva, Inc. and/or any of its Subsidiaries or Affiliates that have employed you or retained your services.

------

**Exhibit 10.2**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)**Non-Disclosure of Confidential Information & Trade Secrets**. During the course of your employment with the Company and thereafter, you shall not use or disclose, except on behalf of the Company and pursuant to the Company's directions, any Company Confidential Information or Trade Secrets. Confidential Information and Trade Secrets are items of information relating to the Company, its products, services, customers, and employees that are of great competitive value to the Company, which have been or will be disclosed to you or of which you have or will become aware as a consequence of your relationship with the Company, which are not generally known or available to the general public or the Company's competitors, and which have been developed, compiled, or acquired by the Company at its great effort and expense. "Confidential Information" includes, but is not limited to: (a) financial and business information, such as information with respect to costs, commissions, fees, profits, sales, sales margins, capital structure, operating results, borrowing arrangements, strategies and plans for future business, pending projects and proposals, and potential acquisitions or divestitures; (b) product and technical information, such as new and innovative ideas, research and development projects, investigations, new business development, trademarks and brand names under development, sketches, plans, drawings, prototypes, methods, procedures, experimental and testing results, devices, machines, equipment, data processing programs, software, software codes, and computer models; (c) marketing information, such as new marketing ideas, strategies, initiatives, business plans, markets, and mailing lists; (d) customer and prospective customer information, such as the identity of the Company's customers and prospective customers, their names, the names of representatives of the Company's customers and prospective customers responsible for entering into contracts with the Company, the financial arrangements between the Company and its customers, the existence and terms of contracts with customers or any future contracts with customers or prospective customers, specific needs, requirements, and preferences of customers, and leads and referrals to certain prospective customers; and (e) personnel information, such as the identity and number of the Company's other employees, consultants and contractors, their salaries, bonuses, benefits, skills, qualifications, and abilities (information in this item (e) is referred to as "Personnel Information"). In addition, Confidential Information shall include combinations, compilations, or aggregations of individual facts, components, or units of information that are in whole or in part publicly known, unless such combination, compilation, or aggregation of those facts is itself publicly known. "Trade Secrets" are items of Confidential Information that meet the requirements of applicable trade secret law. Confidential Information and Trade Secrets can be in any form, including, without limitation, oral, written, or machine readable, including electronic files.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)**Limited Use of Confidential Information and Trade Secrets.** Notwithstanding any of the foregoing to the contrary, nothing in this Agreement prohibits Employee from filing a charge with or participating, testifying, or assisting in any investigation, hearing, whistleblowing proceeding, or other proceeding before any federal, state, or local government agency (*e.g.,* EEOC, NLRB, SEC, etc.). In addition, under the federal Defend Trade Secrets Act of 2016, Employee shall not be held criminally or civilly liable under any federal or

------

**Exhibit 10.2**

state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made to Employee's attorney in relation to a lawsuit for retaliation against Employee for reporting a suspected violation of law; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)**Non-Solicitation of and Non-Interference with Employees**. While you are employed by the Company and for a period of one (1) year after your employment ends, whether voluntarily or involuntarily, you shall not, either on your own account or on behalf of any other individual or entity, directly or indirectly solicit or induce any employee of the Company to work for any other individual or entity, or otherwise cause any employee of the Company to leave employment with or service to the Company or diminish his or her services to the Company. This restriction shall apply only to current employees of the Company and any former employees of the Company with whom you came into contact during your employment with the Company. For purposes of this Section, the term "current" with respect to employees of the Company refers to those individuals who are employed or associated with the Company at the time of their solicitation, hiring, or inducement to leave the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)**Non-Solicitation and Non-Service of Customers**. During your employment and for a period of one (1) year after your employment with the Company ends, whether voluntarily or involuntarily, you will not directly or indirectly solicit customers of the Company for the purpose of selling or providing any competing product or service offered by the Company for which you had responsibility during the two (2) years preceding your termination of employment with the Company. This restriction shall apply only to those customers of the Company: (a) with whom you had personal contact within the last one (1) year of your employment, or (b) about whom you learned Confidential Information or Trade Secrets during the last one (1) year of your employment with the Company. For the purposes of this Section, the term "contact" means interaction between you and the customer or prospective customer that takes place to further the business relationship with, make sales to, or perform services for the customer on behalf of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)**Non-Competition**. During your employment and for a period of one (1) year after your employment with the Company ends, whether voluntarily or involuntarily, you will not, without the express written consent of the President of the Company or his or her designee, directly or indirectly perform the same or similar duties that you performed for the Company during the two (2) years preceding the termination of your employment, for any Competing Business. A "Competing Business," as used in this Agreement, means any individual or entity that develops, manufactures, sells, and/or distributes a product or service that competes directly or indirectly with those products or services offered by the Company, and: (a) which Employee had responsibility for or worked with in the last two (2) years of Employee's employment, or (b) about which Employee acquired knowledge of or access to Confidential Information and Trade Secrets in the last two (2) years of Employee's employment. In recognition of the international nature of the Company's business, which includes the sale of its

------

**Exhibit 10.2**

products and services globally, this restriction shall apply to each state or territory of the United States of America, and each country of the world outside of the United States of America, in which the Employee was employed or had responsibility within the last two (2) years of Employee's employment. Notwithstanding any of the foregoing to the contrary, if Employee is employed by the Company in Georgia, Louisiana, or South Dakota, then the geographic scope of this restriction is limited to the counties, municipalities, and/or parishes in which Employee worked for the Company, and all directly adjacent counties, municipalities, and/or parishes within the same state.

The restrictive periods set forth in this Restricted Conduct section shall not expire and shall be tolled during any period in which you are in violation of such restrictive periods; and therefore, such restrictive periods shall be extended for a period equal to the duration of your violations thereof.

You further acknowledge and agree that any breach, material or otherwise, of this Agreement or any other agreement between Company and you shall not excuse your performance under this Agreement, including your obligation to honor the restrictions set forth in this section.

You further agree that you will promptly disclose the existence of the post-employment restrictions contained herein to all subsequent employers and/or prospective employers until all such covenants have expired.

The Restricted Conduct set forth herein is in addition to, and not in place of, any contractual requirements that may govern your obligations to the Company during and after your employment.

**Applicable Policies &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**This Award shall be subject to the Company's clawback policy; Corteva, Inc. Insider Trading Policy, including the anti-hedging and anti-pledging provisions thereunder; and/or share ownership guidelines (in each case as they may be amended from time to time), the terms of which are incorporated herein by reference. For purposes of the foregoing, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold your Shares and other amounts acquired pursuant to your Restricted Stock Units to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company upon the Company's enforcement of the clawback policy and/or for purposes of complying with any applicable law. To the extent that this Agreement and the clawback policy conflict, the terms of the clawback policy shall prevail.

**Repayment/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Any benefits you may receive hereunder shall be

**Forfeiture** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject to repayment or forfeiture as required to comply with the requirements of the U.S. Securities and Exchange Commission or any applicable law, including the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act, or any securities exchange on which the Shares are traded, as may be in effect from time to time.

**Withholding** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You acknowledge that the Company or, if different, the Subsidiary or Affiliate that employs you (the "Employer") (1) make no representations or undertakings regarding the treatment of any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-

------

**Exhibit 10.2**

related items related to the Plan and legally applicable to you ("Tax-Related Items") in connection with any aspect of the Restricted Stock Units, including, but not limited to, the grant, vesting or settlement of the Restricted Stock Units, the subsequent sale of Shares acquired pursuant to such settlement and the receipt of any dividends and/or any dividend equivalents; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Restricted Stock Units to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction, the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

In connection with any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (i) requiring you to make a payment in a form acceptable to the Company; or (ii) withholding from your wages or other cash compensation payable to you by the Company and/or the Employer; or (iii) withholding from proceeds of the sale of Shares acquired upon settlement of the Restricted Stock Units either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent); or (iv) withholding in Shares to be issued upon settlement of the Restricted Stock Units; or (v) any other method of withholding determined by the Company and to the extent required by Applicable Law or the Plan, approved by the Committee; provided, however, that if you are subject to the short-swing profit rules of Section 16(b) of the Exchange Act, then the Company will withhold in Shares upon the relevant taxable or tax withholding event unless otherwise determined by the Committee.

The Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates, up to and including maximum applicable rates, in the jurisdictions applicable to you, in which case, you may receive a refund of any over-withheld amount in cash and will have no entitlement to the equivalent in Shares. If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full number of Shares subject to the vested Restricted Stock Units, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items.

Finally, you agree to pay to the Company or the Employer, any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.

Notwithstanding anything in this section to the contrary, to avoid a prohibited acceleration under Section 409A of the Code, if Shares subject to the Restricted Stock Units will be withheld (or sold on your behalf) to satisfy any Tax Related

------

**Exhibit 10.2**

Items arising prior to the date of settlement of the Restricted Stock Units for any portion of the Restricted Stock Units that is considered nonqualified deferred compensation subject to Section 409A of the Code, then the number of Shares withheld (or sold on your behalf) shall not exceed the number of Shares that equals the liability for Tax-Related Items.

**Severability** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

**Waiver &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You acknowledge that a waiver by the Company or breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other participant.

**Privacy** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to this Agreement, the Company may collect, use, transfer and share your personal information, such as your name, contact information and banking information. The Company may share personal information with its Affiliates and selected third parties outside of your country of residence, including the United States, which may have data protection rules that are different from those of your country, to perform this Agreement and for purposes consistent with our privacy statement: https://www.corteva.com/privacy.html.

**Insider Trading/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You may be subject to insider trading restrictions and/or

**Market Abuse Laws** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker's country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares under the Plan during such times as you are considered to have "inside information" regarding the Company (as defined by Applicable Laws). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (a) disclosing the inside information to any third party and (b) "tipping" third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Corteva, Inc. Insider Trading Policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you should speak to your personal advisor on this matter.

**Imposition of Other** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company reserves the right to impose other requirements on

**Requirements &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**your participation in this Agreement, on the Restricted Stock Units and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

------

**Exhibit 10.2**

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

## Exhibit 10.3

**Exhibit 10.3**

**AWARD TERMS OF**

**PERFORMANCE-BASED RESTRICTED STOCK UNITS GRANTED UNDER THE**

**CORTEVA, INC. 2019 OMNIBUS INCENTIVE PLAN**

**FOR GRANTEES LOCATED IN THE U.S. (OUTSIDE OF CALIFORNIA)**

<br> <br>

---

| | |
|:---|:---|
| **Introduction** | You have been granted performance-based Restricted Stock Units ("Units") under the Corteva, Inc. 2019 Omnibus Incentive Plan ("Plan"), subject to the following Award Terms. This grant is also subject to the terms of the Plan, which is hereby incorporated by reference. However, to the extent that an Award Term conflicts with the Plan, the Plan shall govern. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in these Award Terms, including any appendices to these Award Terms (hereinafter, collectively referred to as the "Agreement"). A copy of the Plan, and other Plan-related materials, such as the Plan prospectus, are available at: www.benefits.ml.com |
| **Grant Award Acceptance** | You must expressly accept the terms and conditions of your Award as set forth in this Agreement. To accept, log on to Merrill Lynch Benefits OnLine at www.benefits.ml.com, select **Equity Plan > Grant Information > Pending Acceptanc**e. If you do not accept your Units in the manner instructed by the Company, your Units will be subject to cancellation |
| **Date of Grant** | **February 24, 2026 ("Date of Grant")** |
| **Type of Award** | Units |
| **Dividend Equivalents** | Dividends payable on the Shares represented by your Units (including whole and fractional Units) will be allocated to your account in the form of Units based upon the closing Share price on the date of the dividend payment. Such Units will be subject to the vesting terms set forth below and all other terms set forth in the Agreement. Dividend equivalent units will be determined after the end of the applicable performance period ("Performance Period") and credited to your account at that time based on the performance-adjusted number of Units in your account. Dividend equivalent units will be calculated by taking the final performance-adjusted Units and calculating the dividend equivalent units for the first dividend payment date for the Performance Period. The resulting number of dividend equivalent units from the first dividend payment date will be added to the final performance-adjusted number of Units before calculating the dividend equivalent units for the second dividend payment date during the Performance Period. This process will be repeated for each subsequent dividend payment date during the Performance Period. |
| **Performance Period** | January 1, 2026 – December 31, 2028 |

---

------

**Exhibit 10.3**

---

| | |
|:---|:---|
| **Vesting Terms** | You may not sell, gift, or otherwise transfer or dispose of any of the Units.<br>If you remain an active employee from the Date of Grant through the last day of the Performance Period, you will vest in the number of Units that become eligible to vest, if any, based on the achievement of the goals set forth in the Performance Metrics section set forth below. Except as set forth below, if you terminate employment after the Date of Grant but prior to the last day of the Performance Period, unvested Units will be forfeited. |
| **Performance** **Metrics** | The total number of Units subject to the Award that will be eligible to vest will be based upon the attainment level of the performance goals related to the Company's (a) Return on Net Assets ("RONA") (as defined below) and (b) 3-Year Cumulative Earnings Per Share ("EPS") (as defined below), in each case, during the Performance Period. The performance attainment level and percent of target payout will be determined independently for each metric, and the two metrics will be weighted in determining the final total number of Units that are eligible to vest (the "Final Award"). The RONA performance goal is weighted at 50% and the 3-Year Cumulative EPS performance goal is weighted at 50%. |

---

The Final Award is the sum of the following two elements:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **RONA Payout %**<br>**x Target Award**<br>**x 50%** | **+** | **3-Year Cumulative EPS Payout %**<br>**x Target Award**<br>**x 50%** | **=** | **Final Award** |

---

The RONA Payout % and the 3-Year Cumulative EPS Payout % are set out below under the headings "RONA Payout % Schedule" and "3-Year Cumulative EPS Payout %" below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.RONA Goal**

"RONA" is equal to Operating Earnings divided by the 4-Quarter Average of Net Working Capital ("NWC") plus net property, plant and equipment ("PP&E"). Descriptions for these components are provided below.

The attainment level of the RONA goal will be measured by adding the RONA that is attained for each of the three fiscal years contained in the Performance Period and dividing this number by three (i.e., average RONA attained over the Performance Period).

"Operating Earnings" means income from continuing operations attributable to Corteva common stockholders, excluding the after-tax impact of significant items, non-operating -benefits (costs), and amortization of intangible assets existing as of the Separation from DowDuPont.

------

**Exhibit 10.3**

"NWC" means current assets, less current liabilities, including cash and short-term debt and calculated as a 4-quarter average.

PP&E = Gross Property Plant and Equipment less Accumulated Depreciation and calculated as a 4-point average

RONA Payout % Schedule

---

| | |
|:---|:---|
| Performance | RONA Payout % |
| Below Threshold | 0% |
| Threshold | 50% |
| Target | 100% |
| Maximum | 200% |

---

RONA is rounded to 1 decimal place (ie. Xx.x%)

Based on the table above, the Company's average RONA during the Performance Period is translated into a percentage payout (of the target) for 50% of the Units subject to the Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. &nbsp;&nbsp;&nbsp;&nbsp;3-Year Cumulative EPS Goal** 

**"Operating Earnings Per Share"** means, for a fiscal year within the Performance Period, Operating Earnings (defined above), ***divided*** by the Diluted Shares Outstanding, rounded to the second decimal place.

**"Diluted Shares Outstanding"** means the number of Shares that are outstanding on a fully diluted basis as of the last day of the fiscal year contained in the Performance Period, as reported in the Company's Form 10-K.

**"3-Year Cumulative EPS"** shall be calculated as the sum of Operating Earnings Per Share (EPS) for each of the fiscal years contained in the Performance Period in accordance with the following formula:

3-Year Cumulative EPS = EPS Year 1 + EPS Year 2 + EPS Year 3

The attainment level of the 3-Year Cumulative EPS goal will determine the payout percentage for the Performance Period in accordance with the schedule outlined below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*3-Year Cumulative EPS Payout % Schedule*

---

| | |
|:---|:---|
| Performance | Payout % |
| Below Threshold | 0% |
| Threshold | 50% |

---

------

**Exhibit 10.3**

---

| | |
|:---|:---|
| Target | 100% |
| Maximum | 200% |

---

\*Interim points are interpolated on a straight-line basis

\*\*Based on the table above, the Company's 3-Year Cumulative EPS during the Performance Period is translated into a percentage payout (of the target) for 50% of the Units subject to the Award.

---

| | |
|:---|:---|
| **Performance Adjustment** | The Committee, in its sole and absolute discretion, may make appropriate and equitable adjustments to the performance goal measurement or the method applied to calculate such measurement or determine the underlying performance metric, in the event of or in connection with, among other items: (i) tax adjustments, (ii) a merger or acquisition or any similar event affecting the Shares or other securities of the Company, (iii) debt incurred relative to pension funding (whether required or driven by de-risking strategies), (iv) the impact of any new accounting standards, and (v) items associated with discontinued operations. |
| **Payment** | Within 70 days following the last day of the Performance Period, vested Units (including dividend equivalents accruing after the end of the Performance Period and prior to the payment date), if any, will be paid to you or your estate, as applicable, in one Share for each whole Unit and a cash payment for any fraction of a Unit. The value of each fractional Unit will be based on the closing price of the Shares as reported on the Composite Tape of the New York Stock Exchange as of the effective date of payment. |

---

---

| | |
|:---|:---|
| **Section 409A of the Code** | The Units are intended to be exempt from or compliant with Section 409A of the Code and the U.S. Treasury Regulations relating thereto so as not to subject you to the payment of additional taxes and interest under Section 409A of the Code or other adverse tax consequences. In furtherance of this intent, the provisions of this Agreement will be interpreted, operated, and administered in a manner consistent with these intentions. The Committee may modify the terms of this Agreement, the Plan or both, without your consent, in the manner that the Committee may determine to be necessary or advisable in order to comply with Section 409A of the Code or to mitigate any additional tax, interest and/or penalties or other adverse tax consequences that may apply under Section 409A of the Code if compliance is not practical. This section does not create an obligation on the part of the Company to modify the terms of this Agreement or the Plan and does not guarantee that the Units or the delivery of Shares upon vesting/settlement of the Units will not be subject to taxes, interest and penalties or any other adverse tax consequences under Section 409A of the Code. In no event whatsoever shall the Company be liable to any party for any additional tax, interest or penalties that may be imposed on you by Section 409A of the Code or any damages for failing to comply with Section 409A of the Code. |

---

------

**Exhibit 10.3**

**Termination**

**of Employment**

---

| | |
|:---|:---|
| **Under Sum of 65 Rule, Due to Disability or Death, Divestiture to Entity Less Than 50% Owned by the Company, or Involuntary Termination Giving Rise to Severance Benefits** | If you are an active employee for six months following the Date of Grant and terminate employment (i) after attainment of age 55 and a minimum of 65 combined years of age and service ; or due to (ii) disability; (iii) death; (iv) liquidation, dissolution or divestiture to an entity less than 50% owned by the Company; or (v) an involuntary termination by the Company or, if different, the Subsidiary or Affiliate that employs you (the "Employer") which gives rise to the payment of severance benefits under a plan maintained by the Company, the Units will remain subject to the Vesting Terms and will be paid in accordance with the Payment terms above. However, the number of Units will be prorated based on the number of months you were employed, and adjusted for periods of unpaid leaves of absence or part-time employment as determined by the Plan Administrator, from the beginning of the Performance Period through the end of the Performance Period |
| **Due to Any Other Reason (including for Cause; Voluntary Termination; or Involuntary Termination Without Severance Benefits)** | Units will be forfeited as of the date on which you terminate employment. |
| **Restricted Conduct** | If you engage in any of the conduct described in subparagraphs (i) through (v) below for any reason, in addition to all remedies in law and/or equity available to the Company or any Subsidiary or Affiliate, you shall forfeit all Units. For purposes of subparagraphs (i) through (v) below, "Company" shall mean Corteva, Inc. and/or any of its Subsidiaries or Affiliates. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) **Confidential Information**. During the course of your employment with the Company and thereafter, you use or disclose, except on behalf of the Company and pursuant to the Company's directions, any Company "Confidential Information" (i.e., information concerning the Company and its business that is not generally known outside the Company, and includes, but is not limited to, (a) trade secrets; (b) intellectual property; (c) information regarding the Company's present and/or future products, developments, processes and systems, including invention disclosures and patent applications; (d) information on customers or potential customers, including customers' names, sales records, prices, and other terms of sales and Company cost information; (e) Company business plans, marketing plans, financial data and projections; and (f) information received in confidence by the Company from third parties. Information regarding products, services or technological innovations in development, in test marketing or being marketed or promoted in a discrete geographic region, which information the Company is considering for broader use, shall be deemed not generally known until such broader use is actually commercially implemented.); and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) **Solicitation of Employees**. During your employment and for a period of one year following the termination of your employment for any reason, you hire, recruit, solicit or induce, or cause, allow, permit or aid others to hire, recruit, solicit or induce, any employee of the Company who possesses Confidential Information of the Company to terminate his/her employment with the Company and/or to seek employment with your new or prospective employer; and/or

------

**Exhibit 10.3**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) **Solicitation of Customers**. During your employment and for a period of one year following the termination of your employment for any reason, you, directly or indirectly, on behalf of yourself or any other person, company or entity, solicit or participate in soliciting, products or services competitive with or similar to products or services offered by, manufactured by, designed by or distributed by the Company to any person, company or entity which was a customer or potential customer for such products or services and with which you had direct or indirect contact regarding those products or services or about which you learned Confidential Information at any time during the two years prior to your termination of employment with the Company; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) **Non-Competition regarding Products or Services**. During your employment and for a period of one year following the termination of your employment for any reason, you, directly or indirectly, in any capacity, provide products or services competitive with or similar to products or services offered by the Company to any person, company or entity which was a customer for such products or services and with which customer you had direct or indirect contact regarding those products or services or about which customer you learned Confidential Information at any time during the two years prior to your termination of employment with the Company; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) **Non-Competition regarding Activities**. During your employment and for a period of one year following the termination of your employment for any reason, you engage in activities which are entirely or in part the same as or similar to activities in which you engaged at any time during the two years preceding termination of your employment with the Company for any person, company or entity in connection with products, services or technological developments (existing or planned) that are entirely or in part the same as, similar to, or competitive with, any products, services or technological developments (existing or planned) on which you worked at any time during the two years preceding termination of your employment. This paragraph applies in countries in which you have physically been present performing work for the Company at any time during the two years preceding termination of your employment.

**Applicable Policies &nbsp;&nbsp;&nbsp;&nbsp;**This Award shall be subject to the Company's clawback policy; the Corteva, Inc. Insider Trading Policy, including the anti-hedging and anti-pledging provisions thereunder; and/or share ownership guidelines, if any, (in each case as they may be amended from time to time), the terms of which are incorporated herein by reference. For purposes of the foregoing, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold your Shares and other amounts acquired pursuant to your Units to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company upon the Company's enforcement of the clawback policy and/or for purposes of complying with any applicable law. To the extent that this Agreement and the clawback policy conflict, the terms of the clawback policy shall prevail.

------

**Exhibit 10.3**

---

| | |
|:---|:---|
| **Repayment/ Forfeiture** | Any benefits you may receive hereunder shall be subject to repayment or forfeiture as required to comply with the requirements of the U.S. Securities and Exchange Commission or any applicable law, including the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act, or any securities exchange on which the Shares are traded, as may be in effect from time to time. |

---

**Withholding** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You acknowledge that the Company and/or the Employer (1) make no representations or undertakings regarding the treatment of any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the Plan and legally applicable to you or deemed applicable to you ("Tax-Related Items") in connection with any aspect of the Units, including, but not limited to, the grant, vesting or settlement of the Units, the subsequent sale of Shares acquired pursuant to such settlement and the receipt of any dividends and/or any dividend equivalent units; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Units or the underlying shares to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction, the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with any relevant taxable or tax withholding event, as applicable, you agree to make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (i) requiring you to make a payment in a form acceptable to the Company; or (ii) withholding from your wages or other cash compensation payable to you by the Company and/or the Employer; or (iii) withholding from proceeds of the sale of Shares acquired upon settlement of the Units either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent); or (iv) withholding in Shares to be issued upon settlement of the Unit; or (v) any other method of withholding determined by the Company and to the extent required by Applicable Law or the Plan, approved by the Committee; provided, however, that if you are subject to the short-swing profit rules of Section 16(b) of the Exchange Act, then the Company will withhold in Shares upon the relevant taxable or tax withholding event unless otherwise determined by the Committee.

The Company may withhold or account for Tax-Related Items by considering applicable statutory withholding rates, up to and including maximum applicable rates, in the jurisdictions applicable to you, in which case, you may receive a refund of any over-withheld amount in cash and will have no entitlement to the equivalent in Shares. If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full number of Shares subject to the vested Units, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items.

------

**Exhibit 10.3**

Finally, you agree to pay to the Company or the Employer, any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the shares or the proceeds of the sale of Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.

Notwithstanding anything in this section to the contrary, to avoid a prohibited acceleration under Section 409A of the Code, if Shares subject to the Units will be withheld (or sold on your behalf) to satisfy any Tax-Related Items arising prior to the date of settlement of the Units for any portion of the Units that is considered nonqualified deferred compensation subject to Section 409A of the Code, then the number of Shares withheld (or sold on your behalf) shall not exceed the number of Shares that equals the liability for Tax-Related Items.

**Severability** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

**Waiver &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You acknowledge that a waiver by the Company or breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other participant.

**Privacy** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to this Agreement, the Company may collect, use, transfer and share your personal information, such as your name, contact information and banking information. The Company may share personal information with its Affiliates and selected third parties outside of your country of residence, including the United States, which may have data protection rules that are different from those of your country, to perform this Agreement and for purposes consistent with our privacy statement: www.corteva.com/privacy

------

**Exhibit 10.3**

---

| | |
|:---|:---|
| **Insider Trading/ Market Abuse Laws** | You may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker's country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Units) or rights linked to the value of Shares under the Plan during such times as you are considered to have "inside information" regarding the Company (as defined by Applicable Laws). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (a) disclosing the inside information to any third party and (b) "tipping" third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Corteva, Inc Insider Trading Policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you should speak to your personal advisor on this matter. |

---

---

| | |
|:---|:---|
| **Imposition of Other Requirements** | The Company reserves the right to impose other requirements on your participation in this Agreement, on the Units and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. |

---

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

## Exhibit 10.4

**Exhibit 10.4**

**AWARD TERMS OF**

**TIME-VESTED RESTRICTED STOCK UNITS GRANTED TO A NONEMPLOYEE DIRECTOR UNDER THE**

**CORTEVA, INC. 2019 OMNIBUS INCENTIVE PLAN**

**Introduction &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You have been granted time-vested Restricted Stock Units under the Corteva, Inc. 2019 Omnibus Incentive Plan (the "Plan"), subject to the following Award Terms. This grant is also subject to the terms of the Plan, which is hereby incorporated by reference. However, to the extent that an Award Term conflicts with the Plan, the Plan shall govern.

Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in these Award Terms, including any appendices to these Award Terms (hereinafter, collectively referred to as the "Award Agreement"). A copy of the Plan, and other Plan-related materials, such as the Plan prospectus, are available upon request or on the Merrill Lynch website at:

**<u>www.benefits.ml.com</u>**

**Date of Grant &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;April 28, 2026** ("Date of Grant")

**Type of Awards &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Time-vested Restricted Stock Units

**Dividend** 

**Equivalents &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Dividends payable on the Shares represented by your Restricted Stock Units (including whole and fractional Restricted Stock Units) will be allocated to your account in the form of additional Restricted Stock Units (whole and fractional) based upon the closing price of a Share on the date of the dividend payment. Such additional Restricted Stock Units will be subject to the Restricted Period and all other terms and conditions of this Award Agreement.

**Restricted Period &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You may not sell, gift, or otherwise transfer or dispose of any of the Restricted Stock Units during the "Restricted Period." The Restricted Period commences on the Date of Grant and lapses upon the earlier of: (i) April 28, 2027, (ii) your "separation from service" (within the meaning of Code Section 409A) unless such separation occurs within six months of the Date of Grant, in which case the Restricted Stock Units are forfeited and (iii) your death or disability (within the meaning of Code Section 409A).

**Payment &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Restricted Stock Units shall be paid to you or your beneficiary, if such a designation is permitted by the Administrator (or estate if there is no beneficiary), as applicable, within sixty (60) days of the date on which the Restricted Period on such Restricted Stock Units lapses, subject to the "Deferral" terms below.

------

**Exhibit 10.4**

Restricted Stock Units are payable in one Share for each whole Restricted Stock Unit and a cash payment for any fraction of a Restricted Stock Unit. The value of each fractional Restricted Stock Unit will be based on the closing price of the Shares as reported on the Composite Tape of the New York Stock Exchange as of the effective date of payment.

**Deferral &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**If you are a U.S. resident director or if permitted by the Administrator, you may defer the settlement of this Award in accordance with the Stock Accumulation and Deferred Compensation Plan for Directors. Payment for deferred Restricted Stock Units is made in accordance with deferral elections and/or the administrative rules for the Stock Accumulation and Deferred Compensation Plan for Directors, as applicable.

**Withholding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Compensation received pursuant to the Restricted Stock Units is subject to various income taxes, including but not limited to federal, state, foreign, local, or self-employment tax ("Taxes"). The Company shall not be responsible for withholding any applicable Taxes, unless required by Applicable Laws. In this regard, under current laws, the Company will not withhold U.S. federal taxes from non-employee directors who are U.S. residents; however, the Company will report the compensation received pursuant to the Restricted Stock Units as non-employee compensation on a Form 1099-MISC.

To the extent that Taxes are required to be withheld under Applicable Laws, the Company will have the power and the right to require you to remit to the Company the amount necessary to satisfy all such applicable Taxes required to be withheld with respect to any taxable event arising as a result of the Restricted Stock Units. Notwithstanding the foregoing, unless otherwise determined by the Administrator, and provided that the withholding obligation does not arise prior to payment of the Restricted Stock Units, any obligation to withhold Taxes will be met by the Company first withholding from any cash amounts due to you upon payment of the Restricted Stock Units and then by withholding from the Shares to be issued upon payment of the Restricted Stock Units that number of Shares with a fair market value on the date on which the amount of Taxes to be withheld is determined sufficient to satisfy the Taxes required to be withheld.

You should consult with a professional tax advisor regarding any Taxes that arise in connection with the Restricted Stock Units. You may rely solely on such advisor and may not rely in any part on any statement or representation of the Company or any of its agents.

------

**Exhibit 10.4**

**Severability &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**The provisions of this Award Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

**Waiver &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You acknowledge that a waiver by the Company of breach of any provision of this Award Agreement shall not operate or be construed as a waiver of any other provision of this Award Agreement, or of any subsequent breach by you or any other participant.

**Imposition of Other**

**Requirements &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**The Company reserves the right to impose other requirements on your participation in this Award Agreement, on the Restricted Stock Units and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

**Privacy**

In relation to this Award Agreement, the Company may collect, use, transfer and share your Personal Information, such as your name, contact information and banking information. The Company may share Personal Information with its affiliates and selected third parties outside of your country of residence, including the United States, which may have data protection rules that are different from those of your country, to perform this Award Agreement and for purposes consistent with our privacy statement: https://www.corteva.com/privacy.html

**Appendices &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Notwithstanding any provision in the Award Terms, if you reside outside the United States, the Restricted Stock Units shall be subject to the additional terms and conditions set forth in Appendix A to the Award Agreement and to any specific terms and conditions for your country set forth in Appendix B to the Award Agreement. Moreover, if you relocate outside the United States or between the countries included in Appendix B, subject to compliance with Code Section 409A, the additional terms and conditions set forth in Appendix A and the terms and conditions for such country set forth in Appendix B will apply to you, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.

------

**Exhibit 10.4**

**APPENDIX A**

ADDITIONAL TERMS AND CONDITIONS

This Appendix includes additional terms and conditions that govern the Restricted Stock Units. These terms and conditions are in addition to, or, if so indicated, in place of, the terms and conditions set forth in the Award Terms. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Award Terms or the Plan.

**Nature of Grant** By participating in the Plan, you acknowledge, understand and agree that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Plan is operated, and the Restricted Stock Units are granted solely by the Company, and only the Company is a party to the Agreement; accordingly, any rights you may have pursuant to the Agreement may be raised only against the Company but not any Subsidiary or Affiliate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the grant of the Restricted Stock Units is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) all decisions with respect to future grants of Restricted Stock Units, if any, will be at the sole discretion of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) you are voluntarily participating in the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) no claim or entitlement to compensation or damages shall arise from forfeiture of the Restricted Stock Units resulting from termination of your service (for any reason whatsoever, whether or not later found to be invalid or in breach of the terms of your service agreement, if any);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Award Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) neither the Company nor any Subsidiary shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Restricted Stock Units or of any amount due to you pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement.

------

**Exhibit 10.4**

**No Advice** 

**Regarding Grant** The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Shares. You understand and agree that you should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.

**Venue** Any and all disputes relating to, concerning or arising from this Award Agreement, or relating to, concerning or arising from the relationship between the parties evidenced by the Restricted Stock Units or this Award Agreement, shall be brought and heard exclusively in the United States District Court for the District of Delaware or the Delaware Superior Court, New Castle County. Each of the parties hereby represents and agrees that such party is subject to the personal jurisdiction of said courts; hereby irrevocably consents to the jurisdiction of such courts in any legal or equitable proceedings related to, concerning or arising from such dispute, and waives, to the fullest extent permitted by law, any objection which such party may now or hereafter have that the laying of the venue of any legal or equitable proceedings related to, concerning or arising from such dispute which is brought in such courts is improper or that such proceedings have been brought in an inconvenient forum**.**

**Language** If you have received this Award Agreement or any other document related to this Award Agreement translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

**Electronic Delivery**

**and Acceptance** The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

**Insider Trading/** 

**Market Abuse Laws** You may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and your country or your broker's country, if different, which may affect your ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares under the Plan during such times as you are considered to have "inside information" regarding the Company (as defined by the laws in the applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (a) disclosing the inside information to any third party and (b) "tipping" third

------

**Exhibit 10.4**

parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Company's insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you should speak to your personal advisor on this matter.

**Foreign Asset/**

**Account Reporting** 

**Requirements** Your country may have certain foreign asset and/or account reporting requirements which may affect your ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends received or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside your country. You may be required to report such accounts, assets or transactions to the tax or other authorities in your country. You also may be required to repatriate sale proceeds or other funds received as a result of your participation in the Plan to your country through a designated bank or broker and/or within a certain time after receipt. You acknowledge that it is your responsibility to comply with such regulations, and you should consult your personal legal advisor for any details.

---

| | |
|:---|:---|
| **Legal, Regulatory and Tax Compliance; Cooperation** | If you reside or are employed outside of the United States, you agree, as a condition of the grant of the Restricted Stock Units, you agree to take any and all actions as may be required to comply with your personal legal, regulatory and tax obligations under local laws, rules and regulations in your country of employment (and country of residence, if different), including (but not limited to) any obligations to repatriate all payments attributable to the Shares and/or cash acquired under the Plan (*e.g.*, dividends and any proceeds derived from the sale of Shares acquired pursuant to the Restricted Stock Units). In addition, you also agree to take any and all actions, and consent to any and all actions taken by the Company and any of its Affiliates, as may be required to allow the Company and any of its Affiliates to comply with local laws, rules and regulations in your country of service (or country of residence, if different). |

---

------

**Exhibit 10.4**

**APPENDIX B**

**COUNTRY-SPECIFIC TERMS AND CONDITIONS**

This Appendix includes additional terms and conditions that govern the Restricted Stock Units granted to you under the Plan if you reside in one of the countries listed herein. These terms and conditions are in addition to, or if so indicated, in place of the terms and conditions set forth in the Award Terms or Appendix A. The information contained in this Appendix B is based on the securities, exchange control, tax and other laws in effect in the respective countries as of April 2025.

You should be aware that local exchange control laws may apply to you as a result of your participation in the Plan. By accepting the Restricted Stock Units, you agree to comply with applicable exchange control laws associated with your participation in the Plan. If you have any questions regarding your responsibilities in this regard, you agree to seek advice from your personal legal advisor, at your own cost, and further agree that neither the Company nor any Subsidiary or Affiliate will be liable for any fines or penalties resulting from your failure to comply with Applicable Laws.

If you are a citizen or resident of a country other than the one in which you are currently working, transfer residency after the Restricted Stock Units are granted or are considered a resident of another country for local law purposes, the terms and conditions contained herein may not be applicable to you, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to you.

**<u>BRAZIL</u>**

**Compliance with Law**. By accepting the Restricted Stock Units, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable Taxes associated with the vesting of the Restricted Stock Units, the receipt of any dividends, and the sale of Shares acquired under the Plan.

**Labor Law Acknowledgment.** This provision supplements the acknowledgments contained in the *Nature of Grant* section of Appendix A:

By accepting the Restricted Stock Units, you agree that (i) the Shares will be issued to you only if the vesting conditions are met and any necessary services are rendered by you over the vesting period, and (ii) the value of the underlying Shares is not fixed and may increase or decrease in value over the vesting period without compensation to you.

**<u>GERMANY</u>**

There are no country specific provisions.

## Exhibit 31.1

**Exhibit 31.1**

**SECTION 302 CERTIFICATIONS**

I, Charles V. Magro, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Corteva, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | May 6, 2026 |
| By: | /s/ Charles V. Magro |
|  | Charles V. Magro |
|  | *Chief Executive Officer* |

---

------

I, Charles V. Magro, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of EIDP, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | May 6, 2026 |
| By: | /s/ Charles V. Magro |
|  | Charles V. Magro |
|  | *Chief Executive Officer* |

---

## Exhibit 31.2

**Exhibit 31.2**

**SECTION 302 CERTIFICATIONS**

I, David P. Johnson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Corteva, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | May 6, 2026 |
| By: | /s/ David P. Johnson |
|  | David P. Johnson |
|  | *Executive Vice President and<br>Chief Financial Officer* |

---

------

I, David P. Johnson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of EIDP, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: | May 6, 2026 |
| By: | /s/ David P. Johnson |
|  | David P. Johnson |
|  | *Executive Vice President and<br>Chief Financial Officer* |

---

## Exhibit 32.1

**Exhibit 32.1**

**Certification of CEO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Quarterly Report of Corteva, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Charles V. Magro, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Charles V. Magro |
| Charles V. Magro |
| Chief Executive Officer |
| May 6, 2026 |

---

------

**Certification of CEO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Quarterly Report of EIDP, Inc. on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Charles V. Magro, as Chief Executive Officer of EIDP, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of EIDP, Inc.

---

| |
|:---|
| /s/ Charles V. Magro |
| Charles V. Magro |
| Chief Executive Officer |
| May 6, 2026 |

---

## Exhibit 32.2

**Exhibit 32.2** 

**Certification of CFO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Quarterly Report of Corteva, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David P. Johnson, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ David P. Johnson |
| David P. Johnson |
| Executive Vice President and <br>Chief Financial Officer |
| May 6, 2026 |

---

------

**Certification of CFO Pursuant to**

**18 U.S.C. Section 1350, As Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the Quarterly Report of EIDP, Inc. on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), David P. Johnson, as Chief Financial Officer of EIDP, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of EIDP, Inc.

---

| |
|:---|
| /s/ David P. Johnson |
| David P. Johnson |
| Executive Vice President and <br>Chief Financial Officer |
| May 6, 2026 |

---

<br>